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General introduction and outline
INTRODUC TION
History of the antiphospholipid syndrome
The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the 
persistent presence of antiphospholipid (aPL) antibodies and thrombosis or pregnancy 
morbidity (1). The first classification criteria for definite APS were published in 1999 
(2). However, the APS story started in 1906 with the development of a diagnostic test 
for syphilis (Figure 1) (3). The Wassermann (reagin) test is a serological assay based on 
complement fixation (3). The ‘Wassermann reagent’ contained a liver extract of newborns 
who had died from congenital syphilis (3–5). In the following years, research showed 
that tissue extracts of animals never exposed to the causative organism of syphilis 
(Treponema pallidum), for example an ethanolic extract of beef heart could also be used 
(4,5). In 1941 a breakthrough occurred as Pangborn identified the antigenic component 
of the reagin test extracted from beef heart, cardiolipin (6). This breakthrough resulted 
in the development and standardization of new tests, including the Venereal Disease 
Research Laboratory (VDRL) test (4,5,7,8). The VDRL test was a screening tool for syphilis 
based upon microflocculation (7,8). Heated serum is mixed with reagin containing 
cardiolipin, lecithin and cholesterol (7,8). In case of positivity, flocculation or clumping 
can be observed using a microscope (7,8). Population screening using the VDRL test 
showed a group of patients that were biologically false positive. The lack of specificity 
to the antigen was already seen with the Wassermann test, which was confirmed by the 
T. pallidum immobilization test (4,5,9). In 1947, Lubinski listed diseases and conditions 
with biological false positive syphilis reactions (10). The list included diseases and 
conditions like malaria, lupus erythematosus and pregnancy (10). In 1952, Mohr and 
Moore found a high incidence of biological false positives due to infections (e.g. leprosy 
and malaria) (11). However, non-infectious diseases like systemic lupus erythematosus 
(SLE) and rheumatoid arthritis had also a high approximate incidence of biological false 
positives of 20% and 5%, respectively.
In the same year Conley and Hartman described two patients with lupus erythematosus 
who both had a biological false positive serological test for syphilis and a prolonged 
prothrombin time (12). This was one of the first descriptions of lupus anticoagulant 
(LAC), a phospholipid dependent prolongation of the clotting time. In 1954, Beaumont 
et al. published a report of a patient with LAC and seven previous abortions (13). 
More than two decades later, Firkin et al. suggested a possible relationship between 
LAC and recurrent abortion, which was later confirmed by Bowie et al. (14,15). In 
the 1950’s it became apparent that some patients with SLE also had a circulating 









False-positive test for syphilis
Association between aPL and thrombosis
1980’s
Association between aPL and pregnancy morbidity
1983 aCL antibodies 
Nomenclature ‘antiphospholipid antibody syndrome’ 
1990 β2glycoprotein I  
1999 Classification criteria for definite APS
2006 Updated classification criteria for APS
1988 Association between LAC and aPT antibodies
1954
1998 Importance of domain I of β2glycoprotein I  
Figure 1. Timeline of key events and discoveries in APS.
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was established (19). Bowie et al. demonstrated that the prolonged clotting time in 
patients could be corrected using soybean phosphatide (inosithin, a platelet substitute) 
and that this correction was related to thrombosis (19). In 1983, Harris et al. described 
a radioimmunoassay for the detection of anti-cardiolipin (aCL) antibodies (20). This 
milestone, resulted in the correlation between aCL antibodies and thrombosis within 
SLE patients. aCL antibodies were also found to correlate with LAC (20). Two years later, 
an enzyme-linked immunosorbent assay (ELISA) for the detection of aCL antibodies was 
described (21). In the 1980’s, the nomenclature ‘antiphospholipid antibody syndrome’ 
(APS) was starting to be widely used (4). However, it was not until 1987 that the first 
article using this terminology was published by Bingley and Hoffbrand (22). In 1988, 
Fleck et al. established a correlation between anti-prothrombin antibodies (aPT) and 
LAC (23). LAC was hypothesized to have immunological specificity for several anionic 
phospholipids including phosphatidylserine, cardiolipin, phosphatidylinositol and 
phosphatidic acid (24). However, Fleck et al. demonstrated that aPT immunoglobulin 
(Ig)G antibodies possessed LAC activity (23). In 1990, it became apparent that 
β2glycoprotein I (β2GPI) was the main target for antibody binding instead of cardiolipin 
itself. These publications already suggest that the term antiphospholipid antibody is a 
misnomer, as the antibodies are not directed against phospholipids per se, but rather 
to phospholipid binding proteins like β2GPI and prothrombin. In 1998, Iverson et al. 
suggested that antibodies directed against the first domain of β2GPI are clinically 
important (25). Seven years later, de Laat et al. confirmed the importance of anti-domain 
I β2GPI antibodies and suggested that these antibodies might be pathogenic as they 
cause LAC activity and strongly correlate with thrombosis (26). In 1999, an international 
consensus was reached for the classification of definite APS and updated in 2006 (1,2). 
First-line treatment for a first or recurrent APS-related venous thrombotic event is 
treatment with vitamin K-antagonists (VKA) (27). According to international guidelines, 
treatment with VKAs is recommended in APS patients with a first arterial thrombosis 
(28). In a recent consensus paper published in The Netherlands Journal of Medicine, 
either treatment with clopidogrel (anti-platelet therapy) or VKAs is recommended in 
APS patients with a first arterial thrombosis (27). Still, both papers discourage the use 
of direct oral anticoagulants (DOACs) like rivaroxaban (direct Xa inhibitor) (27–29). 
DOACs have shown to be non-inferior to VKAs for treatment and secondary prevention 
of venous thromboembolic events and prevention of stroke and systemic embolism 
in patients with non-valvular atrial fibrillation (27,30). The use of DOACs over VKAs has 
many advantageous, including no need for frequent laboratory monitoring, which is 
very much desired in patients with APS who are mostly young women of fertile age 
(31). It was until 2018 that an article was published evaluating the use of DOACs in triple 
positive (combined positivity for LAC, aCL and aβ2GPI antibodies) APS patients (32). 
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Pengo et al. showed that rivaroxaban therapy was associated with an increased rate of 
arterial events, compared to warfarin treatment (32). However, an explanation for the 
observed increased rate of arterial events in patients treated with DOACs is unknown 
and should be further explored. Overall, the efficacy of DOAC use in APS patients should 
be further studied.
Pathophysiology of the antiphospholipid syndrome
Multiple studies have reported an association between aPL antibodies and thrombosis 
or pregnancy morbidity (1). However, the underlying mechanisms are poorly understood 
(33,34). Patients with the persistent presence of aPL antibodies do not constantly 
develop thrombosis, suggesting that other factors play a role in the development of 
thrombotic APS (35). A “two hit” theory is suggested, in which aPL antibodies induce 
a thrombophilic state (first hit), and the second hit is another thrombophilic stimulus 
(36,37). In agreement, antibodies from APS patients only induce thrombosis in mice 
upon induction of vessel wall injury (38,39). However, the “two hit” theory seems not 
to apply for obstetric complications as antibodies with aPL activity induce fetal loss in 
naive pregnant mice (36).
B cells produce aβ2GPI antibodies which can form β2GPI immune complexes on cellular 
surfaces (33). Binding of β2GPI immune complexes to endothelial cells requires priming 
with pro-inflammatory factors (40). β2GPI immune complexes have also shown to bind 
to monocytes and platelets, inducing their proinflammatory and procoagulant state 
(41,42). Activation of inflammatory and endothelial cells by β2GPI immune complexes 
results in the activation of the complement pathway, upregulation of adhesion molecules 
(E-selectin), upregulation of TF, increased level of vascular endothelial growth factor 
and the release of neutrophil extracellular traps (33,34). Prothrombotic changes by aPL 
antibodies may be caused by increased expression of the platelet fibrinogen receptor 
glycoprotein IIb/IIIa, suppressing the activity of tissue factor pathway inhibitor, protein 
C activity and fibrinolysis (33,34). aPL antibodies have also an effect on the placenta, 
non-thrombotic mechanisms include activation of the complement system, increased 
trophoblast apoptosis, decreased human chorionic gonadotropin, proliferation and 
syncytia formation (33,34). Activation of coagulation, inflammatory and endothelial cells 
and interference with trophoblasts and decidual cells can lead to clinical manifestations 
of APS like thrombosis and pregnancy complications (33,34). However, aPL antibodies 
are also correlated with non-criteria manifestations like inflammation and vasculopathy 
(33,34). Despite all the efforts made, our understanding of the molecular mechanisms 
causing the development of aPL antibodies and APS related clinical manifestations is 
poorly understood.
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Antiphospholipid antibodies
For the classification of APS, a patient has to meet at least one clinical and one laboratory 
criterion (Table 1). Laboratory criteria include positivity for LAC, aCL IgG/M or aβ2GPI 
IgG/M antibodies on two occasions at least 12 weeks apart (1,43). The prevalence of 
APS is estimated to be around 50 per 100,000 of the population (44). Frequency of aPL 
is estimated at 9.5% in deep vein thrombosis, 11% in myocardial infarction, 13.5% in 
stroke and 6% in pregnancy morbidity (45). As clinical features of APS occur frequently 
and independent of APS, reliable aPL detecting assays are of utmost importance.
TABLE 1. Classification criteria of APS.
APS is present if a patient meets at least one of the following 
clinical criteria and one of the laboratory criteria (1)
Clinical criteria Laboratory criteria
1. Vascular thrombosis
One or more clinical episodes of confirmed arterial, 
venous, or small vessel thrombosis, in any tissue or 
organ.
2. Pregnancy morbidity
(a) One or more unexplained deaths of a 
morphologically normal fetus at or beyond the 10th 
week of gestation, or
(b) One or more premature births of a 
morphologically normal neonate before the 34th 
week of gestation, or
(c) Three or more unexplained consecutive 
spontaneous abortions before the 10th week of 
gestation.
1. Lupus anticoagulant present in plasma, on 
two or more occasions at least 12 weeks apart, 
detected according to the guidelines of the ISTH-
SSC (46).
2. Anticardiolipin antibody of IgG and/or IgM 
isotype present in serum or plasma on two or 
more occasions, at least 12 weeks apart (47).
3. Anti‐β2 glycoprotein‐I antibody of IgG and/
or IgM isotype present in serum or plasma on 
two or more occasions, at least 12 weeks apart 
(47).
Lupus anticoagulant
LAC is detected by a phospholipid dependent prolongation of the clotting time (1). 
The detection of LAC is a three-step procedure including a screening, mixing and 
confirmatory test. Citrated blood is collected and platelet free plasma is made by 
double centrifugation (46). LAC should be detected based on two different principles, 
preferably using a dilute Russell's viper venom time (dRVVT) and a LAC sensitive 
activated partial thromboplastin time (aPTT) (46). Patients referred for LAC testing are 
tested for prolongation of the clotting time (screening). Next, patient plasma is diluted 
with pooled normal plasma (1:1) to exclude clotting factor deficiencies (mixing). Lastly, 
LAC is confirmed using an excess of hexagonal phase II phospholipids (46). LAC is the 
only functional assay within the aPL-panel and considered the strongest predictor of 
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thrombosis and pregnancy morbidity (48,49). LAC has been shown to be dependent 
on aPT or aβ2GPI antibodies (23,50–52). However, it has also been demonstrated 
that LAC can occur in the absence of these antibodies (53). Isolated LAC positivity is 
considered to be less correlated with thrombosis than triple positivity (54). Still, the risk 
of a first thrombotic event in isolated LAC positives is higher than controls without aPL 
antibodies of the same age (54,55). Many efforts have been made in standardization 
of aPL antibody testing. In 2009, the International Society on Thrombosis and 
Haemostasis-Scientific and Standardization Committee (ISTH-SSC) subcommittee on 
lupus anticoagulant/anti-phospholipid antibodies published detailed guidelines for 
LAC detection (46). Laboratory testing for LAC remains complicated with many pitfalls 
in the implemented procedure as well as in the interpretation (56). LAC detection 
has many drawbacks, including sensitivity to anticoagulant therapy, difficulties in the 
interpretation of mixing studies, the use of normal pooled plasma and lack of consensus 
on the calculation of cut-off values (46,57–62).
Anti-cardiolipin antibodies
Traditionally, aCL antibodies are measured by an ELISA. Typically, the ELISA plate is 
coated with cardiolipin and incubated overnight (63). Plates are blocked with the use 
of adult bovine serum (ABS) or fetal bovine serum (FBS). The use of phosphate buffered 
saline (PBS), bovine serum albumin (BSA) or casein to block non-specific binding are 
not recommended as they do not contain β2GPI. ABS and FBS do contain β2GPI, which 
is crucial for binding of pathogenic ‘aCL’ antibodies (63,64). After blocking the plate, 
samples are diluted and incubated. A secondary conjugated antibody (anti-IgG, anti-
IgM or anti-IgA) is incubated for the detection of aCL antibodies (63). Quality control 
is important for the detection of aCL antibodies and inter-assay variation should 
not exceed 20% for ELISAs detecting aCL antibodies (47). Nowadays, automated 
immunoassays have become available for the detection of aCL and aβ2GPI antibodies 
using different solid phases (magnetic particles, microbeads, coated polystyrene 
cups or membranes) with various detection systems like chemiluminescence, flow 
cytometry and multiplex systems (65–67). These automated systems have shown to 
have less inter-assay variation and inter-laboratory variation compared to traditional 
ELISAs (47,65,68). Automated systems are also less labor intensive, more rapid and can 
detect several aPL antibodies simultaneously in one sample (65). Cut-off values are 
recommended calculated from at least 120 plasmas or sera of which the 99th percentile 
is calculated (47). However, it is not always possible to collect samples from 120 healthy 
donors. Alternatively, manufacturer’s recommended cut-off values can be validated on 
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a limited number of at least 20 healthy donors and transferred (47). Similar to LAC and 
aβ2GPI, aCL positivity should be confirmed after at least 12 weeks to rule out transient 
positivity induced by infections or drugs (1).
Anti-β2glycoprotein I antibodies
aβ2GPI antibodies are traditionally detected by ELISA, but equally as for aCL automated 
systems are available (65–67). For the detection of aβ2GPI antibodies, (high-binding) 
ELISA plates are coated with β2GPI overnight (69). Wells are then blocked with a 
blocking agent and samples are diluted and incubated (69). A secondary conjugated 
antibody (anti-IgG, anti-IgM or anti-IgA) is then incubated for the detecting of aβ2GPI 
antibodies (69). The absence of cardiolipin is theorized to increase the detection of 
clinically relevant antibodies (70). However, not all aβ2GPI antibodies are correlated 
with thrombosis (26).
Cofactors for anti-phospholipid antibodies
β2GPI and prothrombin are considered the most important cofactors for aPL antibodies.
β2glycoprotein I
β2GPI is an abundant plasma protein (approximately 200 µg/ml) which is produced in 
the liver and placenta (26,71–73). β2GPI is an anionic 50-kDa protein, is evolutionary 
conserved and has shown to regulate haemostasis as well as the complement system 
(38,39,72,74–77). Also, β2GPI is considered the main antigenic target for aPL antibodies 
(78). Still, β2GPI-deficient humans and mice do not express a clear phenotype of 
thrombosis or bleeding, indicating it is not essential for life (71,72,79,80). Notably, 
breeding of β2GPI null mice results in reduced percentage of offspring, suggesting that 
the lack of β2GPI is a selective disadvantage for survival (72,75,80). β2GPI is a highly 
glycosylated phospholipid-binding protein, consisting of four complement control 
protein (CCP) domains of 60 amino acids each. Domain V is different as it consists of 82 
amino acids and a phospholipid-binding site (26,72,81–86). The CCP domain functions 
as a module for protein-protein interactions in many different proteins (72). Domain 
V of β2GPI contains a large positively charged patch that determines the affinity for 
anionic phospholipids. β2GPI can be found in two distinct conformations: a ‘circular’ 
(native) conformation in plasma and an ‘activated’ (open) conformation (87). Upon 
binding of β2GPI to an anionic phospholipid surface, circular β2GPI unfolds to an open 
conformation, exposing cryptic epitopes. One of these cryptic epitopes is Gly40-Arg43, 
located in the first domain of β2GPI. Antibodies against the cryptic epitope Gly40-Arg43 




Prothrombin, also known as coagulation factor (F)II, is a 72-kDa, vitamin K-dependent 
zymogen produced in the liver. Prothrombin has a plasma concentration of 
approximately 100 μg/mL. Prothrombin is converted to thrombin upon vessel wall 
injury. Coagulation factor Xa cleaves prothrombin at Arg271-Thr272 and Arg320-Ile321 
generating the enzyme thrombin and fragment 1.2 (89,90). Thrombin is a central 
coagulation factor that cleaves fibrinogen to fibrin to produce a firm clot.
Genetic depletion of prothrombin in adult mice is not compatible with survival (91,92). 
To date, no living patient has been reported with undetectable plasma prothrombin, 
suggesting that prothrombin is essential for life. Like β2GPI, prothrombin can be found 
in an open and closed conformation. aPT antibodies are a heterogenous group of 
antibodies of which it has become more apparent that the conformation of prothrombin 
and the target epitope is of clinical importance, similar to β2GPI (93–96).
Non-Criteria anti-phospholipid antibodies
The first international consensus statement on the classification criteria for definite APS 
included the detection of LAC, aCL IgG and aCL IgM (2). In 2006, classification criteria 
were revised and the detection of aβ2GPI IgG and aβ2GPI IgM was added to the aPL 
panel (1). Inclusion of other aPL antibodies like aCL IgA, aβ2GPI IgA, aPT and anti-
phosphatidylserine/prothrombin (aPS/PT) antibodies needed further investigation (1).
Domain I antibodies
aβ2GPI antibodies may be directed to any epitope or part of the molecule. However, 
antibodies directed to the first domain of β2GPI have shown to be pathogenic by both 
in vivo and in vitro studies. In vitro, anti-domain I antibodies have shown to display LAC 
activity, increase resistance to the anticoagulant properties of annexin A5 and activated 
protein C (APC) and neutralize the inhibitory function of β2GPI on von Willebrand factor 
induced platelet aggregation (26,97–102). In vivo, domain I antibodies have shown to 
be pathogenic by inducing thrombosis and/or fetal loss in mice and rats (103–105). 
Antibodies against domain V failed to exert a thrombogenic effect in rats (105). However, 
APS patients could have both anti-domain I and anti-domain V antibodies. Antibodies 
against domain V bind circulating β2GPI, blocking interaction of β2GPI with anionic 
phospholipid surfaces and therefore hindering the conformational change of β2GPI to 
an open conformation and exposing cryptic epitopes. It is hypothesized that patients 
with anti-domain I β2GPI IgG antibodies and anti-domain V antibodies have a lower 
thrombotic risk if the anti-domain V level exceeds the level of anti-domain I (105,106). 
Anti-domain V antibodies might therefore be protective as these antagonize the 
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procoagulant activity of domain I antibodies. Calculating a ratio of anti-domain I to anti-
domain 4/5 might be useful for risk stratification (106). Although domain I antibodies 
are not part of the current classification aPL-panel, commercial assays for the detection 
of anti-domain I antibodies have become available (107). Unfortunately, a commercial 
chemiluminescence immunoassay (CIA) detecting anti-domain I antibodies failed to 
expose the cryptic epitope Gly40-Arg43, hampering the use of anti-domain I antibodies 
in APS patients (107). These results highlight the importance of standardization of solid 
phase assays detecting aPL antibodies (59,107).
Anti-cardiolipin and anti-β2glycoprotein I IgA antibodies
aCL and aβ2GPI IgA antibodies are not included in the current classification criteria 
for APS (1). Nevertheless, multiple studies have demonstrated an association between 
IgA aPL antibodies and thrombosis or pregnancy morbidity (108–118). The ISTH-SSC 
committee concluded in 2008 that aCL IgA does not add diagnostic power to the 
current aPL-panel. Data supporting the inclusion of aβ2GPI IgA antibody testing was 
found to be inadequate (1). Another point of discussion raised by the committee, is 
the lack of uniform guidelines on how to perform the assay, unavailability of control 
material and lack of consensus on units of measurement (1). Since 2006, new data on 
the association between IgA aPL antibodies and clinical manifestations of APS became 
available (108,111–116,118). A systematic review was published concerning the clinical 
relevance of aCL and aβ2GPI IgA antibodies and concluded that there is not enough 
evidence to recommend aCL and/or aβ2GPI IgA antibody testing as diagnostic accuracy 
is not improved (119). However, new assays for the detection of aCL and aβ2GPI IgA 
antibodies have become commercially available, but their value in the current aPL 
panel remains to be investigated (117).
Anti-prothrombin antibodies and anti-phosphatidylserine/prothrombin 
antibodies
For the detection of aPT antibodies, prothrombin is directly coated on irradiated ELISA 
plates (120). Detection of anti-phosphatidylserine/prothrombin (aPS/PT) antibodies 
is performed by coating phosphatidylserine/prothrombin complex on non-irradiated 
ELISA plates (120,121). Although a correlation has been shown between aPS/PT and 
aPT antibodies, it is hypothesized that these aPL antibodies belong to a different 
population of antibodies (120,122,123). In a systematic review, aPT antibodies 
correlated less with thrombosis than aPS/PT antibodies. Already in 1988, an association 
was established between aPT antibodies and LAC, which is considered the strongest 
predictor of thrombosis and pregnancy morbidity in APS, making aPS/PT antibodies an 
interesting group of aPL antibodies to further investigate (23,48,49). aPS/PT antibodies 
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are frequently found in patients with APS and suggested to be included in the current 
aPL-criteria (1,121,124). They may have a potential role in risk stratification and are 
strongly correlated with isolated LAC in APS patients, as well as in asymptomatic carriers 
(94,95,125–127).
Antiphospholipid profile
Although every aPL antibody in the current panel (LAC, aCL IgG, aCL IgM, aβ2GPI IgG, 
aβ2GPI IgM) for the classification of APS has the same diagnostic value, it is more apparent 
to evaluate the complete aPL-profile (1,128,129). Evaluation of an aPL profile can be 
important for risk stratification of thrombosis or pregnancy morbidity and “reliability” 
of diagnosis. Single positivity or isolated positivity, is positivity for one of the five 
consensus aPL antibodies but negative results for the other four aPL antibodies. Double 
positivity is referred as aCL and aβ2GPI positivity, but negative for LAC. Triple positivity 
is referred as combined positivity for LAC, aCL and aβ2GPI from the same isotype. LAC is 
considered the main predictor of thrombosis and pregnancy morbidity in APS (49,130). 
However, single LAC positivity is not considered a high risk profile for thrombosis or 
pregnancy morbidity in comparison to triple positivity (131–133). A strong correlation 
with thrombosis is found when aβ2GPI antibodies are present with LAC (134). Single 
LAC positivity in patients receiving anticoagulation must be interpreted carefully as 
anticoagulation therapy can induce a false positive LAC result (62). Antibodies against 
other cardiolipin binding proteins (complement factor 4 or Factor H) and β2GPI-
independent aCL antibodies are also detected (135,136). aCL and aβ2GPI assays contain 
the same antigen (β2GPI), an overlap is therefore expected. A positive aCL result with 
the absence of aβ2GPI antibodies and LAC should therefore be interpreted with care as 
no association is found for isolated aCL positivity (131). Also, isolated aβ2GPI antibodies 
are not correlated with thrombosis and hypothesized to be of no importance as these 
antibodies do not induce LAC activity (131,136). For example, aβ2GPI antibodies might 
occur in patients with leprosy in which thrombosis is uncommon (137). However, these 
aβ2GPI antibodies are not directed against the first epitope of β2GPI (137). It became 
apparent that positivity for multiple aPL is highly associated with clinical manifestations 
of APS (138–140). Triple positivity is more strongly associated with thrombosis than 
single and double positivity (129,141). Not only for recurrent thrombosis, but also for a 
first thrombotic event in asymptomatic carriers, triple positivity is a risk factor (141,142). 
Double positive patients are at lower risk to develop APS related clinical manifestations 
than triple positive patients, and single positive patients are even less likely to develop 
thrombosis (43,67,136).
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Anti-cardiolipin and anti-β2glycoprotein I isotype
The isotype of aCL and aβ2GPI antibodies should be taken into consideration for 
diagnosis of APS and correct interpretation of the assays (136). A laboratory test result 
with positivity for aCL IgG and aβ2GPI IgM, but not for aCL IgM and aβ2GPI IgG aPL 
should be classified as “inappropriate” (136). Concordance of isotype in aCL and aβ2GPI 
detection is essential, but not required according to the updated classification criteria 
(1,136). The isotype of aCL and aβ2GPI is not only a valuable tool for the interpretation 
of the aPL assays, but may also help in evaluating the risk for thrombosis or pregnancy 
morbidity. A meta-analysis found more significant correlations with thrombosis for the 
IgG isotype compared to the IgM isotype (143). aCL IgM antibodies have shown to be 
important in obstetric APS (130,144). However, the relevance of aCL and aβ2GPI IgM 
antibodies in thrombosis is debated (143).
OUTLINE
Classification of APS is dependent on the detection of aPL antibodies by laboratory 
tests. This includes the detection of LAC, aCL IgG/M antibodies and aβ2GPI IgG/M 
antibodies. Multiple studies have concluded that aPL antibody detecting assays show a 
large inter-assay variability. It is hypothesized that the inter-assay variation for aCL and 
aβ2GPI detected automated systems is lower compared to traditional ELISAs. Chapter2 
assesses the agreement between four commercially available and fully automated 
assays detecting aCL and aβ2GPI IgG/M antibodies in patients with APS and controls. In 
addition, the association of aPL antibodies with clinical manifestations is investigated. 
Patients with triple positive aPL antibodies have a high risk for a first thrombotic 
event and recurrence. Subsequently, clinicians may adapt their treatment strategy. 
Altogether, reliable detection is of utmost importance in triple positive patients. 
Triple positivity is often associated with high aCL and aβ2GPI titers and therefore 
hypothesized to be less affected by variations between solid phase assays. In chapter3, 
agreement between four aCL and aβ2GPI assays in the detection of triple positive 
APS patients is investigated. In the current classification criteria, positivity for aCL or 
aβ2GPI, independent of the isotype (IgG/M) is sufficient to fulfill the laboratory criteria 
of APS. However, the relevance of IgM antibodies in the classification of thrombotic APS 
is debated. We therefore investigated in chapter 4 the relevance of aCL and aβ2GPI 
IgM antibodies in thrombosis and pregnancy morbidity. Chapter 5 studies the added 
value of aCL IgA and aβ2GPI IgA antibodies in APS. aCL IgA and aβ2GPI IgA antibodies 
have shown to correlate with thrombosis and induce thrombosis in mice. However, IgA 
is still not included in the current aPL-panel for the classification of APS. Antibodies 
against domain I of β2GPI are considered pathogenic and correlate well with LAC. The 
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significance of anti-domain I antibodies in APS is reviewed in chapter 6. In chapter 7, 
we investigate whether anti-domain I antibodies can be used as a tool to identify high-
risk APS patients. The role of aPT antibodies in platelet activation is investigated in 
chapter 8. Finally, chapter 9 summarizes key findings of this thesis and discusses these 
findings in relation to the literature.
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Background: The antiphospholipid syndrome (APS) is characterized by thrombosis 
and/or pregnancy morbidity with persistent presence of antiphospholipid antibodies 
(aPL). Laboratory criteria include aPL detection by coagulation tests for lupus 
anticoagulant (LAC) or solid phase assays measuring anti-β2glycoprotein I (aβ2GPI) or 
anti-cardiolipin (aCL) immunoglobulin (Ig) G/IgM antibodies. External quality control 
programs illustrate that commercially available aPL assays produce variable results.
Objective: We aimed to investigate the agreement and diagnostic accuracy of solid 
phase assays.
Materials and Methods: In this multi-centre study, 1,168 patient samples were tested 
on one site for aCL and aβ2GPI IgG/IgM antibodies by four solid phase test systems. 
Samples included APS patients, controls and monoclonal antibodies (MoAB) against 
different epitopes of β2GPI. LAC was determined by the local centre.
Results: aCL IgM assays resulted in the most discrepancies (60%), while aCL IgG and 
aβ2GPI IgM assays resulted in lower discrepancies (36%), suggesting better agreement. 
Discrepant samples displayed lower median aPL titers. Dependent on the solid phase 
test system, odds ratios ORs for thrombosis and pregnancy morbidity ranged from 1.98 
to 2.56 and 3.42 to 4.78, respectively. Three platforms showed lower sensitivity for MoAB 
directed against the glycine (Gly) 40-arginine (Arg) 43 epitope of domain I of β2GPI.
Conclusion: Poor agreement was observed between different commercially available 
aCL and aβ2GPI IgG/IgM assays, hampering uniformity in the identification of aPL-
positive patients. Clinical association was globally concordant between solid phase test 
systems considering results of the four aPL together. An assay sensitive in detecting the 
MoAB against Gly40-Arg43 of domain I of β2GPI reached the highest OR for thrombosis.
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INTRODUC TION
The anti-phospholipid syndrome (APS) is characterized by thrombosis and/or 
pregnancy morbidity with the persistent presence of anti-phospholipid antibodies (aPL) 
(1). Laboratory criteria include aPL detection by phospholipid-dependent prolongation 
of coagulation tests referred to as lupus anticoagulant (LAC) or by solid phase assays 
measuring anti-β2glycoprotein I (aβ2GPI) and anti-cardiolipin (aCL) immunoglobulin 
(Ig) G/IgM antibodies (1). For the classification of APS at least one clinical and one 
persistent positive laboratory criterion is required (1). Given the high frequency of 
clinical manifestations (thrombosis and pregnancy morbidity) associated with APS in 
the general population, laboratory tests are of utmost importance for the classification 
of patients with APS. Although LAC positivity is considered the strongest predictor of 
clinical manifestations of APS, aCL and aβ2GPI IgG/IgM antibodies have the same value 
in the current classification criteria (1–5)
Anti-β2GPI antibodies are detected using β2GPI as antigen, while both cardiolipin and 
β2GPI are used as antigens in aCL immunoassays. The use of antigens from human 
sources is preferred above antigens from animal origin (e.g. bovine) to avoid false-
positives (6). In contrast to aβ2GPI immunoassays, antigens used in aCL immunoassays 
are not exclusively from human origin (Supplemental Table 1). Traditionally, aCL and 
aβ2GPI antibodies are detected with an enzyme-linked immunosorbent assay (ELISA). 
Nowadays, more advanced and automated systems have become available for the 
detection of aCL and aβ2GPI aPL (7–10). Automated systems make use of an alternative 
solid phase (e.g. magnetic beads) and use alternative detection methods, such as 
chemiluminescence or (enzyme linked) fluorescence. A large variety of assays are used 
in clinical laboratories as there is no consensus on a ‘gold standard’ for the detection 
of aCL and aβ2GPI aPL (6). Reports from external quality control programs illustrate 
that aPL assays produce variable results (11,12). Detection of aβ2GPI antibodies is 
challenging as some antibodies may be directed against a cryptic epitope that is only 
exposed after conformational shape change (13,14). Exposure of this cryptic epitope, 
spanning glycine (Gly) 40-arginine (Arg) 43 in the first domain of β2GPI, has been shown 
to vary across commercial aβ2GPI IgG assays (7,15). In addition, variability between 
assays might be due to the heterogeneous origin of aPL, differences in local working 
conditions, differences in assay design and a lack of standardization (6). As classification 
of APS heavily depends on the detection of aPL, variation within these tests will affect 
the treatment strategy.
Therefore, we aimed to investigate the agreement and diagnostic accuracy of commonly 
used commercially available solid phase assays measuring IgG and IgM aCL and aβ2GPI 
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aPL. Samples and normal pooled plasma supplemented with monoclonal antibodies 
(MoAB) against different domains of β2GPI were tested with four assays at one location 
by a single technician to exclude inter-laboratory and inter-operator variation.
MATERIALS AND METHODS
Patient cohort
We obtained 1,168 samples from 8 European centers. Classification of APS was 
based on the Sydney criteria (1). Patients were classified by the corresponding centre 
resulting in 259 thrombotic APS patients (APS thrombosis), 204 patients with a history 
of thrombosis and negative for laboratory criteria of APS (non-APS thrombosis), 122 
obstetric APS patients (APS obstetric), 33 patients with pregnancy complications 
and negative for laboratory criteria of APS (non-APS obstetric), 196 patients with an 
autoimmune disease other than APS (autoimmune diseases), 100 individuals with a 
normal pregnancy (normal pregnancy), 194 controls that were referred for aPL testing 
for other reasons than the clinical criteria of APS, like subfertility and prolonged activated 
partial thromboplastin time (controls) and 60 women that were diagnosed with APS 
without information on the specification of the clinical manifestations (unspecified 
APS). Centers with the indicated number of samples included Ghent (469), London 
(196), Nîmes (164), Nancy (114), Kraków (101), Milan (52), Geneva (50) and Apeldoorn 
(22). The study was approved by the central and the local ethical committees.
Assays
aCL IgG, aCL IgM, aβ2GPI IgG and aβ2GPI IgM aPL were measured in the Ghent 
University Hospital (Ghent, Belgium) by four commercially available immunoassays: 
BioPlex2200 (Bio-Rad, Bio-Rad Laboratories, Hercules, USA), ImmunoCapEliA (Thermo 
Fisher Scientific/Phadia, Uppsala, Sweden), ACL AcuStar (Werfen/Instrumentation 
Laboratories, Bedford, USA) and QUANTA Lite ELISA (Inova Diagnostics, San Diego, USA) 
(Supplemental Table 1). Assays were selected based on frequently used assays in the 
External quality Control of diagnostic Assays and Tests program and the willingness 
of manufacturers for collaboration. Due to shortage of patient sample, three and 
two patients were excluded for aCL IgG and aβ2GPI IgG detection by BioPlex2200, 
respectively. Manufacturers’ recommended cut-off values were used upon confirmation 
in 20 healthy volunteers, in accordance with the Scientific and Standardization 
committee (SSC) guidelines of the International Society on Thrombosis and 
Haemostasis (16). Assays were performed according to the manufacturer’s instructions. 
All four methods were performed in parallel in runs of 40 samples. According to the 
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guidelines, single measurement was used on the automated systems (BioPlex2200, 
ImmunoCapEliA and ACL AcuStar) as the intra- and inter-run imprecision coefficient 
of variation was <10% and duplicate measurement for the ELISA (QUANTA Lite ELISA) 
(16). aPL titers were expressed in arbitrary units (GPL, MPL, U/ml, SGU and SMU). All 
samples were measured by the same technician and values below the calculated limit 
of detection (LOD) were replaced by the calculated LOD.
Monoclonal antibodies
Two human-derived MoAB P2-6 and P1-117 were used to test the specificity and 
sensitivity of the four commercially available aCL and aβ2GPI IgG assays. P2-6 
recognizes β2GPI independently of its conformation and P1-117 recognizes β2GPI in 
its open conformation binding to the Gly40-Arg43 epitope of the domain I (15,17). 
Serial dilutions of antibodies (0-250 µg/ml) in normal pooled plasma were tested in 
duplicate for all platforms included in the study. Platforms were used according to the 
manufacturer’s recommendations and these spiked samples were handled as patient 
samples and tested in the same conditions. The threshold for positivity corresponding 
to a positive titer of aCL or aβ2GPI was determined.
Statistical analysis
Solid phase assays were compared pairwise as no ‘gold standard’ for aPL detection 
exists. Agreement between assays in positivity was assessed by 2 x 2 contingency 
tables in all measured samples. Comparison of discrepancies between aCL IgG, aCL IgM 
and aβ2GPI IgG and aβ2GPIgM positivity was calculated: positivity discrepancy (%) = 
(only positive for method A + only positive for method B) / (all positives) x 100. Median 
aPL titers within one platform were calculated with titers above the cut-off value. 
Correlation between solid phase assays was performed by a Spearman’s rank correlation 
coefficient. Diagnostic accuracy was assessed by calculating odds ratios, sensitivity, 
specificity, negative predictive value (NPV), positive predictive value (PPV) and the 
receiver operator curve (ROC). The area under the ROC curve between solid phase 
assays was compared using DeLong et al.'s method (18). Significance of differences was 
determined with the Mann-Whitney U test, as appropriate using the statistical package 
for social sciences (SPSS 23.0; SPSS, Chicago, Illinois, United States) and MedCalc 




We measured aCL IgG/IgM and aβ2GPI IgG/IgM aPL in 1,168 individuals with a mean age 
of 43 years ranging from 16 to 87 years old (Table 1) with four commercially available 
assays (Supplemental Table 1).
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177 313 104 31 4 21
Abbreviations: APS, anti-phospholipid syndrome; NA= not applicable; NS = not specified.
Laboratory criteria for the classification of APS require at least one positive aPL. 
We therefore compared positivity for at least one aPL between platforms using 2 x 
2 contingency tables (Table 2). Discrepancies varied between 79 (ACL AcuStar vs. 
BioPlex2200) and 164 (ACL AcuStar vs. ImmunoCapEliA) samples. aCL IgM and aβ2GPI 
IgG positivity resulted in the most discrepancies, varying from 69 to 162 and 44 to 153 
samples, respectively (Table 3). On the other hand, aCL IgG and aβ2GPI IgM positivity 
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resulted in less discrepancies between assays, varying from 49 to 98 and 34 to 58 
samples, respectively. Comparison of discrepancies between aCL IgG/IgM and aβ2GPI 
IgG/IgM positivity was calculated by the percentage of discrepancies from all positives, 
resulting in a maximum discrepancy of 36, 60, 53 and 36% for aCL IgG, aCL IgM, aβ2GPI 
IgG and aβ2GPI IgM positivity, respectively. In accordance, aCL IgM titers were less 
correlated between the solid phase assays compared to aCL IgG and aβ2GPI IgM with 
Spearman’s rank correlation coefficients.
TABLE 2. Number of samples positive for aCL IgG, aCL IgM, aβ2GPI IgG or aβ2GPI IgM by BioPlex2200, 
ImmunoCapEliA, ACL AcuStar and QUANTA Lite ELISA are compared pairwise
BioPlex 2200 ImmunoCap EliA ACL AcuStar
- + - + - +
BioPlex 2200 -
+
ImmunoCap EliA - 755 37
+ 108 268
ACL AcuStar - 795 11 717 89
+ 68 294 75 287
QUANTA Lite ELISA - 792 64 751 105 753 103
+ 71 241 41 271 53 259
Abbreviations: aCL, anti-cardiolipin; aβ2GPI anti- β2 glycoprotein I; Ig, immunoglobulin.
In accordance, aCL IgM titers were less correlated between the solid phase assays 
compared to aCL IgG and aβ2GPI IgM with Spearman’s rank correlation coefficients of 
≥0.514 (95% confidence interval [CI], 0.471-0.555), ≥0.635 (95% CI, 0.599-0.668) and 
≥0.738 (95% CI, 0.711-0.763) respectively (Table 4).
aPL positive samples not in agreement across the platforms were characterized by lower 
median aPL titers than positives in agreement (Figure 1). However, for the majority of 
discrepancies observed, respective individuals suffered from clinical manifestations 
of APS (thrombosis and/or pregnancy morbidity) (Figure 1). Clinical implications of 
the observed (dis)agreements were assessed by calculating the sensitivity, specificity, 
NPV, PPV and OR for thrombosis, pregnancy morbidity or both clinical criteria (Table 
5). Positivity was defined when at least one aPL was positive. Clinically affected and 
non-clinically affected patients were set as outcome variable rather than APS/non-APS 
in order to be independent of aPL presence previously detected by the medical centers 
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TABLE 3. Discrepancies in aPL positivity detection between platforms
BioPlex® 2200 ImmunoCap® EliA ACL AcuStar®
- + - + - +
A BioPlex® 2200 -
+
ImmunoCap® EliA - 892 59
+ 25 190
ACL AcuStar® - 905 37 913 30
+ 12 212 40 185
QUANTA Lite ELISA® - 897 78 913 46 919 58
+ 20 171 22 169 24 167
B BioPlex® 2200 -
+
ImmunoCap® EliA - 895 69
+ 18 184
ACL AcuStar® - 874 5 867 14
+ 39 248 99 188
QUANTA Lite ELISA® - 909 115 964 62 877 149
+ 4 138 2 140 4 138
C BioPlex® 2200 -
+
ImmunoCap® EliA - 930 28
+ 119 91
ACL AcuStar® - 989 9 897 101
+ 60 110 61 109
QUANTA Lite ELISA® - 971 27 906 92 946 52
+ 78 92 52 118 52 118
D BioPlex® 2200 -
+
ImmunoCap® EliA - 1007 23
+ 29 109
ACL AcuStar® - 1028 26 1024 30
+ 8 106 6 108
QUANTA Lite ELISA® - 997 19 996 20 1006 10
+ 39 113 34 118 48 104
Abbreviations: aCL, anti-cardiolipin; aβ2GPI anti- β2 glycoprotein I; aPL, anti-phospholipid antibodies; Ig, 
immunoglobulin. Note: Number of samples positive for aCL IgG, aβ2GPI IgG, aCL IgM and aβ2GPI IgM by 
BioPlex2200, ImmunoCapEliA, ACL AcuStar and QUANTA Lite ELISA are compared pairwise.
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that collected the samples, minimizing selection bias. Independent from the assay 
used, a statistically significant association with thrombosis and/or pregnancy morbidity 
was found. ORs for thrombosis varied between 1.98 (95% CI, 1.46-2.69) and 2.56 (95% 
CI, 1.82-3.59) detected by ImmunoCapEliA and BioPlex2200, respectively. ORs for 
pregnancy morbidity ranged between 3.42 (95% CI, 2.32-5.05) and 4.78 (95% CI, 3.14-
7.27) detected by ImmunoCapEliA and QUANTA Lite ELISA, respectively. Although not 
the most sensitive aPL detection platform for thrombosis and/or pregnancy morbidity, 
the QUANTA Lite ELISA resulted in the highest specificity (87.76% [95% CI, 84.52-90.52%]) 
FIGURE 1. Anti-phospholipid antibodies (aPL) titers of samples in (dis)agreement. Titers of samples positive 
for all assays and assay discrepancies are shown as detected with (A) BioPlex2200, (B) ImmunoCapEliA, (C) 
ACL AcuStar and (D) QUANTA Lite ELISA. Patients with thrombosis and/or pregnancy morbidity are indicated 
in black and without in red. Titers are expressed as the median value of positive aPL titers with interquartile 
ranges. ***p < 0.001. AU, arbitrary units.
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and OR (4.24 [95% CI, 3.10-5.79]). PPVs for thrombosis and/or pregnancy morbidity 
ranged from 74.73% (95% CI, 70.74-78.35%) to 80.77% (95% CI, 76.47-84.44%) and NPVs 
ranged from 49.71% (95% CI, 48.07-51.35%) to 50.23% (95% CI, 48.57-51.90%) as shown 
in Table 5. The area under the ROC curve of the solid phase assays for thrombosis and/
or pregnancy morbidity was low as expected and was not significantly different among 
the tested solid phase assays.
BioPlex2200 aCL and aβ2GPI IgG showed the highest and equal sensitivity for both 
MoAB P2-6, that recognizes β2GPI independently of its conformation, and P1-117, 
which only recognizes β2GPI upon exposure of the Gly40-Arg43 epitope in domain I 
(Table 6). ACL AcuStar aCL and aβ2GPI IgG sensitivity was slightly lower for P1-117, in 
the same extent for aCL and aβ2GPI. QUANTA Lite ELISA and ImmunoCapEliA showed 
much lower sensitivity for P2-6 and P1-117, with large difference in sensitivity for P2-6 
and P1-117. Both aCL assays did not detect P1-117 at all. OR for thrombosis and/or 
pregnancy morbidity for aCL and aβ2GPI (Table 5) ranged from 4.24 to 6.12 and 3.49 to 
6.56, respectively. The platform (BioPlex2200) with the highest sensitivity in detecting 
the P1-117 MoAB also reached the highest OR for thrombosis, but not for pregnancy 
morbidity.





































































Abbreviations: aCL, anti-cardiolipin; aβ2GPI, anti- β2 glycoprotein I; CI, Confidence interval; Ig, immunoglobulin.
Note: Spearman Rank Correlation rho coefficients with their respective 95% confidence intervals are shown.
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TABLE 5. Diagnostic accuracy of aPL detection by BioPlex2200, ImmunoCapEliA, ACL AcuStar and QUANTA 
























































































































































































Abbreviations: aPL, anti-phospholipid antibodies; APS, anti-phospholipid syndrome; AUC, area under the curve; CI, 
confidence interval; LAC, lupus anticoagulant; NPV, negative predictive value; PPV, positive predictive value.
Note: Samples were defined as positive if at least one aPL was positive, excluding LAC.
aAUC from the receiver operator curve (ROC) were not significantly different between solid phase assays.
bAPS thrombosis + non-APS thrombosis + AID + controls.




APS classification strongly depends on the laboratory criteria. Besides the clinical 
criteria, thrombosis or pregnancy morbidity, often due to other causes than aPL, APS 
is defined by the persistent presence of aPL (1). aPLs are detected by LAC assays or 
by semi-quantitative solid phase assays measuring aCL IgG, aCL IgM, aβ2GPI IgG or 
aβ2GPI IgM antibodies (1). Many studies on head-to-head comparisons of solid phase 
assays with different study designs, already have shown that solid phase assays differ in 
performance and agreement. In our study we analyzed a large cohort of APS and non-APS 
patients simultaneously with four different platforms, allowing comparison of different 
methods on the same patient population. LAC was determined by the local center but 
excluded from the comparative analysis investigate the variation solely introduced by 
solid phase assays. aPLs have a low prevalence (1-5%) in the general population, and 
APS is even more infrequent (40-50/100,000 persons) (19,20). As a consequence, studies 
comparing aPL detection methods are often based on a small patient group and/or 
lack diagnostic accuracy. We investigated the (dis)agreement and diagnostic accuracy 
of four commercially available solid phase assays for the detection of aCL IgG, aCL IgM, 
aβ2GPI IgG and aβ2GPI IgM antibodies in 1,168 samples from eight European centers. 
As in the Sydney criteria, all individual aPL are part of the laboratory criteria for APS, 
diagnostic accuracy was assessed for positivity for at least one aPL detected by a solid 
phase assay (aCL IgG, aCL IgM, aβ2GPI IgG or aβ2GPI IgM) (1). Positivity for at least one 
aPL detected by a solid phase assay was significantly correlated with thrombosis and/or 
pregnancy morbidity, independent from the solid phase assay used. The highest OR for 
thrombosis was obtained by detection of aPL by BioPlex2200 (2.56 [95%CI, 1.82-3.59]). 
Detection of aPL by ImmunoCapEliA resulted in the lowest OR (1.98 [95%CI, 1.46-2.69]), 
mainly because of lower specificity. aPL detection by BioPlex2200 and QUANTA Lite 
ELISA resulted in similar OR for thrombosis and/or pregnancy morbidity, higher than 
OR obtained by detection with ImmunoCapEliA and ACL AcuStar. Calculated sensitivity, 
NPV and AUC for thrombosis and/or pregnancy morbidity were low as expected, 
since we included patients with thrombosis and/or pregnancy morbidity without 
APS (negative for aPL). Inclusion of only APS patients would lead to a selection bias as 
diagnosis of APS is dependent on the aPL detection assays used by the local centre.
In our study, a maximum discrepancy of 36, 60, 53 and 36% for aCL IgG, aCL IgM, aβ2GPI 
IgG and aβ2GPI IgM positivity was found, respectively. Detection of aCL IgG and aβ2GPI 
IgM resulted in the best agreement. However, still a substantial number of samples were 
in disagreement. Conversely, a study comparing different kits detecting aCL and aβ2GPI 
IgG/IgM found better agreement between aβ2GPI ELISAs than aCL ELISAs (21). This 
might be a consequence of the small number of aβ2GPI positive samples in this study 
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(21). Another study compared the performance of aCL IgG and IgM antibody detection 
of the ImmunoCapEliA with their in-house aCL ELISA in 1,143 routine samples (22). The 
authors reached a good agreement (>90%) between the automated systems and their 
in-house ELISA assay (22). As expected, positivity for aPL proved to be relatively rare, 
because of which the majority of
TABLE 6. Threshold for positivity: titer of MoAB corresponding to a positive titer of aCL or aβ2GPI IgG

































































P2-6 (µg/ml) 1.95 125 15.63 62.5 1.95 31.25 1.95 62.5
P1-117 (µg/ml) 1.95 Nega 31.25 Nega 1.95 125 7.81 125
Abbreviations: aCL, anti-cardiolipin; aβ2GPI, anti-β2 glycoprotein I; Ig, immunoglobulin; MoAB, monoclonal 
antibodies. aNegative results for all concentrations.
routine samples were classified as negative independent of the method used, resulting 
in a high agreement. Importantly, more samples were classified positive by only 
ImmunoCapEliA or only the in-house ELISA than by both methods (116/179 and 72/90 
for aCL IgG and aCL IgM, respectively), suggesting a poor agreement comparable to our 
findings (22). We observed large differences in positivity across platforms, even between 
automated systems sharing the same solid phase (BioPlex2200 vs ACL AcuStar). In a 
collaborative study the inter-laboratory variability of aβ2GPI IgG and aβ2GPI IgM 
antibodies was assessed in 30 serum samples from 22 centres (22). Poor agreement was 
found between centers as positivity ranged from 50 to 93% and 13 to 70% for aβ2GPI 
IgG and aβ2GPI IgM detection, respectively (23). We excluded inter-laboratory variability 
and found the best agreement between BioPlex2200 and ACL AcuStar. However, OR for 
clinical features of APS obtained by BioPlex2200 were more comparable with an ELISA 
assay (QUANTA Lite ELISA) than an assay sharing the same solid phase (ACL AcuStar). 
BioPlex2200 and QUANTA Lite ELISA were in poor agreement but characterized by a 
comparable diagnostic accuracy. Our results highlight the importance of measuring 
both the agreement between assays as well as their diagnostic accuracy. It seems 
also important that in daily practice the four aPLs are measured with a same platform. 
Although some small differences exist in the diagnostic performance of the tested 
platforms, the values of sensitivity and specificity for APS related clinical symptoms and 
OR for clinical events are essentially comparable. This may be explained by the higher 
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agreement that was observed in samples with higher levels of aPL (Figure 1). That 
newer generation ELISA and automated systems show low agreement but comparable 
diagnostic accuracy was also illustrated in other studies (9,10,24–26).
In our study, guidelines from the SSC were followed by confirming manufacturer’s cut-
off values in at least 20 healthy volunteers (16). In practice, most laboratories transfer 
their cut-off values similarly, predominately due to practical difficulties to calculate the 
99th percentiles in a population of at least 120 healthy volunteers. Positivity for aPL 
not in agreement across the assays were characterized by lower median aPL titers. The 
majority of samples positive for aCL and/or aβ2GPI IgG/IgM detected by one assay, but 
not for all solid phase assays fulfilled the clinical criteria of APS, suggesting that higher 
cut-off values result in reduced sensitivity for APS. The clinical relevance of aPL levels 
below the 99th percentile, needs to be further studied (27). Lower levels of antibodies 
are observed especially in obstetric APS (28,29).
Variability between aPL detecting assays is hypothesized to result from pre-analytical, 
analytical, and post-analytical conditions, calibration and assay-specific issues (30,31). In 
our study, detection of aPL and analysis was performed by a single operator, eliminating 
inter-laboratory and inter-operator variation. Traditionally, aCL and aβ2GPI antibodies 
are detected by ELISAs. Nowadays, automated systems become available which are 
hypothesized to improve agreement (8). Automation of assays indeed improved intra-
laboratory and inter-laboratory reproducibility compared with non-automated ELISA. 
In general, ELISAs have shown large inter-laboratory variation and limited consensus in 
external quality control programs (11,12). The lack of international calibration standards 
makes the comparison between assays challenging. Efforts have been made for 
standardization by international reference materials, such as the Harris standards (pool 
of patient material and thus limited in production) and Koike standards (directed against 
a single epitope, thus decreasing the sensitivity of the assay in which it is used as aPL), 
although not reflecting the real life since aPL of patients are a heterogeneous group of 
antibodies [31]. Variation in aPL detection might be introduced by the heterogeneous 
origin of aPL, differences in assay design and a lack of standardization. All four tested 
aβ2GPI antibody detection assays make use of an antigen of human origin. However, 
for detection of aCL antibodies only BioPlex2200 uses human β2GPI and non-animal 
derived cardiolipin. Human antigen source is considered more specific than animal CL 
and/or β2GPI (6). Different preparations of human β2GPI have shown not to influence 
agreement in aβ2GPI IgG and IgM detection (32). Indeed, BioPlex2200 and QUANTA Lite 
ELISA showed high specificity for thrombosis and/or pregnancy morbidity. However, 
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our results show that the QUANTA Lite ELISA using purified cardiolipin and bovine β2GPI 
as antigen source resulted in the highest specificity for thrombosis and/or pregnancy 
morbidity.
Anti-β2GPI immunoassays detect antibodies against all five domains of β2GPI, including 
non-pathogenic antibodies, phospholipid-independent and low affinity aβ2GPI (6,33). 
The use of negative surface charge of the solid phase in aβ2GPI ELISAs have shown to 
increase the antigen density and exposure of cryptic epitopes of β2GPI such as Gly40-
Arg43 in domain I, mimicking the binding between negatively charged phospholipids 
and β2GPI (6,13,14). Variation in solid phase may lead to variability in exposure of the 
epitope Gly40-Arg43 (15). Hence, antibodies against the Gly40-Arg43 epitope are 
considered pathogenic and have shown to highly correlate with thrombosis (13,14,34). 
We used patient derived MoAB P1-117 and P2-6 to verify and assess variability in 
exposure of epitopes of β2GPI (7,15,17). We confirmed that the platform most sensitive 
in detecting P1-117 (the MoAB reactive against Gly40-Arg43 in domain I) by both the 
aCL and aβ2GPI IgG assay has the highest OR for thrombosis. Other platforms are 
less sensitive in detecting P1-117 compared to P2-6 (the MoAB recognizing β2GPI 
irrespective of its conformation), resulting in lower OR for thrombosis.
In conclusion, we found poor agreement between commercially available immunoassays 
detecting aCL and aβ2GPI IgG/IgM antibodies, which may hamper uniformity in the 
classification of aPL positive samples. However, computed OR for thrombosis and/or 
pregnancy morbidity in our study, considering results of the four aPL together, were 
globally concordant among solid phase test systems. Since our comparison between 
systems is based considering measurement of the four aPL within one test system, 
classification and follow-up of patients for aPL is preferable when performed with the 
same system.
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Background: The antiphospholipid syndrome (APS) is characterized by thrombosis and/
or pregnancy morbidity with the persistent presence of antiphospholipid antibodies 
(aPL). Triple-positivity, (i.e. positivity for lupus anticoagulant [LAC], anti-cardiolipin [aCL] 
and anti-β2glycoprotein I [aβ2GPI] antibodies) is associated with a high thrombotic risk.
Objectives: We investigated the variability in triple-positivity detection by measuring 
the same samples with four commercially available solid phase assays. In addition, the 
added clinical value of aPL in LAC positive patients was investigated, as well as the 
association of IgM triple-positivity and thrombosis.
Patients/Methods: We included 851 patients from seven European medical 
centers. Anti-CL and aβ2GPI IgG/IgM antibodies were determined by four platforms: 
BioPlex®2200, ImmunoCap®EliA, ACL AcuStar® and QUANTA Lite ELISA®.
Results: Triple-positivity detection by solid phase assays varied, ranging from 89 up to 
118 in thrombotic APS patients (n=258) of which 86 were detected independent of the 
platform. Lupus anticoagulant positivity resulted in an odds ratio (OR) for thrombosis 
of 3.4; triple-positivity (irrespective of the isotype) increased the OR from 4.3 up to 5.2, 
dependent on the platform. Triple-positivity solely for the IgM isotype did not increase 
the OR for thrombosis compared with LAC positivity. The highest OR for thrombosis was 
reached for positivity for IgG and IgM aβ2GPI and aCL (8.6 up to 28.9).
Conclusions: Triple-positivity proved to be highly associated with thrombosis, but 
identification is assay dependent. Within triple-positivity, IgM antibodies only have an 
added clinical value in patients positive for IgG antibodies.
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INTRODUC TION
The antiphospholipid syndrome (APS) is characterized by thrombosis and/or pregnancy 
morbidity with the persistent presence of antiphospholipid antibodies (aPL) [1]. 
Laboratory criteria include aPL detection by phospholipid-dependent coagulation 
tests referred to as lupus anticoagulant (LAC) or by quantitative solid phase assays 
measuring anti-β2glycoprotein I (aβ2GPI) and anti-cardiolipin (aCL) IgG/IgM antibodies 
[1]. Given the high-frequency of thrombosis irrespective of the syndrome, laboratory 
tests are of utmost importance for the classification of APS. Detection of aPL by solid 
phase assays is associated with high inter-laboratory and inter-method variation [2, 3]. 
Reports from external quality control programs illustrate that commercially available 
aPL assays produce variable results [4-6].
In order to improve the identification of patients at risk, it was suggested that APS 
patients should be evaluated according to their aPL profile [1, 7]. Combined positivity for 
LAC, aCL and aβ2GPI antibodies (i.e. triple-positivity) has shown to be associated with a 
high risk for both a first thrombotic event and recurrence [8-10]. In the NOH-APS study, 
a large observational study, triple-positivity was a predictor for thrombosis in purely 
obstetric APS patients [11]. However, computed risks for thrombosis of LAC positivity 
and triple-positivity were globally concordant, with the exception of pulmonary 
embolism [11]. Despite the high correlation of triple-positives with thrombosis, the 
predictive value is argued to originate from LAC positivity [12]. Recently, the detection 
of triple-positivity (i.e. positivity for LAC, aCL and aβ2GPI antibodies) was suggested to 
be method and platform independent [13].
Looking at the isotype of aPL, both IgG and IgM antibodies directed against cardiolipin 
and β2GPI are included in the Sydney criteria [1]. However, the clinical value of IgM 
antibodies in thrombotic APS is debated [14]. To date, the thrombotic association of IgM 
antibodies in aPL profiles like triple-positivity is not known. In this study we included 
851 patients from seven European medical centers. Four solid-phase assay platforms 
were selected based on frequency of use and the willingness of manufacturers to 
provide their assays. The samples were tested with all assays at one location by a single 
technician.
In a retrospective multicenter study we aimed to investigate the variability in triple-
positivity detection between different aPL detection platforms and the impact of the 
platform on the association of triple-positivity with thrombosis. In addition, we aimed 
to assess the added value of aPL detection in LAC positive patients and the impact of 





We included 851 patients from seven European medical centers. Classification of 
APS was based on the Sydney criteria [1]. Patients were classified by the local centers 
resulting in 258 thrombotic APS patients (APS thrombosis), 204 patients with a history 
of thrombosis and negative for laboratory criteria of APS (non-APS thrombosis), 196 
patients with an autoimmune disease other than APS, like systemic lupus erythematosus 
(52%) and systemic sclerosis (27%), without thrombotic complications (AID controls) 
and 193 controls that were referred for aPL testing for other reasons than the clinical 
criteria of APS, including subfertility and prolonged activated partial thromboplastin 
time (controls). Patients were enrolled within a timespan of 1 year, with patient samples 
stored less than 5 years. Thrombosis was objectively confirmed according the Sydney 
criteria [1]. The majority of thrombotic APS patients received anticoagulant therapy 
including vitamin K antagonists (VKA) (46%), low molecular weight heparins (LMWHs) 
(5%) and direct oral anticoagulants (DOACs) (4%). Twenty-seven patients (10%) received 
anti-platelet therapy and only 2% of patients with thrombotic APS received both 
anticoagulant and anti-platelet therapy. Details on anti-coagulant and anti-platelet 
therapy of the remaining 84 patients are not available. Women classified with obstetrical 
APS were excluded. The study was approved by the local ethical committees. Lupus 
anticoagulant positivity was determined by the local center, according to the ISTH-
SSC (International Society of Thrombosis and Haemostasis-Scientific Standardisation 
Subcommittee) guideline [15]
Solid phase assays
Commercially available solid phase assays (Supplemental Table 1) were selected based 
on frequently used assays in the external quality control program of the ECAT (External 
quality Control of diagnostic Assays and Tests, Leiden, The Netherlands) and the 
willingness of manufacturers for collaboration. Anti-CL IgG, aCL IgM, aβ2GPI IgG and 
aβ2GPI IgM antiphospholipid antibodies were detected by BioPlex®2200 (Bio-Rad, Bio-
Rad Laboratories, Hercules, USA), ImmunoCap®EliA (Thermo Fisher Scientific/Phadia, 
Uppsala, Sweden), ACL AcuStar® (Werfen/Instrumentation Laboratories, Bedford, USA) 
and QUANTA Lite ELISA® (Inova Diagnostics, San Diego, USA) in the Ghent University 
Hospital (Ghent, Belgium). Reagents used for the detection of aCL and aβ2GPI IgG/
IgM antibodies were measured with their corresponding instruments according to the 
manufacturer’s instructions. All four methods were performed in parallel runs of 40 
samples. Anti-phospholipid antibody titers were expressed in arbitrary units (GPL, MPL, 
U ml-1, SGU or SMU). All samples were measured by the same technician and values 
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below the calculated limit of detection (LOD) were replaced by the LOD. Manufacturer’s 
recommended cut-off values were used upon confirmation in 20 healthy volunteers, in 
accordance with the ISTH-SSC guideline [16].
Statistics
Significance of differences between aPL titers was determined with the Mann-Whitney 
U test. Diagnostic efficacy was assessed within the total population by sensitivity, 
specificity and odds ratios (ORs) using the statistical package for social sciences (SPSS 
23.0; SPSS, Chicago, IL) and MedCalc Statistical Software version 17.7.2 (MedCalc 
Software bvba, Ostend, Belgium). Statistical significance was set at P value less than 
0.05.
RESULTS
We measured aCL IgG/IgM and aβ2GPI IgG/IgM aPL in 833 individuals with a mean age 
of 46 years ranging from 16 to 87 years old (Table 1) with four commercially available 
assays (Supplemental Table 1). In our study population, venous thrombosis (VT), was 
more common than arterial thrombosis (AT), both in the APS and control group. In 
addition, primary APS (PAPS) was more prevalent than APS secondary to an underlying 
connective tissue disorder (SAPS).
From the 851 samples tested, 274 were LAC positive, and for these triple-positivity 
ranged from 106 (39%) up to 146 (53%) detected by QUANTA Lite ELISA® and 
BioPlex®2200, respectively (Table 2). In patients diagnosed with thrombotic APS (n=258), 
202 were positive for LAC. From these 202 LAC positive samples 118, 101, 111 and 89 
were defined as triple-positive (positivity for LAC, aCL IgG or IgM aβ2GPI IgG or IgM) 
detected with the solid phase assays: BioPlex® 2200, ImmunoCap® EliA, ACL AcuStar® 
and QUANTA Lite ELISA®, respectively (Table 2). By a comparison of two proportions, 
triple-positivity detection was found to be statistically different between BioPlex® 2200 
and QUANTA Lite ELISA® (P=0.0122). Other combinations proved not to be statistically 
different, although the comparison of ACL AcuStar® and QUANTA Lite ELISA® almost 
reached statistical significance (P=0.0586). Of the LAC positive patients not defined as 
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TABLE 2. Triple-positive patients detected with BioPlex®2200, ImmunoCap®EliA, ACL AcuStar® and QUANTA 
Lite ELISA® in patients with thrombotic antiphospholipid syndrome (APS), patients with non-APS thrombosis, 













APS Thrombosis (n 
= 258)
202 118 101 111 89
Non-APS Thrombosis 
(n = 204)
0 0 0 0 0
AID controls (n = 
196)
56 22 18 19 14
Controls 
(n = 193)
16 6 6 4 3
Total patient 
population (n = 851)
274 146 125 134 106
TABLE 3. Discrepancies in triple-positivity detection with pairwise comparison. Number of LAC-positive 
samples and those positive for aCL and aβ2GPI antibodies (irrespective of the isotype) detected by 
BioPlex®2200, ImmunoCap®EliA, ACL AcuStar® and QUANTA Lite ELISA®.
BioPlex® 2200 ImmunoCap® EliA ACL AcuStar®
- + - + - +
BioPlex® 2200 -
+
ImmunoCap® EliA - 696 30
+ 9 116
ACL AcuStar® - 704 13 706 11
+ 1 133 20 114
Quanta Lite ELISA® - 701 44 722 23 713 32
+ 4 102 4 102 4 102
Agreement of triple-positivity detection by solid phase assays was assessed by a 2 x 2 
contingency table within the total population (Table 3). Discrepancies varied between 
14 (BioPlex®2200 vs ACL AcuStar®) and 48 (BioPlex® 2200 vs QUANTA Lite ELISA®) 
individuals. In patients diagnosed with thrombotic APS (n=258) 118 triple-positives 
were detected by BioPlex® 2200 of which 86 patients were defined triple-positive, 
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independent of the solid phase assay used (Table 4). On the other hand, 32 patients 
were defined as triple-positive by BioPlex® 2200 but negative by all the other tested 
solid phase assays (Table 4). However, the majority of patients with discrepant results 
by the tested solid phase platforms have a history of thrombosis, illustrating clinical 
relevance (Table 4). Median aPL titers were calculated by aCL and aβ2GPI antibody titers 
above the cut-off. Triple-positives in agreement across all platforms displayed higher 
median aPL titers than triple-positive samples not positive for all tested platforms 
(Figure 1). Statistical difference was reached for BioPlex®2200 (P < 0.001), ACL AcuStar® 
(P < 0.001) and QUANTA Lite ELISA® (P = 0.0029), but not for ImmunoCap®EliA (P = 
0.5851), as shown in Figure 1.
The sensitivity of triple-positivity for thrombosis was low compared to LAC alone and 
varied from 19% (95% confidence interval [95% CI], 16-23%) up to 26% (95% CI, 22-30%) 
between the tested assays (Figure 2A). However, higher specificity for thrombosis was 
obtained, ranging from 93% (95% CI, 90-95%) up to 96% (95% CI, 93-97%), as shown in 
Figure 2(B). Lupus anticoagulant positivity resulted in an OR of 3.63 (95% CI, 2.76-4.76). 
Triple-positivity was statistically correlated with thrombosis, independent of the solid 
phase assay used to detect aCL and aβ2GPI IgG/IgM antibodies (Figure 2B). Odds ratios 
for thrombosis ranged from 4.3 (95% CI, 2.7-6.8) up to 5.2 (95% CI, 3.0-8.9) among the 
platforms (Table 5).
TABLE 4. Discrepancies in triple-positivity detection between BioPlex®2200, ImmunoCap®EliA, ACL AcuStar® 
and QUANTA Lite ELISA®. Number of triple-positives in (dis)agreement among all four solid phase assays in 











among all solid 
phase assays
APS-thrombosis 32 15 25 3 86
AID 10 6 7 2 12
Controls 3 3 1 0 3
Total 45 24 33 5 101
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FIGURE 1. Antiphospholipid antibody (aPL) titers of triple-positives in (dis)agreement. Log transformed aPL 
titers in agreement for all platforms tested are indicated by solid dots, disagreements are indicated by solid 
squares. Patients without the clinical criteria for the anti-phospholipid syndrome (APS) are indicated in red 
and patients with a history of thrombosis are indicated in black. Titers are expressed as the median value of 
positive aPL titers with interquartile ranges. AU, arbitrary units.
FIGURE 2. Diagnostic efficacy of lupus anticoagulant (LAC) and triple-positive patients detected by 
BioPlex®2200, ImmunoCap®EliA, ACL AcuStar® and QUANTA Lite ELISA®. (A) Sensitivity and (B) specificity for 
thrombosis (mean ± 95% confidence interval [95 % CI]).
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Triple-positivity for aCL IgG and aβ2GPI IgG or aCL IgM and aβ2GPI IgG IgM was 
significantly correlated with thrombosis, independent of the solid phase assay used. 
However, positivity for the IgM isotype (aCL IgM and aβ2GPI IgM) was more correlated 
with thrombosis than triple-positivity for the IgG isotype (aCL IgG and aβ2GPI IgG) 
upon aCL and aβ2GPI detection by BioPlex® 2200, ImmunoCap® EliA and ACL AcuStar®. 
On the other hand, triple-positivity for the IgG isotype was stronger correlated with 
thrombosis than for the IgM isotype upon detection of aPL by QUANTA Lite ELISA®. 
However, the majority of triple-positives for the IgM isotype were also positive for the 
IgG isotype (data not shown). Isolated triple-positivity for the IgG isotype increased the 
OR for thrombosis compared to LAC positivity only in two out of the four tested aPL 
solid phase assays (ACL AcuStar® and QUANTA Lite ELISA®), as shown in Table 5. In triple-
positivity, isolated IgM positivity did not increase OR compared with LAC. Moreover, 
isolated triple-positivity for the IgM isotype did not reach statistical difference when aPL 
were detected with BioPlex® 2200 and ACL AcuStar® (1.9 [95% CI, 0.6-5.4] and 2.0 [95% 
CI, 0.7-5.9], respectively). Positivity for all tested aPL (LAC, aCL IgG, aCL IgM, aβ2GPI IgG 
and aβ2GPI IgM) resulted in the highest OR for thrombosis ranging from 8.6 (95% CI 3.1-
24.4) up to 28.9 (3.9-212.4) detected by BioPlex® 2200 and ACL AcuStar® respectively.
TABLE 5. Correlation of aPL profiles with thrombosis. Odds ratios (ORs) with 95% confidence intervals (CIs) 
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DISCUSSION
Detection of aPL antibodies is accompanied by large inter-method and inter-laboratory 
variation [2, 4, 5, 17, 18]. Traditionally, aCL and aβ2GPI antibodies are detected by ELISA. 
Nowadays, more advanced (automated) systems are available, which are suggested to 
reduce inter-laboratory variation [4, 17, 19-21]. We excluded inter-laboratory variation, 
by detecting aCL and aβ2GPI antibodies in the same samples at one laboratory (Ghent, 
Belgium), carried out by a single technician. Despite many efforts, standardization 
of antiphospholipid antibody (aPL) assays is far from reached as poor consensus is 
obtained between assays when measuring the same sample [2, 20]. The identification 
of triple-positive patients was recently suggested to be less affected by inter-method 
variation, thereby better classifying APS patients at risk [13]. In a retrospective cross-
sectional study, the authors suggested that identification of patients with triple aPL 
positivity is platform and method independent, having compared two methods with a 
different solid phase from the same manufacturer [13]. However, they found a disparity 
of 6 or 9 triple-positives out of 220 patients (121 with APS and 99 with systemic lupus 
erythematosus), depending on the cut-off value used, already suggesting the presence 
of patients with low levels of aβ2GPI and aCL aPL titers and difficulties in reaching 
consensus in the classification of these patients [13, 22]. In our cohort, the highest 
discrepancy in number of triple-positive samples was found between BioPlex® 2200 
and QUANTA Lite ELISA® with a discrepancy of 29 triple-positives out of 202 LAC-
positive samples (14%). Similar to single positivity, identification of triple-positives 
was found to be assay dependent. In addition, we did not assess the variation of triple-
positivity detection introduced by LAC assays. Indeed, an external quality control 
program concluded that inter-method and inter-laboratory variation is higher in 
solid phase assays than LAC detection by dilute Russell's Viper Venom Time (dRVVT) 
assay [3]. However, still difficulties persist in reaching consensus among weak-positive 
samples [2-4, 23]. The presented variation in triple-positivity detection may therefore 
be underestimated. A possible limitation of our study is that thrombotic patients under 
treatment during the time of blood collection, could result in an increased risk of false 
positive LAC tests.
Samples positive for LAC, aCL and aβ2GPI antibodies by one solid phase platform but 
not by all four tested platforms have lower median aPL titers, suggesting difficulties in 
consensus on positivity among low aPL titers (Figure 1) [24] . We accept that the cut-off 
calculated by the 99th percentile of a normal population is the best consensus between 
sensitivity and specificity, and the clinical relevance of aCL and/or aβ2GPI results that 
are below the 99th percentile needs to be further studied [25]. Few studies showed that 
low titers of aCL also were predictive for thrombotic recurrence [26]. In this study, we 
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transferred the manufacturer’s cut-off after confirmation, as recommend by the ISTH-
SSC guidelines [16]. In terms of clinical practice, a recent questionnaire raised by the 
SSC showed that the majority of laboratories use the same approach, because only a 
minority of laboratories have the resources to calculate a cut-off value from at least 120 
normals. With this cut-off choice applied for all platforms, the majority of discrepant 
samples in our study were from patients that experienced a thrombotic event (Table 4).
A minority of non-thrombotic patients (n=582, auto-immune disease and controls) in 
our study population showed triple-positivity (n=17-28/583 or 2.9%-4.8%, depending 
on the platform). These should be regarded as asymptomatic carriers, what is in line 
with the findings of Mustonen et al. who found that 5% of asymptomatic triple-positives 
were carriers [27].
The association of thrombosis and single aPL positivity is debated because results are 
contrary. Recent studies showed that the risk of thrombotic events increases with the 
number of positive tests in APS patients and the creation of antibody profiles and test 
combinations increases the association with thrombosis [7, 8, 28-30]. On the other 
hand, another study showed a strong association between single aPL positivity and 
thrombosis in paediatric APS patients [31]. Although single positivity is not always 
significantly correlated with thrombosis, within the current guidelines all aPL have the 
same diagnostic value [1]. In our cohort, we confirmed the strong correlation between 
triple-positivity and thrombosis, as triple-positivity was significantly correlated with 
thrombosis independent of the platform used. A large observational study investigated 
the incidence of thrombosis in obstetric APS patients. Frequencies of thrombotic 
events were assessed in 517 APS patients, 279 women carrying a genetic thrombophilia 
polymorphism and 796 women with negative thrombophilia polymorphism results 
[11]. Computed risks for thrombosis of LAC positivity and triple-positivity were globally 
concordant [11]. However, triple-positivity was a predictor for pulmonary embolism, 
whereas LAC positivity alone was not [11]. In an Italian cohort, 618 patients were referred 
to aPL testing, of which 55% met the clinical criteria consistent with the Sapporo criteria 
[7]. A statistically significant correlation between LAC and thrombosis was found (OR 
4.4, 95% CI 1.5-13.3) [7]. In triple-positive patients the association with thrombosis 
increased even further (OR 33.3, 95% CI 7.0-157.6), suggesting an additional value of 
triple-positivity detection in thrombotic risk stratification [7]. Patient population and aPL 
detection method may impact the correlation of thrombosis with triple-positivity and 
the role of aCL and aβ2GPI antibodies in addition to LAC. It has already been shown that 
the presence of aCL and aβ2GPI of the same isotype reinforces the clinical probability 
of APS [32]. We confirmed that ORs for all platforms are higher for triple-positivity with 
concordance of isotype compared to triple-positivity including combinations of aCL 
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and aβ2GPI irrespective of isotype, except for one platform (QUANTA Lite ELISA®) with 
lower OR for IgM triple-positivity compared with the OR for triple-positivity irrespective 
of the isotype.
Our results clearly illustrate the wide variation in thrombotic association introduced 
by aPL detection methods. In LAC positives, “isolated” IgM or “isolated” IgG aPL was 
less correlated with thrombosis than triple-positivity irrespective of the isotype. 
Interestingly, positivity for LAC, aCL and aβ2GPI antibodies for both isotypes resulted in 
the strongest correlation with thrombosis. Therefore, both IgG and IgM antibodies are 
of added value in stratification of risk of thrombosis in APS. However, IgM did not add 
any value in thrombotic association to LAC positives in the absence of IgG aPL.
In conclusion, detection of triple-positivity varied among commercially available 
solid phase assays detecting aCL and aβ2GPI antibodies. However, triple-positivity 
(irrespective of the isotype) was statistically correlated with thrombosis, independent of 
the solid phase assay used. Except for one platform, concordance of isotype resulted in 
the highest OR. Detection of IgM antibodies in triple-positivity was only of added clinical 
value in combination with LAC, aCL IgG and aβ2GPI IgG positivity. These data confirm 
the high association of triple-positivity with thrombosis and show that the isotype and 
solid phase assay used to detect aPL affect the association with thrombosis. As triple-
positive APS patients have an increased risk of thrombotic recurrence, standardization 
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Background: The antiphospholipid syndrome (APS) is characterized by thrombosis 
and/or pregnancy morbidity with the persistent presence of lupus anticoagulant 
(LAC), anti-cardiolipin (aCL) and/or anti-b2glycoprotein I (aβ2GPI) antibodies of the 
immunoglobulin G/ immunoglobulin M (IgG/IgM) isotype. However, the role of aCL and 
aβ2GPI IgM as a serologic marker in APS is debated.
Objectives: We aimed to assess the diagnostic and clinical value of IgM antiphospholipid 
antibodies (aPL) in APS within the classification criteria.
Patients/Methods: Our multicenter study comprised of 1008 patients, including APS 
patients and controls. Anti-CL and aβ2GPI IgG and IgM antibodies were detected with 
four commercially available solid phase assays.
Results: Positivity for aCL and/or aβ2GPI antibodies was significantly correlated with 
thrombosis and pregnancy morbidity, independent of the isotype and solid phase assay. 
Higher odds ratios were obtained for IgG compared to IgM positivity. Isolated IgM was 
rare in thrombotic APS, but more frequent in obstetric APS, ranging from 3.5% to 5.4% 
and 5.7% to 12.3%, respectively, dependent on the solid phase assay. In a multivariate 
logistic regression analysis of aPL, IgM positivity was found to be associated with 
pregnancy morbidity. However, detection of IgM was not independently associated 
with thrombosis. Combined positivity for LAC, IgG and IgM was highly associated with 
thrombosis and pregnancy morbidity.
Conclusions: Our data support testing for aCL and aβ2GPI IgM in women suspected of 
obstetric APS. However, no added value was found for testing IgM in patients suspected 
of thrombotic APS. Still, IgM aPL might be useful as a second-line test to improve 
thrombotic risk stratification.
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INTRODUC TION
The antiphospholipid syndrome (APS) is characterized by thrombosis and/or pregnancy 
morbidity with the persistent presence of antiphospholipid antibodies (aPL) [1]. 
Obstetrical complications include fetal loss after the 10th week of gestation, recurrent 
early miscarriages and premature birth due to severe preeclampsia or intrauterine 
growth restriction [1]. Thrombotic APS is characterized by venous, arterial and/or small 
vessel thrombosis [1]. Diagnosis of APS predominantly relies on aPL assays detecting 
lupus anticoagulant (LAC) by a functional assay or detection of anti-cardiolipin (aCL) 
immunoglobulin G/ immunoglobulin M (IgG/IgM) antibodies and anti-β2glycoprotein 
I (aβ2GPI) IgG/IgM antibodies by solid phase assays [1–3]. Within the current criteria, 
persistent presence of either IgG or IgM aPL with associated thrombosis and/or 
pregnancy morbidity is sufficient for the classification of APS [1]. However, the value of 
IgM aCL and aβ2GPI antibodies in APS classification is debated [4–10].
Recently a meta-analysis aimed to assess the clinical value of IgM aCL and aβ2GPI 
antibodies in thrombotic APS and found a stronger thrombotic correlation for IgG 
than for IgM antibodies [4]. Studies that found a statistical association for aCL and 
aβ2GPI IgM antibodies with thrombosis mostly also found a significant association for 
the IgG isotype, suggesting a limited role of IgM in thrombotic APS [4]. In the meta-
analysis, two studies were included that found a protective role of IgM antibodies in 
thrombosis [4,11,12]. In 2006, another meta-analysis assessed the association between 
aCL antibodies and recurrent fetal loss in women without an autoimmune disease and 
found a statistical association for both isotypes (IgM and IgG) [6]. However, in both 
meta-analyses authors were unable to evaluate IgM antibodies as a single serologic 
marker, because of unavailability of separate IgG and IgM results [4,6]. In addition, 
comparison of clinical studies is difficult as multiple study designs are used with a wide 
variety of aPL assays. Solid phase assays are poorly standardized and external quality 
control programs have shown that aPL assays produce variable results [13,14].
More evidence has become available that hints towards evaluation of the complete aPL 
profile to improve risk stratification of APS patients [2,15–17]. In an observational study 
among purely obstetric APS patients, aCL and aβ2GPI positivity together with LAC (triple 
positivity) was a predictor of pulmonary embolism while single LAC positivity was not 
[18]. Another study found that the presence of any aPL at any time did not result in a 
significant increase in the risk of thrombotic recurrence, while the persistent presence 
of the same type increased the risk of thrombotic recurrence significantly [15]. Multiple 
aPL positivity at the same time or at different time points even further increased the risk 
of recurrence [15]. We have previously shown that the thrombotic association of IgM 
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antibodies within triple positive (positivity for LAC, aCL and aβ2GPI) patients is limited 
[19]. Here, we aimed to assess the value of IgM antibodies as a single serologic marker 
in APS and its clinical value in aPL profiles within the current classification criteria. Four 
commercially available solid phase assays were used, reducing assay dependency on 
the association of IgM antibodies and thrombosis or obstetric complications.
METHODS
Study population
Patient samples were collected from eight medical European centers within a timespan 
of one year, with patient samples stored less than five years at or below -80°C. The Sydney 
classification criteria were followed for the diagnosis of thrombotic and obstetric APS 
[1]. Thrombosis was defined as one or more clinical episodes of arterial, venous, or small 
vessel thrombosis, in any tissue or organ, confirmed by objective validated criteria (e.g. 
unequivocal findings of appropriate imaging studies or histopathology) [1]. Pregnancy 
morbidity was defined as: (1) one or more unexplained deaths of a morphologically 
normal fetus at or beyond the 10th week of gestation, with normal fetal morphology 
documented by ultrasound or by direct examination of the fetus; (2) one or more 
premature births of a morphologically normal neonate before the 34th week of 
gestation because of: eclampsia or severe pre-eclampsia defined according to standard 
definitions, recognized features of placental insufficiency; (3) three or more unexplained 
consecutive spontaneous abortions before the 10th week of gestation, with maternal 
anatomic or hormonal abnormalities and paternal and maternal chromosomal causes 
excluded [1]. Patients were classified as thrombotic or obstetric APS by the local center. 
Control populations consisted of patients with an autoimmune disease other than 
APS (e.g. systemic lupus erythematosus and systemic sclerosis) without thrombotic 
complications (autoimmune disease [AID] controls); patients that were referred for aPL 
testing for other reasons than the clinical criteria of APS (e.g. subfertility and prolonged 
activated partial thromboplastin time [aPTT], controls); patients with a previous 
thrombotic event negatively tested for aPL (non-APS thrombosis); and patients that 
experienced obstetric complications in the absence of aPL (non-APS obstetric). The 
study was approved by the local ethical committees.
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LABOR ATORY ASSAYS
Lupus anticoagulant
Lupus anticoagulant assays were performed by the local center, according to the 
International Society of Thrombosis and Haemostasis-Scientific Standardisation 
Subcommittee (ISTH-SSC) guideline [20]. Briefly, citrated blood was double centrifugated 
for 15 minutes at 2000 g (room temperature) [20]. After transferring the plasma in a 
non-activating plastic centrifuge tube, the plasma was centrifugated for an additional 
10 minutes at > 2500 g (room temperature) [20]. The obtained platelet poor plasma was 
tested for a prolonged clotting time with two tests based on different principles (e.g. 
aPTT and dilute Russell viper venom time). Lupus anticoagulant testing was performed 
by a three-step procedure including screening, mixing, and confirmation.
Solid phase assays
Commercially available solid phase assays were selected based on frequently used 
assays in the external quality control program of the ECAT (External quality Control 
of diagnostic Assays and Tests, Voorschoten, The Netherlands) and the willingness of 
manufacturers for collaboration. Anti-CL IgG, aCL IgM, aβ2GPI IgG and aβ2GPI IgM aPL 
were detected by four solid phase assays: BioPlex®2200 (Bio-Rad, Bio-Rad Laboratories, 
Hercules, USA), Phadia® (Thermo Fisher Scientific/Phadia, Uppsala, Sweden), ACL 
AcuStar® (Instrumentation Laboratories, Bedford, USA) and QUANTA Lite® ELISA 
(Inova Diagnostics, San Diego, USA) in the Ghent University Hospital (Ghent, Belgium). 
Detection of aCL and aβ2GPI antibodies was performed according manufacturer’s 
instructions. Manufacturer’s recommended cut-off values were used upon confirmation 
in 20 healthy volunteers, in accordance with the ISTH-SSC guideline [21].
Statistical analyses
Crude odds ratios for thrombosis were calculated within patients with thrombotic 
APS, non-APS thrombosis, AID controls and controls. Crude odds ratios for pregnancy 
morbidity were calculated within women with obstetric APS, non-APS obstetric 
APS, normal pregnancy, AID controls and controls. Differences in IgM titers above 
the threshold were assessed with the Mann-Whitney U test. In a multivariate logistic 
regression analysis, a backward variable selection was performed with variables having 
a P-value < 0.2. In order to evaluate independent variables for thrombosis, analysis 
was performed on the total population with a model including age, sex, pregnancy 
morbidity, LAC, IgG and IgM. Within women, age, thrombosis, LAC, IgG and IgM were 
included in the multivariate model to evaluate independent variables for pregnancy 
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morbidity. Odds ratios with their respective 95% confidence interval was determined 
for each variable in the final model. A P-value < 0.05 was regarded as statistically 
significant. Statistical analyses were performed using the statistical package for social 
sciences (SPSS 23.0; SPSS, New York, USA) and MedCalc Statistical Software version 
17.7.2 (MedCalc Software bvba, Ostend, Belgium).
RESULTS
Patient characteristics
We included 1008 patients of whom 75.7% were female with a mean age of 44 years 
(Table 1). Venous thrombosis was more prevalent compared to arterial thrombosis in 
thrombotic APS and non-APS thrombosis patients, 62% and 73% respectively (Table 
1). The majority of thrombotic APS patients received anticoagulant therapy including 
vitamin K antagonists (46%), low molecular weight heparins (5%) and direct oral 
anticoagulants (4%). Twenty-seven patients (10%) received antiplatelet therapy and 2% 
of patients with thrombotic APS received both anticoagulant and antiplatelet therapy. 
Details on anticoagulant and anti-platelet therapy of the remaining 84 patients were 
not available.
Diagnostic role of aCL and aβ2GPI IgG/IgM antibodies in thrombosis
Lupus anticoagulant positivity resulted in an odds ratio (OR) for thrombosis of 3.4 (95% 
confidence interval [95% CI], 2.5-4.7) (Table 2). Positivity for aCL or aβ2GPI antibodies 
was significantly associated with thrombosis, independent of the isotype or solid 
phase assay used (Table 2). Positivity for IgG aCL or aβ2GPI antibodies was more 
strongly correlated with thrombosis than IgM aCL or aβ2GPI antibodies (Table 2). Lupus 
anticoagulant, IgG aCL or aβ2GPI and IgM aCL or aβ2GPI were analyzed in a multivariate 
model in which IgM aCL or aβ2GPI antibodies resulted not to be an independent variable 
for thrombosis, independent of the solid phase assay used. In addition, we performed a 
subanalysis separately on patients with venous or arterial thrombosis in which IgM aCL 
or aβ2GPI antibodies were not an independent variable for both types of thrombosis 
(data not shown for the separate subpopulations). Within the multivariate model, lupus 
anticoagulant and IgG aCL or aβ2GPI antibodies were independent variables with OR 
between 2.3 (95%CI, 1.6-3.3) and 2.4 (95%CI, 1.7-3.4) and 2.3 (95%CI, 1.6-3.5) and 3.2 
(95%CI, 2.0-5.0), respectively (Table 2).
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Diagnostic role of aCL and aβ2GPI IgG/IgM antibodies in pregnancy 
morbidity
Similar to thrombosis, positivity for aCL or aβ2GPI antibodies was significantly 
associated with pregnancy morbidity, independent of the isotype or solid phase assay 
used (Table3). Positivity for IgG aCL or aβ2GPI antibodies clearly resulted in higher 
crude OR for obstetric complications than positivity for IgM aCL or aβ2GPI antibodies 
(Table 3). In contrast to thrombosis, IgM aCL or aβ2GPI antibodies was an independent 
variable for pregnancy morbidity with OR ranging between 1.7 (95% CI, 1.1-2.8) and 2.0 
(95% CI, 1.1-3.5). The OR of LAC positivity varied between 3.6 (95% CI,2.3-5.7) and 3.9 
(95% CI, 2.5-6.1) (Table 3). IgG aCL or aβ2GPI antibodies was an independent variable 
with three out of the four tested solid phase assays, resulting in OR between 1.9 (95% CI, 
1.1-3.2) and 2.5 (95% CI, 1.5-4.4).
Additional diagnostic value of aCL and aβ2GPI IgM antibodies in 
thrombotic patients
Positivity for IgM aCL or aβ2GPI antibodies ranged from 26% to 36% among thrombotic 
APS patients, 0% to 3.4% among non-APS thrombosis patients and 6.4% to 16% 
among patients with an autoimmune disease and controls (Table 4). Thrombotic APS 
patients with isolated IgM aCL or aβ2GPI positivity ranged from 3.5% to 5.4% (Table 
4). In addition, up to 2.5% patients classified as non-APS thrombosis were found to be 
isolated positive for IgM aCL or aβ2GPI antibodies (Table 4). The prevalence of isolated 
IgM aCL or aβ2GPI antibodies in controls and AID patients was 1.8% to 10% as detected 
by BioPlex®2200 and Phadia®, respectively (Table 4).
83
Is there a need to detect IgM antibodies in APS?



































































































Odds ratios (ORs) are shown with their respective 95% confidence interval. IgG antibodies, aCL, or aβ2GPI IgG 
antibodies; IgM antibodies, aCL, or aβ2GPI IgM antibodies; NS, nonsignificant
Multivariate analysis, adjusted for age, sex, and pregnancy morbidity.










































































































Odds ratios (ORs) are shown with their respective 95% confidence interval. IgG antibodies, aCL, or aβ2GPI IgG 
antibodies; IgM antibodies, aCL, or aβ2GPI IgM antibodies; NS, nonsignificant
Multivariate analysis, adjusted for age and thrombosis.
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FIGURE 1. Titers of patients with thrombosis or pregnancy morbidity positive for IgM antibodies versus 
controls (autoimmune disease and controls) positive for IgM antibodies. Log transformed IgM titers of 
patients with (A) thrombosis or (B) pregnancy morbidity are indicated in red and patients without the clinical 
criteria for APS are indicated in black. Titers are expressed as the median value of positive IgM titers with their 
95% confidence interval. * P-value < .05. NS, not significant; AU, arbitrary units
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LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG
+ - + - + - + - + - + - + -
IgM + 95 23 0 0 58 9 0 0 19 7 12 6 6 1
- 304 586 3 201 157 35 0 33 72 24 56 122 16 171




















LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG
+ - + - + - + - + - + - + -
IgM + 135 72 2 5 80 14 1 2 30 12 15 25 7 14
- 273 528 10 187 136 29 1 29 62 18 51 105 13 160




















LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG
+ - + - + - + - + - + - + -
IgM + 123 37 0 1 71 10 0 1 24 9 21 10 7 6
- 294 554 7 196 153 25 0 32 70 19 50 115 14 167




















LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG LAC/IgG
+ - + - + - + - + - + - + -
IgM + 113 56 0 1 70 14 0 2 24 15 15 19 4 5
- 276 563 5 198 143 32 1 30 66 17 47 115 14 171
Total 389 619 5 199 213 46 1 32 90 32 62 134 18 176
Note: figures indicate the number of patients testing positive or negative for IgM antibodies or LAC/IgG. 
A BioPlex®2200 B, Phadia® C, ACL AcuStar® and D, QUANTA Lite® ELISA. AID, autoimmune disease; APS 
antiphospholipid syndrome; IgG antibodies, aCL, or aβ2GPI IgG antibodies; IgM antibodies, aCL, or aβ2GPI IgM 
antibodies; LAC, lupus anticoagulant.
Additional diagnostic value of aCL and aβ2GPI I IgM antibodies in 
patients with pregnancy morbidity
Positivity for IgM aCL or aβ2GPI antibodies ranged from 21% to 34% among obstetric 
APS patients, 0% to 9.1% among non-APS obstetric patients (Table 2), and 6.4% to 16% 
among female patients with an autoimmune disease and controls. Isolated IgM aCL or 
aβ2GPI positivity ranged from 5.7% to 12.3% in APS-obstetric patients (Table 2). Up to 
6% of the patients classified as non-APS obstetric were found to be isolated positive for 
IgM aCL or aβ2GPI and up to 10% of female patients with an autoimmune disease and 




IgM antibody titers in thrombotic patients and controls
Positive IgM aCL or aβ2GPI antibody titers were compared between patients with 
thrombosis and controls (AID and control) within one solid phase assay. No significant 
difference in IgM aCL or aβ2GPI antibody titers was found between patients with 
thrombosis and our control population with the exception of one solid phase assay 
(Phadia®) (Figure 1A).
IgM antibody titers in obstetric patients and controls
IgM aCL or aβ2GPI antibody titers were not significantly different between patients 
with pregnancy morbidity and the control population with all solid phase assays tested 
(Figure 1B). Of note, maximum IgM aCL or aβ2GPI antibody titers measured were higher 
in thrombotic patients versus obstetric patients: 3708 versus 995 (BioPlex®2200), 1056 
versus 410 (Phadia®), 2798 versus 785 (ACL AcuStar®) and 320 versus 250 (QUANTA Lite® 
ELISA) of the respective units.
Additional clinical value of aCL and aβ2GPI I IgM antibodies in thrombotic 
patients
Within the current criteria positivity for either LAC, IgG aCL/aβ2GPI or IgM aCL/aβ2GPI 
is sufficient for classification of APS. In our cohort, these classification criteria resulted in 
OR between 2.4 (95% CI, 1.8-3.2) and 2.9 (95% CI, 2.2-3.9) (Table 5). Combined positivity 
for LAC and IgG aCL or aβ2GPI antibodies resulted in higher OR than combined positivity 
for LAC and IgM aCL or aβ2GPI antibodies with two out of the four tested solid phase 
assays. With the other solid phase assays, combined positivity for LAC and IgM aCL or 
aβ2GPI reached higher OR than positivity for LAC and IgG aCL or aβ2GPI. The variation 
in OR for thrombosis among solid phase assays increased in combined positivity for 
IgG aCL or aβ2GPI and IgM aCL or aβ2GPI antibodies from 2.6 (95% CI, 1.6-4.5) up to 7.1 
(95% CI, 3.0-16.7) (Table 5). The combination of positive LAC, IgG aCL or aβ2GPI and IgM 
aCL or aβ2GPI results is highly associated with thrombosis with OR between 5.5 (95% CI, 
2.6-11.8) and 9.6 (95% CI, 3.4-27.1) (Table 5).
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Note: Odds ratios (ORs) were calculated in a subpopulation of 853 patients consisting of thrombotic APS (n=259), 
non-APS thrombosis (n=204), AID controls (n=196) and controls (n=194). ORs are shown with their respective 95% 
confidence interval. IgG antibodies, aCL, and/or aβ2GPI IgG antibodies; IgM antibodies, aCL and/or aβ2GPI IgM 
antibodies; LAC, lupus anticoagulant
















































Note: Odds ratios (ORs) were calculated in a subpopulation of 483 patients consisting of, obstetric APS (n=122), 
non-APS obstetric (n=33), female AID controls (n=158) and female controls (n=170). ORs are shown with their 
respective 95% confidence interval. IgG antibodies, aCL, and/or aβ2GPI IgG antibodies; IgM antibodies, aCL and/or 
aβ2GPI IgM antibodies; LAC, lupus anticoagulant
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Additional clinical value of aCL and aβ2GPI IgM antibodies in patients 
with pregnancy morbidity
Positivity for either LAC, IgG and/or IgM antibodies resulted in OR between 4.9 (95% 
CI, 3.2-7.4) and 6.6 (95%CI, 4.3-10.0) (Table 6). In contrast to thrombosis, combined 
positivity for LAC and IgG aCL or aβ2GPI or LAC and IgM aCL or aβ2GPI antibodies did 
not increase the association with pregnancy morbidity compared to the classification 
criteria (Table 6). Positivity for LAC and IgG aCL or aβ2GPI antibodies resulted in OR 
between 2.5 (95% CI, 1.5-4.2) and 4.3 (95% CI, 2.2-8.6) (Table 6). Positivity for LAC and 
IgM aCL or aβ2GPI antibodies resulted in OR between 2.7 (95% CI, 1.3-5.6) and 3.5 
(95% CI, 1.5-8.3) (Table 6). The association between pregnancy morbidity and LAC, 
IgG and/or IgM aCL or aβ2GPI positivity were similar (Table 6). However, positivity for 
IgG aCL or aβ2GPI and IgM aCL or aβ2GPI antibodies resulted in a large variation of OR 
for pregnancy morbidity among solid phase assays. Combined positivity for IgG aCL 
or aβ2GPI and IgM aCL or aβ2GPI antibodies resulted in OR between 2.7 (95% CI. 1.4-
5.2) and 8.0 (95% CI, 3.1-20.2). IgM aCL or aβ2GPI positivity in combination with LAC 
and IgG aCL or aβ2GPI positivity is highly associated with pregnancy morbidity with OR 
between 4.9 (95% CI, 2.0-12.3) and 8.7 (95% CI, 2.8-26.6).
DISCUSSION
The role of IgM aCL or aβ2GPI antibodies as a serologic marker in APS is debated 
[1,4,7,8,22]. Although most studies were unable to demonstrate an association 
between IgM aCL or aβ2GPI antibodies and thrombosis, a questionnaire by the SSC of 
the ISTH indicated that most of the respondents found it too early to eliminate IgM aCL 
or aβ2GPI antibodies from the criteria [8]. We demonstrated a significant correlation for 
both IgG and IgM aCL and aβ2GPI antibodies with thrombosis as well as pregnancy 
morbidity. However, IgM positivity was mostly associated with positivity for LAC and/
or IgG aPL. The presence of isolated IgM antibodies in thrombotic APS patients was 
rare (3.5%-5.4%, Table 4), and not an independent variable for thrombosis. In addition, 
IgM aCL or aβ2GPI was not found to be an independent variable for arterial nor venous 
thrombosis. These results are in line with prospectively collected data from patients 
referred to Italian thrombosis centers in which only a minority of APS patients was 
found to be positive for predominantly aCL or aβ2GPI IgM antibodies (>40 MPL units 
and < 40 GPL units) [16]. A thrombotic association of true isolated IgM has not been 
reported in literature. One study concluded that “isolated” IgG antibodies are more 
prevalent in deep venous thrombosis and pulmonary embolism while “isolated” aCL 
IgM antibodies were frequently found in patients with a cerebrovascular infarction [23]. 
However, patients were only tested for aCL and aβ2GPI IgG/IgM antibodies and not for 
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LAC, rendering the identification of true isolated IgG or IgM antibodies impossible [23]. 
While we showed that IgM was not an independent variable of thrombosis along with 
LAC and IgG, another study even found that in SLE patients aβ2GPI IgM antibodies were 
protective against lupus nephritis and renal damage [24].
Within the current aPL-panel, LAC is considered the strongest predictor of thrombosis 
and pregnancy morbidity [25,26]. In 2003, a meta-analysis assessed the role of LAC and 
aCL antibodies in thrombosis. Computed ORs for both LAC and aCL positivity were only 
available in five studies of which none was able to illustrate a significant association 
between thrombosis and IgG or IgM aCL antibodies [26]. We found an association 
between LAC as well as aCL antibodies and thrombosis, independent of the isotype 
and solid phase assay used. As argued by de Groot et al most of the studies included 
in the meta-analysis did not follow the ISTH-SSC guidelines, in which it is stated that 
aCL antibodies should bind to cardiolipin in a b2GPI-dependent manner [1,3,27–29]. A 
more recent meta-analysis included studies between 2001 and 2014 and showed that 
aCL antibodies are associated with thrombosis, especially aCL IgG antibodies [4]. In our 
cohort, LAC was an independent variable for thrombosis, illustrating its importance 
in thrombotic APS. In addition, LAC showed the highest association with pregnancy 
morbidity within the current aPL panel.
Thrombotic and obstetric APS are hypothesized to have a distinct aPL profile with more 
frequent IgM positivity in obstetrical APS [30]. Our results suggest comparable IgM 
positivity in obstetrical APS to thrombotic APS, 21%-34% and 26%-36%, respectively 
(dependent on the solid phase assay). However, LAC, aCL, and aβ2GPI IgG/IgM 
antibodies were found to be independently associated with pregnancy morbidity. 
In contrast, IgM was not independently associated with thrombosis. In agreement, a 
systematic review and meta-analysis found a significant association of LAC, aCL IgG/
IgM, and aβ2GPI IgG/IgM antibodies with pre-eclampsia and fetal death [31]. Another 
study found that positivity for LAC, aCL IgG, and aCL IgM were associated with recurrent 
fetal loss in women without autoimmune disease [6]. In the same study, no significant 
association was found between aβ2GPI positivity and recurrent loss, presumably due 
to the small study population [6]. In a population-based, case-control study, aPL were 
measured in 582 stillbirth deliveries and 1547 live birth deliveries [32]. Women with a 
stillbirth were found to be more likely to have elevated aCL and aβ2GPI IgG levels, but 
not aCL and aβ2GPI IgM levels compared to those with term live births [32]. We found 
a significant association between aCL IgM or aβ2GPI IgM antibodies and pregnancy 
morbidity, but were not able to differentiate in subgroups due to unavailability 
of detailed description of obstetric complications. The PROMISSE (Predictors of 
pRegnancy Outcome: bioMarkers In antiphospholipid antibody Syndrome and 
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Systemic lupus Erythematosus) study has shown that LAC is the primary predictor of 
obstetric complications after 12 weeks of gestation in aPL associated pregnancies [25]. 
Positivity for aCL and aβ2GPI antibodies did not predict adverse pregnancy outcomes 
if LAC was absent [25]. In contrast, we found that positivity for aCL and aβ2GPI IgG and 
IgM were independently associated with a history of pregnancy morbidity. However, 
LAC showed the highest association with pregnancy morbidity within the current aPL-
panel. In addition, the presence of isolated IgM antibodies in obstetric APS patients was 
rare (5.7%-12.3%, Table 4), dependent on the solid phase assay.
Some studies found a strong correlation of high aPL titers with clinical manifestations 
of APS [9,33–35]. However, previous reports on the association between aPL titers 
and pregnancy morbidity are conflicting [32,36,37]. In a retrospective study a higher 
cut-off value did not result in a stronger association with stillbirth [32]. Another study 
assessed whether there is a relationship between low aPL levels and obstetrical 
complications [36]. The authors found that patients with low aPL titers have similar 
obstetrical outcomes compared to confirmed APS patients [36]. In contrast, the risk 
of adverse fetal/neonatal outcome was found to be higher in APS-obstetrical patients 
with high aPL titers (≥ 4 times upper limit of normal) compared to APS-obstetrical 
patients with aPL titers < 4 times the upper limit of normal [37]. Our results showed 
that IgM titers were not significantly different between obstetrical patients and our 
control population. Of note, the maximum IgM titer measured in obstetric patients was 
lower than the maximum titers measured in thrombotic patients. In addition, patients 
with a history of thrombosis did not have significant differently IgM titers than patients 
without thrombosis. Future studies are needed to investigate the relationship between 
aPL titers and clinical manifestation of APS in more detail. Categorizing aPL titers into 
low, medium and high positivity might help to study the correlation between aPL titers 
and thrombosis or pregnancy morbidity.
In APS, multiple aPL positivity (aPL profiles) have shown to be of added value in 
thrombotic risk stratification [15,17,38]. In agreement we found that OR for thrombosis 
were highest in patients positive for LAC, IgG, and IgM. One study assessed the role of 
aβ2GPI and aCL antibodies in 87 LAC positive patients and found that the presence of 
IgG but not IgM antibodies in LAC-positives predicts an increased risk of thrombosis 
[39]. We found that combined positivity for LAC and IgG as well as combined positivity 
for LAC and IgM were significantly associated with thrombosis. However, in two out of 
four solid phase assays OR of combined LAC and IgG aCL or aβ2GPI was higher than 
positivity for LAC and IgM aCL or aβ2GPI. Within pregnancy morbidity, combined 
positivity for LAC and IgG or positivity for LAC and IgM did not increase the OR compared 
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to the current criteria aPL-panel. Combined positivity for LAC, IgG, and IgM was more 
associated with pregnancy morbidity than the current aPL-panel with three out of the 
four tested solid phase assays.
Diagnosis of APS is dependent on laboratory tests detecting aPL antibodies [10,14,40]. 
Currently no gold standard exists for the detection of aPL antibodies. Solid phase 
assays are poorly standardized and many studies have shown that different results are 
obtained by measuring the same sample [10,14]. In addition, studies have shown that 
solid phase assays are associated with a large inter-laboratory variation [10,41]. In order 
to be independent of the solid phase assay used and minimize the interlaboratory and 
interindividual variation in aPL detection, a single operator performed all assays within 
one laboratory. Although we demonstrated a largely similar clinical performance for 
all platforms, these data indicate that results for single parameters may vary between 
platforms. One of the four tested solid phase assay was unable to demonstrate a 
significant association between IgG aCL or aβ2GPI antibodies and pregnancy morbidity 
within a multivariate model, while IgG aCL or aβ2GPI was an independent variable 
within the other tested solid phase assays. In addition, combinations of IgG and IgM 
showed higher variation of OR among the solid phase assays. Combined positivity for 
LAC, IgG, and IgM aCL or aβ2GPI antibodies was highly associated with thrombosis 
and pregnancy morbidity. However, calculated OR varied strongly among solid phase 
assays, accompanied with wide 95% confidence intervals.
In conclusion, in a large multicenter study aCL and aβ2GPI IgM antibodies were 
significantly correlated with clinical features of APS. However, IgM is only independently 
associated with pregnancy morbidity and not with thrombosis. Altogether, our data 
support the usage of two separate decision trees for thrombosis versus pregnancy 
morbidity, in which aCL and aβ2GPI IgM is tested in women suspected of obstetric APS 
but not in patients suspected of thrombotic APS (Figure 2A-B). However, IgM aPL might 
be useful as a second line test to improve thrombotic risk stratification in LAC- and/or 
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Background: Anticardiolipin (aCL) and anti-β2glycoprotein I (aβ2GPI) immunoglobulin 
A (IgA) antiphospholipid antibodies (aPL) have shown to associate with thrombosis and 
pregnancy morbidity. However, inclusion of IgA aPL in the classification criteria of the 
antiphospholipid syndrome (APS) has been debated.
Objectives: We investigated the value of aCL and aβ2GPI IgA aPL in the detection of 
thrombosis and pregnancy morbidity in addition to the current aPL panel for APS.
Methods: We included 1,608 patients from eight European medical centers: 259 
thrombotic APS patients, 122 obstetric APS patients, 204 non-APS thrombosis patients, 
33 non-APS obstetric patients, 60 APS patients with unspecified clinical manifestations, 
196 patients with autoimmune diseases and 194 controls. aCL and aβ2GPI IgG/M/A 
were detected with four commercial assays and lupus anticoagulant was determined 
by the local center.
Results: Positivity for IgA aPL was found in 17 to 26% of the patients with clinical 
manifestations of APS and in 6 to 13% of the control population. Both aCL and aβ2GPI 
IgA were significantly associated with thrombosis and pregnancy morbidity. Isolated 
IgA positivity was rare in patients with clinical manifestations of APS (0.3-5%) and not 
associated with thrombosis and/or pregnancy morbidity. Addition of IgA to the current 
criteria panel did not increase odds ratios for thrombosis nor pregnancy morbidity.
Conclusions: aCL and aβ2GPI IgA are associated with clinical manifestations of 
APS. However, isolated IgA positivity was rare and not associated with thrombosis 
or pregnancy morbidity. These data do not support testing for aCL and aβ2GPI IgA 
subsequent to conventional aPL assays in identifying patients with thrombosis or 
pregnancy morbidity.
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INTRODUC TION
Clinical manifestations of the antiphospholipid syndrome (APS) include thrombosis 
and pregnancy morbidity (1). However, these manifestations occur frequently and 
often independent of APS. Therefore, classification of APS predominantly relies on 
antiphospholipid (aPL) assays detecting lupus anticoagulant (LAC) by coagulation tests 
or detection of anticardiolipin (aCL) and anti-β2glycoprotein I (aβ2GPI) antibodies from 
the immunoglobulin G (IgG) or immunoglobulin M (IgM) isotype by solid-phase assays 
(1,2). aCL and aβ2GPI antibodies from the IgA isotype are not included in the current 
classification criteria (1,2). Multiple studies have illustrated an association of aCL and 
aβ2GPI immunoglobulin A (IgA) antibodies with thrombosis and pregnancy morbidity 
(3–12). Still, aCL and aβ2GPI IgA are not included in the current guidelines (1,2). The 
main reason is unavailability of data to show the clinical significance of aCL or aβ2GPI 
IgA with clinical manifestations of APS in addition to the current aPL panel (1,13).
In a mouse model for thrombosis, IgA antibodies isolated from APS patients resulted in 
increased thrombus area, faster thrombus formation and decreased time of thrombus 
disappearance compared with control IgA (14). Outcomes of clinical studies have 
been contradictory regarding the association of aCL and/or aβ2GPI IgA with clinical 
symptoms of APS and their role in identifying additional APS patients with thrombosis 
or pregnancy morbidity (3–12,15,16). Multiple studies have shown that IgA is associated 
with thrombosis and pregnancy morbidity (3–12), other studies report no association 
of aCL or aβ2GPI IgA with thrombosis or pregnancy morbidity (15,16). Isolated aCL 
and/or aβ2GPI IgA positivity was often found not to be associated with thrombosis 
or pregnancy morbidity (4,9,15–17). However, some studies concluded that aCL and/
or aβ2GPI IgA is an independent risk factor for thrombosis (6,10,18). In addition to the 
clinical manifestations of APS, IgA positivity has also been associated with systemic 
lupus erythematosus (SLE), thrombocytopenia, heart valve disease, livedo reticularis 
and epilepsy (5,19). Comparison of clinical studies is difficult as multiple study designs 
are used with a wide variety of aPL assays and aPL cut-off values. Furthermore, solid-
phase assays detecting aCL and aβ2GPI antibodies are poorly standardized and produce 
variable results in a head-to-head comparison (20–22).
In this multicenter study, we used four commercially available solid-phase assays to 
detect aCL and aβ2GPI IgG/M/A, to assess for an association of aCL and aβ2GPI IgA 
and thrombosis or obstetric complications. A total of 1,608 patients were included of 
which 678 patients with clinical manifestations of APS and 390 patients who served 
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as controls. We aimed to assess the added value of aCL and aβ2GPI IgA antibodies as 
a biomarker for thrombosis and pregnancy morbidity within the current aPL panel 
consisting of LAC, aCL IgG/M, and aβ2GPI IgG/M.
MATERIALS AND METHODS
Study population
A total of 1,608 patient samples were collected from eight medical European centers. 
The Sydney classification criteria were followed for the classification of thrombotic 
and obstetric APS (Table 1) (1). Classification of thrombotic or obstetric APS was 
determined by the local center. In addition to APS patients, we included patients with 
an AID other than APS (e.g., 54% SLE and 29% systemic sclerosis) without thrombotic 
complications (AID controls); patients that were referred for aPL testing for other 
reasons (e.g., subfertility and prolonged activated partial thromboplastin time [aPTT]) 
than the clinical criteria of APS (controls); patients with a previous thrombotic event 
and negatively tested for aPL (non-APS thrombosis); and patients who experienced 
obstetric complications in the absence of aPL (non-APS obstetric). The study was 
approved by the local ethical committees.
LABOR ATORY ASSAYS
Lupus anticoagulant
LAC assays were performed by the local center, according to the International Society 
of Thrombosis and Haemostasis-Scientific Standardization Subcommittee (ISTH-
SSC) guideline (23). Briefly, citrated plasma was tested in a multiple-step procedure 
(screening, mixing, confirmation step) with two test systems based on different 
principles (LAC-sensitive aPTT and dilute Russell viper venom time) (1,23).
Solid-phase assays
Commercially available solid-phase assays were selected based on frequently used 
assays in the external quality control program of the ECAT (External quality Control 
of diagnostic Assays and Tests, Voorschoten, The Netherlands) and the willingness of 
manufacturers for providing the reagents. aCL and aβ2GPI antibodies from the IgG, IgM 
and IgA isotype were detected at one occasion by four solid-phase assays: BioPlex2200 
(Bio-Rad, Bio-Rad Laboratories, Hercules, USA), Phadia (Thermo Fisher Scientific/Phadia, 
Uppsala, Sweden), HemosIL AcuStar (Instrumentation Laboratories, Bedford, USA) and 
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QUANTA Lite ELISA (Inova Diagnostics, San Diego, USA) in the Ghent University Hospital 
(Ghent, Belgium). Detection of aCL and aβ2GPI antibodies was performed according 
to manufacturer’s instructions. Manufacturer’s recommended cut-off values were used 
upon confirmation in 20 healthy volunteers, in accordance with the ISTH-SSC guideline 
(Supplemental Table 1) (24).
Statistical analyses
Associations of aCL and aβ2GPI IgA positivity and clinical manifestations of APS were 
assessed by calculating odds ratios (ORs) with their respective 95% confidence intervals 
(CIs). Thrombotic association with IgA aPL was assessed within patients with thrombotic 
APS, non-APS thrombosis, AID controls and, controls (n = 853). Obstetric association 
with IgA aPL was assessed within female patients with obstetric APS, non-APS obstetric 
APS, AID controls and controls (n = 483). The additional diagnostic value of aCL and 
aβ2GPI IgA antibodies was assessed by 2 x 2 contingency tables. Kruskal–Wallis test 
was used to evaluate differences in IgA titers. To compare numbers (percentages) of 
positive tests between systems, the comparison of two proportions (from independent 
samples) was used. Statistical analyses were performed using the statistical package for 
social sciences (SPSS 23.0; SPSS, Chicago, IL) and MedCalc Statistical Software version 
17.7.2 (MedCalc Software bvba, Ostend, Belgium). Statistical significance was set at 
P-value less than 0.05.
RESULTS
Patient characteristics
We included 1,608 patients of which 678 patients had clinical manifestations of APS and 
390 controls (Table 1). In thrombotic APS, venous thrombosis was more prevalent than 
arterial thrombosis (160 [62%] versus 55 [21%] patients, respectively; Table 1). From 
the 204 non-APS thrombotic patients, 149 (73%) had a history of venous thrombosis 
and 47 (23%) had a history of arterial thrombosis (Table 1). From the 259 thrombotic 
APS patients, the majority (40%) received Vitamin K antagonists, 5% received low-
molecular-weight heparin, 4% direct oral anticoagulants, 10% antiplatelet therapy, 8% 
a combination of oral anticoagulants and antiplatelet therapy. Details on anticoagulant 
and antiplatelet therapy of the remaining 83 (32%) patients are not available. Patients 
classified as non-APS thrombosis and non-APS obstetric were negatively tested 
for criteria aPL by the local medical center. However, retesting of the 204 non-APS 
thrombosis patients resulted in 1.5 to 8% positives for aCL and/or aβ2GPI IgG/IgM, 
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depending on the solid-phase assay (Table 2). Retesting of 33 non-APS obstetric 
patients resulted in 0 to 12% positives for aCL and/or aβ2GPI IgG/IgM, depending on 
the solid-phase assay (Table 2).
Prevalence of (isolated) aCL and/or aß2GPI IgA
Among patients with clinical manifestations of APS, 17 to 26% tested positive for aCL 
and/or aβ2GPI IgA antibodies (Table 2). Positivity for aCL and/or aβ2GPI IgA antibodies 
in thrombotic APS ranged between 26 and 37%, depending on the solid-phase assay 
used to detect IgA antibodies (Table 2). Within obstetric APS, positivity for aCL and/or 
aβ2GPI IgA ranged between 16 and 34%, depending on the solid-phase assay (Table 
2). In the control group, consisting of AID patients and controls 6 to 8% were positive 
for aCL and/or aβ2GPI IgA aPL (Table 2). Isolated positivity for aCL and/or aβ2GPI IgA 
(positive for IgA with negative LAC, IgG and IgM results) was rare in thrombotic and 
obstetric patients with a prevalence of 0 to 3% and 1 to 5%, respectively (Table 2). 
Within AID and controls, isolated aCL and/or aβ2GPI IgA positivity ranged between 1 
and 4% (Table 2). With two (BioPlex2200 and HemosIL AcuStar) out of the four tested 
solid-phase assays, only 1% of the total study population was positive for IgA with 
negative LAC, IgG, and IgM results (Table 2). The other two solid-phase assays detected 
more isolated IgA patients, 2% (Phadia) and 3% (QUANTA Lite ELISA) (Table 2).
Correlation of aCL and/or aß2GPI IgA with criteria aPL
Within the total population consisting of 1,608 patients, 408 (38%) were positive 
for LAC, thereby the most prevalent aPL (Supplemental Table 2). IgG was the most 
prevalent aCL or aβ2GPI antibody isotype in the total study population (Supplemental 
Table 2). Only 6% of the total patient population was positive for aCL IgA, detected 
with QUANTA Lite ELISA (Supplemental Table 2). By a comparison of two proportions, 
a significant difference (P < 0.0001) was found for the number of patients positive for 
aCL IgA and aCL IgM, detected with either BioPlex2200 or Phadia. Detection of aβ2GPI 
IgM and IgA resulted in a significant difference in number of positive samples with the 
BioPlex2200 system only (P = 0.0001). aβ2GPI IgG was more prevalent than aβ2GPI IgA 
antibodies, except when detected with BioPlex2200 (P = 0.0007). By a comparison of 
two proportions, significant differences were found between aCL IgG and aCL IgA for all 
solid-phase assays. Prevalence of aPL in the subgroups (controls, AID, APS thrombosis, 
non-APS thrombosis, APS obstetric, non-APS obstetric, and APS patients) are shown 
in Supplemental Table 2. LAC and aCL or aβ2GPI IgA were highly correlated, as 63 to 
80% IgA-positive patients were also characterized by positive LAC results (data not 
shown). Similarly, 72 to 83% of the patients positive for aCL IgG, were also positive for 
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or aβ2GPI IgM were less correlated with LAC, 59-74% and 72-75%, respectively. Upon 
detection with BioPlex2200, positivity for IgA aPL also highly correlated with triple 
positivity. Within the total population, the BioPlex2200 identified 221 triple positive 
patients of which 162 (73%) were positive for aCL and/or aβ2GPI IgA antibodies. Other 
solid-phase assays tested showed less correlation between IgA aPL and triple positivity 
(Phadia [49%], HemosIL AcuStar [60%] and QUANTA Lite ELISA [48%]).
Association of aCL and/or aß2GPI IgA with thrombosis and pregnancy 
morbidity
Both aCL and aβ2GPI IgA positivity were significantly associated with thrombosis (Table 
3). Positivity for aCL IgA reached ORs for thrombosis of 3.0 (95% CI, 1.9-4.9) to 9.9 (95% 
CI, 3.5-27.8) (Table 3). aβ2GPI IgA positivity showed ORs for thrombosis between 2.4 
(95% CI, 1.5-3.9) and 3.1 (95% CI, 1.9-5.2) (Table 3). A stronger thrombotic association 
was found with aCL IgA assays than with the aβ2GPI IgA assay (Table 3). Detection of 
aCL IgA with QUANTA Lite ELISA reached the highest OR for thrombosis (9.9; 95% CI, 
3.5-27.8) (Table 3). However, from the 47 patients positive for aCL IgA, only 43 patients 
with a history of thrombosis were detected with this assay, while the aCL IgA assay from 
BioPlex2200 detected 130 patients of which 100 patients with a history of thrombosis 
(Table 3). Positivity for aCL and/or aβ2GPI IgA reached comparable ORs for thrombosis, 
between the tested assays with ORs between 2.2 (95% CI, 1.4-3.5) and 3.0 (95% CI, 2.0-
4.5) (Table 3).
Positivity for both aCL and aβ2GPI from the same isotype is considered to be more 
reliable for diagnosis of APS. ORs for thrombosis did not increase in patients positive 
for aCL and aβ2GPI IgA aPL, compared with patients positive for aCL IgA or aβ2GPI IgA 
when detected with the BioPlex2200 and HemosIL AcuStar (Table 3). The other two 
tested solid-phase assay showed an increase of OR for thrombosis in patients positive 
for aCL and aβ2GPI IgA compared with ORs obtained from the aCL and aβ2GPI IgA assay 
separately, most pronounced for QUANTA Lite ELISA (Table 3). In comparison, patients 
positive for both aCL and aβ2GPI IgG were characterized with a similar or slightly higher 
OR than positivity for aCL IgG or aβ2GPI IgG (Supplemental Table 3). However, the 
increase in OR for double IgG positivity for QUANTA Lite ELISA was less pronounced 
compared with the increase observed in double IgA positivity for that platform. Also, 
for the IgM isotype similar results were obtained (Supplemental Table 3). Patients 
positive for both aCL and aβ2GPI IgM antibodies were characterized with similar ORs for 
thrombosis than OR from an aCL IgM or aβ2GPI IgM assay alone (Supplemental Table 3).
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TABLE 3. Thrombotic and obstetric association of aCL and aβ2GPI IgA antibodies
BioPlex2200 Phadia HemosIL AcuStar QUANTA Lite ELISA
Thrombosis
aCL 3.3 (2.1-5.1) 3.1 (1.6-6.1) 3.0 (1.9-4.9) 9.9 (3.5-27.8)
n 130 49 101 47
aβ2GPI 2.8 (1.8-4.3) 2.4 (1.5-3.9) 2.5 (1.5-4.0) 3.1 (1.9-5.2)
n 124 94 88 91
aCL and/or aβ2GPI 3.0 (2.0-4.5) 2.2 (1.4-3.5) 3.0 (1.9-4.9) 3.0 (1.8-4.8)
n 133 103 101 99
aCL and aβ2GPI 3.1 (2.0-4.8) 4.2 (1.8-9.6) 2.4 (1.5-4.0) 35.8 (4.8-254.5)
n 121 40 88 39
Pregnancy morbidity
aCL 3.6 (2.1-6.1) 3.5 (1.5-8.3) 2.4 (1.3-4.5) 5.0 (1.5-16.5)
n 67 23 47 13
aβ2GPI 2.9 (1.7-4.9) 1.9 (1.0-3.5) 2.2 (1.2-4.1) 2.7 (1.4-5.3)
n 65 42 45 37
aCL and/or aβ2GPI 3.6 (2.1-5.9) 1.8 (1.0-3.4) 2.6 (1.4-4.7) 2.4 (1.3-4.6)
n 73 49 48 41
aCL and aβ2GPI 2.9 (1.7-5.0) 4.9 (1.7-14.5) 2.1 (1.1-3.9) 17.8 (2.2-143.6)
n 59 16 44 9
Abbreviations: aβ2GPI, anti-β2 glycoprotein I; aCL, anticardiolipin; CI, confidence interval; n, number of patients 
positive for aCL or aβ2GPI IgA within the population; OR, odds ratio. Note: Odds ratios for thrombosis are calculated 
in a subpopulation including controls, AID, non-APS thrombosis, and APS thrombosis patients (n = 853). Odds 
ratios for pregnancy morbidity are calculated in a female subpopulation including controls, AID, non-APS obstetric, 
and APS obstetric patients (n = 483).
IgA aPL was significantly correlated with pregnancy morbidity, independent of the 
solid-phase platform (Table 3). Similar to thrombosis, the aCL IgA assay from QUANTA 
Lite ELISA reached the highest OR (5.0 (95% CI, 1.5-16.5)) for pregnancy morbidity 
(Table 3). Double positivity for IgG or IgM resulted in slightly higher OR for three out of 
the four platforms (supplemental Table 4). Double positivity for IgA (Table 3) resulted 
in significant higher OR for one platform (QUANTA Lite ELISA), in agreement with the 
thrombosis results.
Association of aCL and aβ2GPI IgA was calculated separately for venous and arterial 
thrombosis (Supplemental Table 5). ORs for venous thrombosis (n = 309) ranged from 1.8 
(95% CI, 1.1-2.8) to 7.0 (95% CI, 2.4-20.7) and 1.8 (95% CI, 1.1-3.0) to 2.4 (95% CI, 1.4-4.2) 
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for aCL and aβ2GPI IgA, respectively (Supplemental Table 5). ORs for arterial thrombosis 
(n = 102) ranged from 2.2 (95% CI, 1.2-4.0) to 14.1 (95% CI, 4.5-44.3) and 2.9 (95% CI, 1.5-
5.6) to 3.8 (95% CI, 1.9-7.4) for aCL and aβ2GPI IgA, respectively (Supplemental Table 5).
TABLE 4. Thrombotic and obstetric association of isolated aCL and aβ2GPI IgA antibodies
BioPlex2200 Phadia HemosIL AcuStar QUANTA Lite ELISA
Thrombosis
aCL 0.6 (0.1-3.4) 1.3 (0.4-4.5) 0.5 (0.4-0.5) 1.7 (0.2-18.7)
n 5 10 4 3
aβ2GPI 0.5 (0.4-0.5) 1.1 (0.4-2.9) 0.5 (0.4-0.5) 0.6 (0.3-1.5)
n 4 16 4 23
aCL and/or aβ2GPI 0.4 (0.08-2.3) 0.9 (0.4-2.2) 0.5 (0.4-0.5) 0.7 (0.3-1.6)
n 6 21 4 26
aCL and aβ2GPI 0.5 (0.4-0.5) 3.4 (0.4-30.5) 0.5 (0.4-0.5) -
n 3 5 4 0
Pregnancy morbidity
aCL 2.1 (0.3-15.3) 2.1 (0.4-10.7) 0.7 (0.1-6.8) 2.1 (0.1-34.2)
n 4 6 4 2
aβ2GPI 2.1 (0.4-10.7) 1.7 (0.5-6.5) 0.7 (0.6-0.7) 1.5 (0.6-4.0)
n 6 9 3 17
aCL and/or aβ2GPI 2.1 (0.4-10.7) 1.1 (0.3-3.6) 0.7 (0.1-6.8) 1.4 (0.5-3.6)
n 6 12 4 18
aCL and aβ2GPI 2.1 (0.3-15.3) 0.3 (0.3-0.4) 0.7 (0.6-0.7) 0.3 (0.3-0.4)
n 4 3 3 1
Abbreviations: aβ2GPI, anti-β2 glycoprotein I; aCL, anticardiolipin; CI, confidence interval; n, number of patients 
positive within the indicated subpopulation; OR, odds ratio. Note: Odds ratios for thrombosis are calculated in a 
subpopulation including controls, AID, non-APS thrombosis, and APS thrombosis patients (n = 853). Odds ratios for 
pregnancy morbidity are calculated in a female subpopulation including controls, AID, non-APS obstetric, and APS 
obstetric patients (n = 483).
Association of isolated aCL and/or aß2GPI IgA with thrombosis and 
pregnancy morbidity
Isolated aCL and/or aβ2GPI IgA positivity was not associated with thrombosis (Table 4). 
ORs varied between 0.4 (95% CI, 0.08-2.3) and 0.9 (95% CI, 0.4-2.2) (Table 4). In a more 
detailed analysis, no significant association was found for arterial or venous thrombosis 
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and isolated IgA aCL or aβ2GPI (Supplemental Table 5). Isolated aCL or aβ2GPI IgA 
positivity was also not significantly associated with pregnancy morbidity with OR 
ranging from 0.7 (95% CI, 0.1-6.8) to 2.1 (95% CI, 0.4-10.7) (Table 4).
Titers of isolated aCL and/or aß2GPI IgA-positive patients
Within the total population, the QUANTA Lite ELISA assay detected the highest number 
of isolated IgA samples (n = 34 patients). Only 12, 47, and 6% of these 34 patients were 
also positive for isolated IgA with the BioPlex2200, Phadia and HemosIL AcuStar assay, 
respectively. Titers of isolated IgA aPL patients were low (Figure 1). Isolated aCL and 
aβ2GPI IgA titers of patients with clinical manifestation were similar to IgA titers in 
the control population. Of note, upon aPL detection with Phadia, one patient with a 
history of thrombosis and one patient with known pregnancy morbidity had an aCL 
and aβ2GPI IgA titer >100 AU, while all patients in the control population had titers 
<100 AU (Figure 1C-D).
aCL and/or aß2GPI IgA titers of triple positive patients
The majority of triple positive patients (LAC, aCL, and aβ2GPI IgG/M positivity, from the 
same isotype) had a history of thrombosis and/or pregnancy morbidity (Figure 2). aCL 
and aβ2GPI IgA titers were found to be significantly different between triple positives 
and nontriple positives, independent of the solid-phase assay (Figure 2). Triple positives 
for the IgG isotype (LAC, aCL IgG and aβ2GPI IgG) had higher aCL and aβ2GPI IgA titers 
than non-triple positive patients, independent of the solid-phase assay (Figure 2). aCL 
and aβ2GPI IgA titers from triple positives for the IgM isotype (LAC, aCL IgM, and aβ2GPI 
IgM) were also significantly higher than nontriple-positives, independent of the solid-
phase assay (Figure 2). aCL and aβ2GPI IgA titers of triple positives for the IgG isotype 
and triple positives for the IgM isotype were not significantly different for all platforms 
(Figure 2).
Additional value in thrombosis of aCL and aß2GPI IgA in the current aPL 
panel
Inclusion of aCL and aβ2GPI IgA antibodies in the current aPL panel consisting of 
LAC, IgG and/or IgM aCL, and/or aβ2GPI did not increase ORs for thrombosis (Table 
5). Replacement of IgM by IgA aPL resulted in similar ORs for thrombosis compared 
with the current classification criteria with most solid-phase assays tested (Table 5). 
However, an aPL panel consisting of LAC, aCL IgG/M/A, and aβ2GPI IgG/M/A resulted in 
similar ORs for thrombosis (2.4 [95% CI, 1.8-3.1] to 2.8 [95% CI, 2.1-3.7]) in comparison 
to calculated OR with an aPL panel consisting of LAC, aCL IgG/M, and aβ2GPI IgG/M (2.4 
[95% CI, 1.8-3.2] to 2.9 [95% CI, 2.2-3.9]) (Table 5).
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Additional value in pregnancy morbidity of aCL and aß2GPI IgA in the 
current aPL panel
Positivity for at least one of the criteria aPL of APS resulted in significant ORs for 
pregnancy morbidity between 4.9 (95% CI, 3.2-7.4) and 6.6 (95% CI, 4.3-10.0), depending 
on the solid-phase assay (Table 6). An aPL panel for the classification of APS, consisting 
of LAC, IgG aCL or aβ2GPI, aCL or aβ2GPI IgA reached similar ORs, between 4.6 (95% 
CI, 3.0-6.9) and 5.1 (95% CI, 3.4-7.7) (Table 6). Positivity for LAC, IgG, IgM or IgA did not 
increase the OR for pregnancy morbidity as ORs between 4.6 (95% CI, 3.1-7.0) and 6.2 
(95% CI, 4.1-9.4) were obtained (Table 6).
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FIGURE 1. Isolated aCL or aβ2GPI IgA titers of controls and AID (control), APS thrombosis and non-APS 
thrombosis (thrombosis), and APS obstetric and non-APS obstetric (pregnancy morbidity). (A) Isolated aCL 
IgA titers detected with BioPlex 2200; (B) isolated aβ2GPI IgA titers detected with BioPlex 2200; (C) isolated 
aCL IgA titers detected with Phadia; (D) isolated aβ2GPI IgA titers detected with Phadia; (E) isolated aCL 
IgA titers detected with HemosIL AcuStar; (F) isolated aβ2GPI IgA titers detected with HemosIL AcuStar; (G) 
isolated aCL IgA titers detected with QUANTA Lite ELISA; (H) and isolated aβ2GPI IgA titers detected with 
QUANTA Lite ELISA. Represented p-values were calculated using the Kruskal–Wallis test. aβ2GPI, anti-β2 
glycoprotein I; aCL, anticardiolipin; APS, antiphospholipid syndrome; IgA, immunoglobulin A.
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FIGURE 2. aCL or aβ2GPI IgA titers of triple-positive patients and non-triple-positive patients. Solid dots in 
black indicate aCL or aβ2GPI IgA titers of patients without clinical manifestations of APS. Solid dots in red 
indicate aCL or aβ2GPI IgA titers of patients with clinical manifestations of APS. (A) aCL IgA titers detected 
with BioPlex 2200; (B) aβ2GPI IgA titers detected with BioPlex 2200; (C) aCL IgA titers detected with Phadia; 
(D) aβ2GPI IgA titers detected with Phadia; (E) aCL IgA titers detected with HemosIL AcuStar; (F) aβ2GPI IgA 
titers detected with HemosIL AcuStar; (G) aCL IgA titers detected with QUANTA Lite ELISA; (H) aβ2GPI IgA titers 
detected with QUANTA Lite ELISA. Mean IgA titers with their 95% confidence intervals are shown. Significance 
was calculated using the Kruskal–Wallis test followed by Mann-Whitney U test. *, p-value < 0.0001. aβ2GPI, 
anti-β2 glycoprotein I; aCL, anticardiolipin; APS, antiphospholipid syndrome; IgA, immunoglobulin A.
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TABLE 5. Additional value of aCL and aβ2GPI IgA antibodies in thrombosis
LAC, aCL IgG, aβ2GPI 
IgG, aCL IgM and/
or aβ2GPI IgM
LAC, aCL IgG, aβ2GPI 
IgG, aCL IgA and/
or aβ2GPI IgA
LAC, aCL IgG, aβ2GPI IgG, 
aCL IgM, aβ2GPI IgM, aCL 
IgA and/or aβ2GPI IgA
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
BioPlex2200 2.9 (2.2-3.9) 2.8 (2.1-3.7) 2.8 (2.1-3.7)
Phadia 2.4 (1.8-3.2) 3.1 (2.3-4.2) 2.4 (1.8-3.1)
HemosIL AcuStar 2.9 (2.1-3.8) 3.0 (2.3-4.1) 2.7 (2.0-3.6)
QUANTA Lite ELISA 2.8 (2.1-3.7) 3.1 (2.3-4.2) 2.6 (2.0-3.5)
Abbreviations: aβ2GPI, anti-β2 glycoprotein I; aCL, anticardiolipin; CI, confidence interval; IgA, immunoglobulin A; 
IgM, immunoglobulin M; LAC, lupus anticoagulant.
TABLE 6. Additional value of aCL and aβ2GPI IgA antibodies in pregnancy morbidity
LAC, aCL IgG, aβ2GPI 
IgG, aCL IgM and/
or aβ2GPI IgM
LAC, aCL IgG, aβ2GPI 
IgG, aCL IgA and/
or aβ2GPI IgA
LAC, aCL IgG, aβ2GPI IgG, 
aCL IgM, aβ2GPI IgM, aCL 
IgA and/or aβ2GPI IgA
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
BioPlex2200 5.1 (3.4-7.7) 4.6 (3.0-6.9) 5.0 (3.3-7.6)
Phadia 4.9 (3.2-7.4) 4.7 (3.1-7.0) 4.6 (3.1-7.0)
HemosIL AcuStar 5.3 (3.5-8.0) 4.8 (3.2-7.2) 5.2 (3.4-7.8)
QUANTA Lite ELISA 6.6 (4.3-10.0) 5.1 (3.4-7.7) 6.2 (4.1-9.4)
Abbreviations: aβ2GPI, anti-β2 glycoprotein I; aCL, anticardiolipin; CI, confidence interval; IgA, immunoglobulin A; 
IgM, immunoglobulin M; LAC, lupus anticoagulant.
DISCUSSION
In this study we evaluated the prevalence of aCL and aβ2GPI IgA antibodies, tested with 
four solid-phase platforms, in 1,608 patients. We also investigated the added value of 
IgA aPL in APS classification.
Of the 1,608 included patients 6 to 19% tested positive for aCL IgA aCL and 12 to 18% 
for aβ2GPI IgA antibodies, dependent on the solid-phase assay used. LAC was by far the 
most prevalent aPL (38%) in our study population consisting of 1,608 APS patients and 
controls. In comparison, a retrospective study included 472 patients with aPL testing 
and found a similar distribution of aCL IgA and aβ2GPI IgA antibodies, 6 and 19% 
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respectively (10). Another study included 314 patients suspected for APS or related AIDs 
(e.g., SLE) and found 28% patients positive for aβ2GPI IgA using the QUANTA Lite ELISA 
(15). We only found 12% of the patients positive for aβ2GPI IgA in the total population 
using the QUANTA Lite ELISA. The lower prevalence of aβ2GPI IgA antibodies might be 
due to a different patient population as we included a large number of patients with a 
history of thrombosis or pregnancy morbidity, but negative for any consensus aPL as 
control population. Another cross-sectional study included 156 patients that fulfilled 
the clinical criteria of APS and found a prevalence of 5 and 29% for aCL IgA and aβ2GPI 
IgA positivity, respectively (8).
In our study, aCL as well as aβ2GPI IgA antibodies were correlated with clinical 
manifestations of APS (thrombosis and pregnancy morbidity), independent of the 
solid-phase platform used. In agreement with our results, multiple studies have shown 
an association between clinical manifestations of APS and aCL and/or aβ2GPI IgA 
antibodies (3–12). However, some studies were only able to show a clinical association 
for either aCL or aβ2GPI IgA aPL detected with an in-house ELISA (3,9). One retrospective 
study including 439 patient samples within a timespan of 6 years found an association 
between aβ2GPI IgA and thrombosis, but not for aCL IgA (3). Another retrospective 
study including 130 SLE patients and 35 patients with primary APS demonstrated a 
correlation of aCL IgA aPL with a history of thrombosis and recurrent fetal loss, but was 
unable to show any correlation of aβ2GPI IgA aPL with clinical manifestations of APS (9).
An external quality control program illustrated that aCL and aβ2GPI IgG/M assays 
produce variable results (20,25). We have previously shown that even within 
commercially available solid-phase assays, detection of aCL and aβ2GPI IgG/M differs 
between platforms (21). Within our total population consisting of 1,608 patients, 19.4, 
13.8, 14.3, and 12.7% patients were found to be positive for aCL and/or aβ2GPI IgA 
antibodies detected with BioPlex2200, Phadia, HemosIL AcuStar and QUANTA Lite 
ELISA, respectively. These data indicate that the detection of IgA aPL also depends on 
the solid-phase assay that is used. Other studies also showed the lack of standardization 
in IgA aPL detecting assays (26–28). In a subpopulation from the PROMISSE cohort, 
aβ2GPI IgA was detected in 18.9% and 55.6% of the patients, detected with QUANTA 
Lite ELISA and BioPlex2200, respectively (26). Taken together, these results indicate that 
the detection and association of IgA aPL is dependent on the solid-phase assay and 
study population.
In agreement with a previous cross-sectional study, we confirmed the association of aCL 
and aβ2GPI IgA with arterial and venous thrombosis (8). However, some studies found 
an association between IgA aPL and venous thrombosis, but were unable to show an 
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association with arterial thrombosis and vice versa (17,18,29). In contrast, a recent study 
could not demonstrate an association between aβ2GPI IgA aPL and thrombosis (15). 
Positivity for aβ2GPI IgA aPL was found in 31% of the included APS patients (15), as well 
as a large portion (30%) of SLE patients was found to be positive for aβ2GPI IgA aPL (15). 
Upon exclusion of SLE patients, a significant association was found between aβ2GPI IgA 
and venous thrombosis (OR 2.5; 95% CI, 1.1-4.9) (15).
In our cohort, positive aCL and/or aβ2GPI IgA results were significantly associated with 
pregnancy morbidity, as defined in the Sydney criteria. However, the non-APS obstetric 
group was relatively small (n = 33), compared with obstetric APS patients (n = 122) 
which might have affected the association of aPL and pregnancy morbidity. Limited 
data are available on the association between IgA aPL and obstetric complications 
(4,8,9,15). Most studies found a value for aCL or aβ2GPI IgA testing in pregnancy 
morbidity (4,8,9). However, a study that included 314 patients suspected from APS or 
related autoimmune diseases (e.g., SLE) did not found a significant association for aCL 
or aβ2GPI IgA aPL with pregnancy morbidity (15). Interestingly, no association of aCL 
IgG/M and aβ2GPI IgG/M with pregnancy morbidity was found within the same study 
(15).
Pathogenicity of IgA aPL has been shown in animal models (14,18). In mice, IgA 
antibodies from APS patients increased the mean thrombus area and mean thrombus 
disappearance time upon induced thrombus formation of a nonocclusive thrombus 
by pinch injury (14). IgA antibodies were purified from two APS patients of which one 
was also positive for aCL IgG and LAC. The other patient was positive for aCL IgA, but 
negative for aCL IgG, aCL IgM and LAC (14). However, the authors did not demonstrate 
that aCL is solely responsible for the observed effect (14). Another study also showed 
that IgA isolated from APS patients is pathogenic as thrombus formation and tissue 
factor activity in mice injected with IgA from APS was increased compared with control 
IgA (18). However, the plasma of the mice injected with IgA from APS patients showed 
LAC activity (18). These data indicate that IgA aPL can be pathogenic (14,18). However, 
pathogenic IgA aPL seem to correlate with LAC.
Despite the association of aCL and/or aβ2GPI IgA aPL with thrombosis shown in 
multiple studies, only some have suggested an added value for IgA testing in patients 
suspected of thrombotic APS (6,8,10,12,18,30). Although an added value was suggested 
for so called “isolated IgA” by some studies, many studies did not include LAC testing, 
hampering assessment of true isolated IgA aPL (8,12,18,30). In a retrospective study 
testing 472 patients with suspected or confirmed thrombophilia, an autoimmune 
disease or pregnancy morbidity (10) IgA (aCL, aβ2GPI and/or antiphosphatidylserine 
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[aPS]) aPL positivity was found to be an independent risk factor for thrombosis using 
a multivariate analysis [10]. Detection of aCL and aPS IgG, IgM, and IgA antibodies 
were performed with another platform than detection of aβ2GPI IgG, IgM and IgA 
antibodies (10). Considering the high variability between solid-phase platforms in 
antibody detection, classification of APS patients and the association of aPL might be 
affected. It is suggested to detect all aPL within the same system for the classification 
of APS patients (21). In addition, the method used to determine the cut-off value for 
an aPL assay has also shown to affect between-assay performance (31). Also, antibody 
heterogeneity has been suggested to attribute to variability in test results (32).
We defined isolated aCL and/or aβ2GPI IgA positivity for aCL and/or aβ2GPI IgA aPL, 
as negative for aCL and/or aβ2GPI IgG/M and/or LAC. Isolated IgA positivity was rare in 
the total population. Overall, the prevalence of isolated IgA was comparable between 
patients with clinical manifestations of APS and patients without a history of thrombosis 
or pregnancy morbidity. Positivity for isolated IgA aPL was not associated with 
thrombosis or pregnancy morbidity as calculated OR did not reach statistical significance. 
Titers of IgA positive patients were characterized by low aCL or aβ2GPI IgA titers, 
around the cut-off value. Other noncriteria aPL like anti-phosphatidylethanolamine, 
negatively charged phospholipids (other than cardiolipin), anti-vimentin/cardiolipin, 
Annexin A5, and aPST/prothrombin (PT) antibodies have been suggested to be clinical 
relevant in patients suspected of APS, but negatively tested for consensus aPL (33). A 
recent systematic review showed a strong association between aPS/PT aPL and clinical 
manifestations of APS, with a high association with LAC (34). However, this needs to be 
validated in a large multicenter study.
In this study, we aimed to investigate the value of aCL and aβ2GPI IgA aPL in addition 
to the current aPL panel (LAC, aCL IgG/M, and aβ2GPI IgG/M). Positivity for IgA aPL was 
found to be associated with thrombosis and pregnancy morbidity. However, isolated 
IgA positivity was rare and not correlated with clinical manifestations of APS. Our results 
do not support testing for aCL and/or aβ2GPI IgA in addition to conventional aPL for 
the identification of patients with clinical manifestations of APS.
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SUPPLEMENTAL TABLE 1. Cut off values of aCL IgG/M/A and aβ2GPI IgG/M/A detected with BioPlex2200, 





IgM aCL IgA aβ2GPI IgA
BioPlex2200 20 20 20 20 20 20
Phadia 10 10 10 10 20 10
HemosIL AcuStar 20 20 20 20 20 20
QUANTA Lite ELISA 20 20 20 20 20 20
Abbreviations: aβ2GPI, anti-β2 glycoprotein I; aCL, anticardiolipin; AID, autoimmune diseases; APS, 
antiphospholipid syndrome; IgA, immuno- globulin A; IgM, immunoglobulin M.
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aCL IgG 3.2 (2.2-4.7) 4.2 (2.7-6.5) 4.1 (2.7-6.3) 4.5 (2.8-7.4)
n 163 137 144 121
aβ2GPI IgG 2.8 (1.9-4.1) 3.5 (2.3-5.4) 2.8 (1.9-3.9) 5.4 (3.0-9.6)
n 166 134 193 91
aCL and aβ2GPI IgG 3.3 (2.2-5.0) 4.1 (2.5-6.7) 4.3 (2.8-6.8) 5.3 (2.9-9.6)
n 157 113 140 84
aCL IgM 2.5 (1.5-4.1) 1.6 (1.1-2.3) 1.7 (1.1-2.5) 2.0 (1.3-3.1)
n 82 147 119 105
aβ2GPI IgM 2.7 (1.6-4.4) 2.2 (1.4-3.4) 2.6 (1.5-4.5) 2.0 (1.3-3.2)
n 86 94 74 97
aCL and aβ2GPI IgM 2.7 (1.6-4.7) 2.7 (1.6-4.6) 2.7 (1.5-4.7) 2.4 (1.4-4.2)
n 76 79 67 74
Abbreviations: aβ2GPI, anti-β2 glycoprotein I; aCL, anticardiolipin; AID, autoimmune diseases; APS, 
antiphospholipid syndrome; IgM, immunoglobulin M. Note: Odds ratios are calculated in a subpopulation 
including controls, AID, non-APS thrombosis, and APS thrombosis patients (n = 853).
SUPPLEMENTAL TABLE 4. Obstetric association of aCL and aβ2GPI IgG/M antibodies





aCL IgG 3.5 (2.2-5.7) 5.1 (3.0-8.7) 4.5 (2.7-7.6) 5.2 (2.9-9.2)
n 89 71 74 59
aβ2GPI IgG 3.3 (2.1-5.3) 3.6 (2.1-6.1) 2.8 (1.8-4.4) 4.2 (2.1-8.6)
n 91 69 102 36
aCL and aβ2GPI IgG 3.7 (2.3-6.1) 4.6 (2.6-8.2) 4.6 (2.7-7.7) 3.8 (1.8-7.8)
n 85 58 72 34
aCL IgM 3.0 (1.6-5.7) 2.0 (1.2-3.3) 2.0 (1.2-3.4) 2.9 (1.7-5.0)
n 41 81 69 61
aβ2GPI IgM 3.1 (1.7-5.8) 3.2 (1.8-5.8) 3.6 (1.8-6.9) 2.7 (1.5-4.7)
n 46 51 40 55
aCL and aβ2GPI IgM 3.2 (1.6-6.2) 3.3 (1.6-6.5) 3.7 (1.8-7.5) 2.9 (1.5-5.6)
n 40 36 36 38
Abbreviations: aβ2GPI, anti-β2 glycoprotein I; aCL, anticardiolipin; AID, autoimmune diseases; APS, 
antiphospholipid syndrome; IgM, immunoglobulin M. Note: Odds ratios are calculated in a female subpopulation 
























































































































































































































































































































































































































































































































The significance of 
antibodies against domain 
I of beta-2 Glycoprotein I in 
antiphospholipid syndrome
Hilde Kelchtermans, Walid Chayoua, Bas de Laat




The antiphospholipid syndrome (APS) is characterized by vascular thrombosis and/
or pregnancy morbidity with the persistent presence of antiphospholipid antibodies 
(aPLs). Progress is being made in understanding the pathogenesis of the syndrome, 
but difficulties persist in the identification of patients at risk for thrombosis and/
or pregnancy morbidity. Beta-2 glycoprotein I (β2GPI), a plasma protein consisting 
of five sushi domains, is thought to be the main antigenic target of aPLs. Antibodies 
recognizing domain I of β2GPI are predominantly present in patients with an elevated 
risk of thrombosis, whereas antidomain IV/V antibodies are found in nonthrombotic 
autoimmune diseases. Indeed, domain I antibodies proved to be pathogenic in 
multiple studies. Retrospective studies have provided evidence for an added clinical 
value of antidomain I antibodies in the risk stratification of patients with APS. Still, wide 
ranges of odds ratio exist between studies, probably due to differences in the study and 
control population, and detection methods used. Despite the proven pathogenicity 
of antidomain I antibodies and their correlations with clinical manifestations of APS, 
heterogeneity of the current studies has prohibited their acceptance in the official 
diagnostic criteria. Well-designed large longitudinal prospective studies with available 
and new, preferentially functional, assays for the risk stratification of patients with APS 
are required.
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INTRODUC TION
Because of the high incidence of thrombosis and pregnancy morbidity independent 
from the antiphospholipid syndrome (APS), the diagnosis of APS predominantly 
relies on laboratory results.1-3 As a consequence, the quality of the assays used 
to detect these antibodies is of utmost importance. The Sydney update of the 
classification criteria for definite APS lad to a substantial improvement of the APS 
diagnosis, but several difficult issues remain unsolved.4,5 Huge progress is being made 
in understanding the pathogenesis, but difficulties persist in the identification of 
patients at risk for thrombosis. In the Sydney criteria, three different types of assays to 
detect antiphospholipid antibodies (aPL) are included: (1) phospholipid-dependent 
prolongation of coagulation assays (Lupus anticoagulant[LA]); (2) detection of IgM/
IgG antibodies against beta2glycoprotein I (β2GPI) antibodies; (3) detection of 
immunoglobulin M (IgM)/immunoglobulin G (IgG) antibodies against cardiolipin (CL).3 
While the role of these criteria can be debated, all assays have a place in the diagnostic 
work-up for APS.
Especially IgG anti-CL/anti-β2GPI antibodies have been shown to correlate with 
thrombosis. A prospective study confirmed that only a minority of patients with APS 
carry IgM anti-CL/anti-β2GPI antibodies and these patients displayed other thrombotic 
risk factors.6 Nonetheless, discrepancies have been found in literature concerning the 
role of IgM antibodies in the pathogenesis of APS. A recent review of the literature 
clearly found more significant correlations with thrombosis for the IgG compared with 
the IgM isotype, but failed to identify the added value of isolated IgM positivity due to 
the unavailability of paired results of IgG and IgM for each separate patient.7
Several other autoantibodies have been proposed to be involved in the pathogenesis 
of APS, and this review will focus on the possible added clinical value of a subset of 
antibodies directed against domain I of β2GPI.
Discovery of domain I as an immunodominant epitope
Upon the general acceptance that a main antigenic target of aPL is phospholipid-bound 
β2GPI, a 50 kDa plasma protein composed of five short consensus repeat domains, 
many studies tried to identify which domains of β2GPI are involved in the binding of 
anti-β2GPI antibodies. Although more domains of β2GPI have been indicated as the 
target location of anti-β2GPI antibodies,
8-11 strong evidence points towards the first 
domain of β2GPI (domain I).
12,13 By using domain-deletion mutants, Iverson et al were 
the first to show that anti-β2GPI antibodies recognize an epitope on domain I.
14 Later 
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spanning amino acids 39/40-43, proved to be important in the binding of anti-β2GPI 
antibodies.15-18 Further research revealed a possible contribution of the domain I-II linker, 
suggesting that antibodies may bind to discontinuous epitopes in this area.19 β2GPI has 
been shown to exist in different conformations, “open” and “closed”.20,21 β2GPI is present 
in plasma in its “closed” native conformation and interaction with anionic surfaces such 
as phospholipids has been found to induce an activated J-shaped conformation. This 
conformational change proved to be mandatory for the exposure of the pathogenic 
epitope G40-R43 on domain I and hence to enable anti-β2GPI antibodies to interact 
with the epitope.22,23 The closed and open conformations of β2GPI were suggested to 
resemble two different redox states of β2GPI, and patients with APS have a significantly 
elevated antigen load in the oxidized/open state.24 Interestingly, patient-derived anti-
β2GPI antibodies display greater avidity to oxidized versus reduced β2GPI.
24
Evidence for domain I pathogenicity: in vivo/in vitro
The pathogenicity of antidomain I antibodies has been demonstrated by both in vivo 
and in vitro studies. In vitro, antidomain I antibodies were found to display LA activity.16,25 
Furthermore, antidomain I antibodies have been shown to increase resistance against 
the anticoagulant properties of annexin A5 and against activated protein C.25-29 LA-
positive anti-β2GPI antibodies, isolated from a subset of patients with APS, were found 
to neutralize the inhibitory function of β2GPI on von Willebrand Factor induced platelet 
aggregation.30 Given the fact that antidomain I antibodies display LA activity, this effect 
may be mediated by antidomain I antibodies. Ninivaggi et al have postulated that 
antidomain I antibodies may interfere with the natural anticoagulant action of “open” 
β2GPI, evidenced by its inhibitory effect on thrombin generation.
31 Our unpublished 
data using antidomain I antibodies confirm this hypothesis.
A first indication of domain I pathogenicity in vivo comes from the fact that human β2GPI 
becomes immunogenic only after incubation with apoptotic cells or phospholipids.32,33 
De Laat et al confirmed the necessity of a conformational change for immunogenicity 
of β2GPI and demonstrated that antibodies displaying LA activity developed in mice 
injected with domain I but not domain II to IV.22 However, another study showed 
that aPLs were induced by immunization with the phospholipid binding site of β2GPI 
(domain V), and these proved to be thrombogenic in a mouse model.34 Importantly, 
both affinity purified IgG antidomain I from APS serum and human monoclonal 
antidomain I IgG have been shown to induce thrombosis and/or fetal loss in mice APS 
models of venous thrombosis.35-37 Interestingly, recombinant human domain I was 
found to abolish antibody-induced thrombosis.38 Accordingly, antidomain I fractions 
from an APS patient induced a higher increase in tissue factor activity and larger thrombi 
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compared with antidomain I poor fractions obtained after affinity purification.39 Given 
the high degree of homology between domain I and an extracellular epitope of toll-like 
receptor 4 (TLR4), the pathogenicity of antidomain I antibodies has been suggested 
to result from stimulation of the TLR4-nuclear factor (NFκB) pathway.40 In this study, 
antibodies directed against a cryptic epitope in domain I were found to engage TLR4 
directly, in the absence of β2GPI, inducing a proinflammatory phenotype in monocytes 
and endothelial cells.
Detection of domain I antibodies
Given the cryptic nature of the domain I epitope, detection of domain I antibodies in the 
current available full-length anti-β2GPI assays depends highly on the availability of the 
epitope. As a sufficiently large fraction of β2GPI needs to be in its “open” conformation, 
the purification/preparation methods of β2GPI and the selection of negatively 
charged Enzyme-Linked Immuno Sorbent Assay (ELISA) plates play an important role 
in the detection of antibodies against the cryptic epitope.15,41 Interestingly, by using 
monoclonal antibody P1-117 recognizing specifically epitope G40-R43, exposed 
only when β2GPI is in the open conformation, versus antibody P2-6 recognizing 
β2GPI regardless of its conformation, we previously demonstrated clear differences in 
exposure of epitope G40-R43 on domain I of β2GPI in commercially available anti-β2GPI 
IgG assays.42,43 Importantly, we found that a significant number of samples positive for 
domain I reactivity are falsely assigned negative in assays characterized by a decreased 
availability of this epitope. These findings have been extended to two automated panels 
for anti-CL and anti-β2GPI IgG.
44 In agreement with these results, a line immunoassay 
was able to discriminate patients with APS from infectious patients and asymptomatic 
carriers, likely through the way β2GPI is oriented on the matrix, resulting in the exposure 
of domain I.45
Apart from these full-length β2GPI assays, specific assays for the detection of domain 
I antibodies have been developed. First reports on domain I reactivity were using 
a baculovirus system to express β2GPI that lacked one or more domains.
14 Next, a 
two-step approach was optimized by coating domain I on both hydrophobic and 
hydrophilic ELISA plates.16 The ratio in optical density (OD) obtained on both plates 
provides an estimation of the relative amount of antibodies reactive with the cryptic 
epitope, as interactions between the positive charge of the epitope and the negative 
charge of the hydrophilic plate hamper interactions of antibodies with that epitope. 
Additionally, other ELISAs based on human recombinant domain I expressed in 
bacteria that was refolded after purification; recombinant domain I expressed in insect 
cells; an N-terminally biotin-(PEG)2 derivative of domain I and competitive inhibition 
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between domain I and full-length β2GPI have been developed.
15,46-49 More recently, 
chemiluminescence immunoassays for the detection of domain I antibodies have been 
described.50,51 Good correlations were demonstrated between the available methods, 
although small differences in specificity and sensitivity were observed. 52,53
Clinical significance of antidomain I positivity
Using the different methods described previously, multiple studies have shown a 
significant association between the presence of antibodies against the cryptic epitope 
of domain I and thrombosis/APS classification (Table 1). Using an antidomain I antibody 
as competitor for patient antibody binding to β2GPI, Arvieux et al already demonstrated 
the presence of antidomain I antibodies in patients with APS with thrombosis, versus, 
probably nonpathogenic, antibodies against other domains in leprosy patients in which 
thrombosis is uncommon.60 In a systematic review of the literature, the prevalence of 
antidomain I antibodies in 548 patients with APS from 11 different centers, proved to 
be 44%.61 In a large retrospective multicenter study on 442 anti-β2GPI-positive patients, 
antidomain I positivity was reported in 55% of the patients, and the presence of these 
antibodies associated significantly with an increased risk for thrombosis and pregnancy 
complications.28 The detection of antibodies against the cryptic epitope in domain I 
frequently proved to be superior over the detection of anti-β2GPI antibodies recognizing 
other domains or the full-length β2GPI, with a higher specificity for both thrombosis and 
pregnancy morbidity.16,28,50 These results are in contrast with two recent studies, in which 
the clinical performances of anti-β2GPI and antidomain I assays proved to be equal.
54,56 
Both studies agree that antidomain I IgG do not provide added clinical value to the 
current classification criteria, but disagree about the potential of antidomain I IgG as 
replacement of anti-β2GPI assays. Other studies confirmed a correlation of antidomain 
I IgG antibodies and thrombosis, but failed to establish an association with pregnancy 
morbidity.48,53,56 In another study, measuring antidomain I antibodies yielded higher 
odds ratio (OR) for clinical manifestations of APS compared with anti-β2GPI antibodies 
(21.0 versus 8.6, respectively) and proved to be suitable to replace anti-β2GPI assays in 
an earlier described antiphospholipid score, aPL-S.52,62
Importantly, looking at aPL profiles, patients at higher clinical risk, i.e. triple positive 
patients6, were shown to display higher levels of antidomain I antibodies compared 
with single or double positive patients.47,51,53,54,56,57 IgG antidomain I antibodies were also 
reported in seronegative patients with APS that fulfilled clinical APS criteria, suggesting 
that detection of antidomain I antibodies potentially improves the classification of 
patients with APS.63,64 Although most studies investigating antidomain I antibodies 
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detect IgG, antidomain I antibodies of all three isotypes have been shown to associate 
with APS with high specificity.48,61 Inconsistently, another study did not find a significant 
association between antidomain I IgA antibodies and thrombosis.66
Looking at the titers of antidomain I antibodies, de Craemer et al demonstrated 
significantly reduced levels in clinically unaffected patients.54 Antidomain I antibodies 
proved to be highly prevalent in patients with a history of thrombosis, whereas 
antibodies targeting other domains were shown in patients with and without 
thrombosis. Interestingly, antidomain I IgG titers proved to be stable over a 12-week 
period, suggesting that a single antidomain I measurement is sufficient to classify 
patients with APS.53,54
Of note, the reported percentage of antidomain I positivity, as well as the OR for clinical 
manifestations of APS varies within the different studies presented in Table 1 and this 
probably can be explained by several causes. First, the patient and control population 
varies widely in the different studies. Although at first sight the obtained ORs for the risk 
on thrombosis of 18.9 and 3.5 in two studies performed in our laboratory seem to be 
contradictory,16,28 the difference is easily explained by the starting populations, being 
broad (APS, systemic lupus erythematosus and lupus like disease patients) versus narrow 
(anti-β2GPI positive patients), respectively. Indeed, recalculating the OR for thrombosis 
of domain I positivity in the first study specifically for the anti-β2GPI positive patients, 
yields an OR of 2.8, which closely resembles the obtained OR of 3.5 in the second 
study. Apart from the starting population, differences in exposure of the pathogenic 
domain I in the domain I detection platforms may add up to the variability.28,42,44,53,56 
Additionally, differences in ORs may result from the selection of cut-off values, as Zhang 
et al recently demonstrated an increase in OR with raising cut-off values. 56 As with the 
assays currently included in the official APS classification criteria, antidomain I assays 
urgently require standardization concerning domain I production and coating, cut-off 
determination and inclusion of reference material. Nonetheless, most studies agree that 
a significant proportion of patients positive for anti-β2GPI antibodies are negative for 
antidomain I antibodies and the existence of autoantibodies reacting with non-domain 
I epitopes has been demonstrated.53,57,66 As a result, to avoid false-negative results, 
replacement of available full-length anti-β2GPI assays with specific antidomain I assays 
may not be advised at this stage. Nevertheless, side by side application may improve 
risk stratification of clinical events.
Correlations of antidomain I antibodies with clinical symptoms apart from APS have 
been assessed. Mullen et al performed a prospective study with patients with transient 
ischemic attack (TIA), in which antidomain I antibodies could not be used as biomarkers 
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of risk on stroke or death after TIA, in contrast to anti-phosphatidylserine/prothrombin 
(anti-PS/PT) antibodies.67 Antidomain I antibodies were observed in patients with 
multiple sclerosis and systemic autoimmune rheumatic disease with no clinical features 
of APS.57,68 However, this may be related to the fact that MS patients display a higher 
risk of thrombosis compared with healthy individuals.69,70 Additionally, antidomain I 
antibodies have been shown to associate with non-criteria-related manifestations of 
APS, including livedo reticularis and heart valve disease.71
Evidence for other noncriteria antibodies
Evidence for the pathogenicity of other non-criteria antibodies is growing. Although IgG 
antibodies against domain IV/V from β2GPI have been shown to be increased in single 
positive anti-β2GPI positive patients, their presence did not correlate with thrombosis.
72 
Epitopes on domain IV or V have shown to be preferentially recognized by IgG 
antibodies in sera from antiphospholipid-positive asymptomatic carriers, individuals 
with leprosy or children with atopic dermatitis. 73,74 In vivo, anti-β2GPI antibodies from 
leprosy patients do not show thrombogenic effects in mice. 75 These findings arise the 
possibility that antidomain IV/V antibodies are present in non-thrombotic autoimmune 
diseases. In the same line, Andreoli et al provided evidence that the ratio of antidomain 
I to antidomain IV/V antibodies can be used to determine the pathogenic potential of 
anti-β2GPI antibodies and discriminate between autoimmune diseases such as APS and 
other pathologies.57
Anti-PS/PT were suggested to be a good alternative to estimate thrombotic risk in 
patients where LA results are difficult to interpret due to the intake of anticoagulants.59 
The clinical significance of these antibodies in APS classification is beyond the scope 
of this review, but has been reviewed before,76 and is the topic of another chapter in 
this issue of the journal. Given their association with both thrombosis and pregnancy 
morbidity, their presence may represent a new risk stratification tool, especially in 
patients negative for the traditional antibodies included in the APS criteria.
Additionally, although IgA antibodies so far have not been included in the current 
classification criteria, measurement of (isolated) IgA anti-β2GPI antibodies, often 
a subclass of IgA antibodies targeting domain IV/V, previously showed to identify 
additional patients with clinical features of APS.48,59,65,77-79 The pathogenicity of purified 
IgA anti-β2GPI antibodies, reactive against domain I and IV/V, was demonstrated in a 
mouse model of thrombosis.77 As positivity for IgA antibodies has been shown to 
largely overlap with other antiphospholipid antibodies, it may be advisable to only 





As misdiagnosis has major implications regarding patient treatment, we believe efforts 
should be taken to improve existing assays for the detection of known pathogenic 
antibodies, including but not limited to the antidomain I antibodies. Of note, a possible 
threat that may delay the inclusion of assays detecting antidomain I antibodies in the 
classification criteria of APS is the wide availability of different assays and their lack 
of standardization, resulting in large inter-assay variability. Apart from the known 
standardization that is currently ongoing for the anti-β2GPI and anti-CL antibodies, 
including preparation of standards, reference material, defining international units and 
establishing cut-off values, additional measures may be required for the antidomain I 
assays. Taking into account that one of its pathogenic epitopes is cryptic and negatively 
charged, one can imagine the importance of strict guidelines regarding the production 
of domain I and the coating procedures. Of note, our antibodies P1-117 and P2-6 may be 
included in the different antidomain I and full-length β2GPI assays as positive controls 
to ensure satisfactory exposure of the cryptic epitope.42,44
Investigation of domain I pathogenicity paved the way for novel therapeutic approaches 
for APS. The idea to specifically block pathogenic antidomain I antibodies without 
interfering with host biology seems to be interesting. The development of recombinant 
domain I or a variant as a potential therapeutic agent has been suggested based on 
its ability to inhibit pathogenic effects of antidomain I antibodies.38 A monoclonal 
antibody against domain I, not able to activate complement was reported as a potential 
therapeutic tool, in both thrombotic and obstetric complications.37 Tolerogenic 
dendritic cells specific for domain I but not domain V resulted in an efficient reduction 
of the fetal loss rate in a mouse model, by induction of regulatory T cells. 81
Importantly, anti-β2GPI and anti-CL antibodies, and in the same line antidomain I 
antibodies, are mainly measured by quantitative endpoint assays. Taking into account 
that not all antibodies directed against β2GPI, cardiolipin/β2GPI and possibly even 
domain I are pathogenic, such non-functional assays will result in a relatively high false 
positivity.5 To reduce the risk of false positive results, we feel efforts should be made in 
the development of functional assays. In contrast with the quantitative anti-β2GPI/CL 
assays, such functional assays should only detect pathogenic antibodies, including the 
antidomain I antibodies, but possibly also other (non-discovered) aPL. Currently, LA is 
the only functional assay included in the Sydney criteria. Probably due to the fact that 
LA measures a functional effect of the antibodies, LA is a better predictor of thrombosis 
than quantitative solid-phase immunoassays. These LA tests are far from ideal since 
they require an adequate plasma preparation and are complicated and labor-intensive, 
as well as being sensitive to the presence of anticoagulants used as therapy in patients 
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with APS.5 Their specificity and sensitivity proved to largely depend on the calculation 
of cut-off values and the choice of the reagents. The relevance of a weak-positive LA, 
and the influence of oral anticoagulants need to be further addressed.
Other functional assays have been developed as research tool, including β2GPI-
dependent LAC test and thrombin generation-based assays, and proved to be promising 
for the diagnosis of APS.82,84 Recently, we combined both assays in one functional ellagic 
acid-triggered thrombin generation assay performed in the absence and presence of 
cardiolipin. Our assay proved to be sensitive to monoclonal anti-β2GPI antibodies and 
was able to discriminate between antidomain I positive patients with APS and healthy 
controls in a small patient cohort. Further validation of this assay in a multi-center study 
is required.
CONCLUSION
With the increasing evidence that not all anti-β2GPI antibodies are pathogenic, the 
detection of anti-β2GPI in the absence of anti-CL and LA may not be sufficient for the 
classification of patients with APS. For this reason, an update of the Sydney criteria 
focusing on aPL antibody profiles rather than single positivity seems to be a logical next 
step. Prospective studies on large population cohorts, including appropriate control 
groups, are urgently required to further evaluate the significance of both criteria and 
non-criteria (isolated) antibodies in the classification and risk stratification of patients 
with APS. To be able to compare results within different centers, a consensus has to be 
reached first on the standardization of the assays. As to the criteria antibodies, using 
the different available methodologies will allow to solidly determine the impact of the 
variable exposure of domain I in the currently available assays on the classification of 
patients with APS. Although diverse retrospective studies have provided evidence for 
an added clinical value of antidomain I antibodies in the risk stratification of patients 
with APS, large longitudinal prospective studies are lacking. In the meanwhile, the 
search for new, preferentially functional, assays should continue. The risk stratification 
potential of thrombin generation assays needs to be properly assessed. Large patient 
studies hopefully will lead to an update of the classification criteria for APS determined 
in Sydney. The accompanied reduction in the false-positive and false-negative rate and 
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Detection of anti-domain I 
antibodies by chemiluminescence 
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high-risk antiphospholipid 
syndrome patients: A multicenter 
multiplatform study
Dong-mei Yin, Walid Chayoua, Hilde Kelchtermans, Philip de Groot, Gary W. Moore, 
Jean-Christophe Gris, Stéphane Zuily, Jacek Musiał, Bas de Laat, Katrien M. J. Devreese




Background: Classification of the antiphospholipid syndrome (APS) relies 
predominantly on detecting antiphospholipid antibodies (aPLs). Antibodies against a 
domain I (DI) epitope of anti-β2 glycoprotein I (β2GPI) proved to be pathogenic, but are 
not included in the current classification criteria.
Objectives: Investigate the clinical value of detecting anti-DI IgG in APS.
Patients/Methods: From eight European centers 1005 patients were enrolled. Anti-
cardiolipin (CL) and anti-β2GPI were detected by four commercially available solid 
phase assays; anti-DI IgG by the QUANTA Flash® β2GPI domain I assay.
Results: Odds ratios (ORs) of anti-DI IgG for thrombosis and pregnancy morbidity 
proved to be higher than those of the conventional assays. Upon restriction to patients 
positive for anti-β2GPI IgG, anti-DI IgG positivity still resulted in significant ORs. When 
anti-DI IgG was added to the criteria aPLs or used as a substitute for a β2GPI IgG/anti-
CL IgG, ORs for clinical symptoms hardly improved. Upon removing anti-DI positive 
patients, LAC remained significantly correlated with clinical complications. Anti-DI IgG 
are mainly present in high-risk triple positive patients, showing higher levels. Combined 
anti-DI and triple positivity confers a higher risk for clinical symptoms compared to only 
triple positivity.
Conclusions: Detection of anti-DI IgG resulted in higher ORs for clinical manifestations 
than the current APS classification criteria. Regardless of the platform used to detect 
anti-β2GPI/anti-CL, addition of anti-DI IgG measured by QUANTA Flash® did not improve 
the clinical associations, possibly due to reduced exposure of the pathogenic epitope 
of DI. Our results demonstrate that anti-DI IgG potentially helps in identifying high-risk 
patients.
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INTRODUC TION
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by 
recurrent thrombosis and/or pregnancy morbidity in combination with the persistent 
presence of antiphospholipid antibodies (aPLs).1 Due to the high prevalence of 
thrombosis and pregnancy morbidity in the general population, classification of APS 
mainly relies on laboratory results.2 Five different assays that detect aPLs are included 
in the current revised laboratory criteria: lupus anticoagulant (LAC), detecting a 
phospholipid-dependent prolongation of in vitro clotting times and two immunological 
quantitative assays measuring immunoglobulin (Ig) G and/or IgM anti-cardiolipin 
antibodies (anti-CL) and anti-β2glycoprotein I (anti-β2GPI) antibodies. Positive tests 
should be repeated with an interval of at least 12 weeks, to avoid transient positivity 
due to infections.3
Although laboratory testing of aPLs is critical to the classification of APS, the application 
and interpretation of these tests remain challenging.4,5 The variable clinical performance 
in conventional commercial and home-made aPL assays not only results from the lack 
of standardization,6,7 but also from the heterogeneity in aPLs.8
Accumulating evidence revealed that aPLs are directed against phospholipid-bound 
plasma proteins, of which β2GPI proved to be the main target.9-11 β2GPI consists of five 
homologous domains (Domain [D]I-DV). In the native circular or S-shaped conformation, 
the critical DI epitope is not exposed. Upon binding to an anionic phospholipid (PL) 
surface through the positively charged patch on DV, β2GPI undergoes a conformational 
change.12 Consequently, the DI-IV spreads out resulting in a more open J shape, 
exposing a cryptic epitope G40-R43 on DI and allowing a subset of anti-DI β2GPI 
autoantibodies to bind.13-15 Various subsets of a nti-β2GPI antibodies targeting different 
domains of the protein have been described with clear differences in clinical potential. 
The subpopulation of aPLs that recognize this epitope comprising at least G40-R43 on 
DI proved to be pathogenic in vitro/in vivo, and in clinical studies,16-20 while aPLs that 
recognize other domains of β2GPI seem to be benign.21-24
The aim of this study is to assess the clinical relevance of antibodies against DI of β2GPI 
in APS patients in an international multicenter study and evaluate the added value 
of detecting anti-DI IgG compared to the conventional assays, as well as whether the 
added value of the anti-DI IgG assay measured by this QUANTA Flash® depends on 
the platform used to detect anti-β2GPI and anti-CL IgG. The commercially available 
chemiluminescence (CIA) assay for anti-DI IgG was used in combination with anti-
CL and anti-β2GPI assays of different manufacturers. Assays were selected based on 
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frequently used assays in the external quality control program of the ECAT (External 
quality Control of diagnostic Assays and Tests, Voorschoten, the Netherlands) and 
willingness of manufacturers for collaboration.
METHODS
Study population
Patient and control samples were collected from eight European medical centers. The 
study was approved by the local ethics committees. General characteristics (eg, age, 
gender, ethnicity), clinical characteristics (eg, thrombotic events with specification 
of the type, pregnancy morbidity, autoimmune disease), and previous laboratory 
determinations (eg, LAC tests, IgG/IgM anti-CL, and anti-β2GPI reactivity) were recorded. 
In total, the database enrolled 1005 samples and samples were allocated to six different 
groups according to the information of the centers.
The classification of APS was based on the Sydney criteria.3 Classification was determined 
using the local aPL assay panel for LAC and IgG/IgM anti-CL or anti-β2GPI antibodies. 
Control populations consisted of patients with an autoimmune disease other than APS 
(eg, systemic lupus erythematosus and systemic sclerosis), meeting the criteria for the 
classification of autoimmune disease without Sydney criteria thrombotic or pregnancy 
morbidity complications (autoimmune disease other than APS [AID] controls); patients 
that were referred for aPLs testing for other reasons than the clinical criteria of APS 
(eg, subfertility and prolonged activated partial thromboplastin time [aPTT], normal 
controls); patients with a previous thrombotic event negatively tested for aPLs (non-
APS thrombosis); and patients that experienced obstetric complications in the absence 
of aPLs (non-APS obstetric). In the normal control-female population (n = 169) there was 
no history of pregnancy morbidity. Of the 169 women 119 (70.4%) were characterized 
by subfertility without previous pregnancy; of the 50 other control females information 
on whether they were (successfully) pregnant before was not available.
Methodology
Anti-CL IgG, anti-CL IgM, anti-β2GPI IgG, and anti-β2GPI IgM were detected by four solid 
phase assays: BioPlex®2200 (Bio-Rad, Bio-Rad Laboratories), Phadia® (Thermo Fisher 
Scientific/Phadia), HemosIL AcuStar® (Instrumentation Laboratories), and QUANTA 
Lite® ELISA (Inova Diagnostics). Anti-DI IgG was detected by the CIA of QUANTA Flash® 
β2GPI domain I assay (Inova Diagnostics) on the ACL AcuStar® platform. All tests were 
performed between February 2016 and October 2016 by a single technician in the 
Ghent University Hospital following the instructions of the manufacturer. Values below 
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the calculated limit of detection (LOD) were replaced by the LOD. The cutoff values 
from the manufacturers’ recommendation were confirmed in 20 healthy individuals 
according to the Clinical and Laboratory Standards Institute (CLSI) guidelines25 and 
guidance from the Scientific and Standardization Committee (SSC) of the International 
Society on Thrombosis (ISTH).5 Based on the cut-off values (20 arbitrary units ie U/mL, 
GPL, MPL, SGU, SMU on platforms of HemosIL AcuStar®, BioPlex®2200, and QUANTA 
Lite® ELISA; 10 arbitrary units on Phadia® for anti-CL IgG/IgM and anti-β2GPI IgG/IgM; 
20 chemiluminescence units [CU] on QUANTA Flash® for anti-DI IgG), positive samples 
were identified. LAC positivity was determined by the individual center, according to 
the ISTH guidelines.7
Statistics
Statistical analyses were performed using IBM SPSS® Statistics 24 (IBM SPSS). To avoid a 
possible bias induced by the classification performed by the eight individual centers, we 
selected “clinically affected versus clinically not affected” as outcome variable instead 
of “APS versus non-APS classification.” Relationships between the different laboratory 
assays and the clinical events (thrombosis or pregnancy morbidity) of the patients 
were investigated by calculating odds ratios (ORs) and 95% confidence intervals (95% 
CI) in the respective subpopulations. To determine the association with thrombosis 
and pregnancy morbidity, analysis was restricted to the thrombosis subpopulation 
(thrombotic APS, non-APS thrombosis, AID, and normal controls [n = 851]) and the 
pregnancy morbidity subpopulation (obstetric APS, non-APS obstetric, female AID, and 
female normal controls [n = 481]), respectively. Subsequently, the chi-squared test was 
used for the comparison of dichotomous variables, and anti-DI IgG titers were compared 
between groups by the Kruskal-Wallis H test (more than two groups) or Mann-Whitney 
U test (two groups). Finally, the kappa agreement of anti-DI IgG and conventional aPL 
tests was studied via the chi-squared test, and the correlation between the titer of anti-
DI IgG, anti-β2GPI IgG, and anti-CL IgG was performed by a Spearman rank correlation 
test. P < .05 (two-tailed) were considered statistically significant.
RESULTS
Characteristics of the study population
The patients’ demographic data and clinical characteristics are summarized in Table 1. 
To evaluate associations with thrombotic events and pregnancy morbidity separately, 
the characteristics of two subpopulations are shown in Table 1.
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TABLE 1. Demographic and clinical characteristics of the study population
A. The thrombosis subpopulation (N = 851)
Thrombotic APS AID Non-APS thrombosis Normal controls
Patients (N) 258 196 204 193
Gender
Female [N(%)] 165 (64.0) 158 (80.6) 116 (56.9) 169 (87.6)
Age (Mean ± SD, years) 49.6 ± 14.7 46.4 ± 14.2 46.5 ± 14.1 39.4 ± 11.0
Clinical features [N (%)]
Thrombosis 258 (100.0) 0 204 (100) 0
AT 54 (20.9) 0 47 (23.0) 0
VT 160 (62.0) 0 149 (73.0) 0
AT + VT 26 (10.1) 0 5 (2.5) 0
Small vessel 4 (1.6) 0 0 (0) 0
Pregnancy morbidity 23 (8.9) 2 (1.0) 0 0
A 6 (2.3) 0 0 0
B 6 (2.3) 0 0 0
C 6 (2.3) 0 0 0
NS/ non-Sydney criteria 5 (1.9) 2 (1.0) 0 0
B. The pregnancy morbidity subpopulation (N = 481)
Obstetric APS AID-female Non-APS obstetric
Normal controls-
female
Patients (N) 121 158 33 169
Age (Mean ± SD, years) 34.3 ± 6.6 45.4 ± 14.5 32.7 ± 5.6 38.4 ± 9.6
Clinical features [N (%)]
Thrombosis 9 (7.4) 0 0 0
AT 3 (2.5) 0 0 0
VT 5 (4.1) 0 0 0
AT + VT 1 (0.8) 0 0 0
Small vessel 0 (0) 0 0 0
Pregnancy morbidity 121 (100.0) 2 (1.3) 33 (100.0) 0
A 35 (28.9) 0 9 (27.3) 0
B 10 (8.3) 0 4 (12.1) 0
C 67 (55.4) 0 6 (18.2) 0
B+C 2 (1.7) 0 1 (3.0) 0
A+C 3 (2.5) 0 1 (3.0) 0
NS/non-Sydney criteria 4 (3.3) 2 (1.3) 12 (36.4) 0
Note: A, history of three or more consecutive unexplained losses <10 weeks gestation; B, history of fetal death after 10 weeks before 
gestation; C, history of premature birth(s) before 34 weeks due to preeclampsia or placental insufficiency based on the Sydney 
classification criteria. NS, non-specified pregnancy complications; non-Sydney criteria, not fulfilling Sydney criteria for pregnancy 
morbidity. Abbreviations: AID, autoimmune disease other than APS; APS, antiphospholipid syndrome; AT, arterial thrombosis; N, 
number of patients; SD, standard deviation; VT, venous thrombosis.
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Association between anti-DI IgG and clinical symptoms of APS
Independent of the platform, a significant association with clinical events was found 
for all tested aPL assays, with ORs varying from 2.7 (95% CI 1.9-3.9) to 5.4 (95% CI 3.0-
9.6) for thrombosis, 2.3 (95% CI 1.5-3.3) to 4.1 (95% CI 2.5-6.6) for arterial thrombosis, 
2.0 (95% CI 1.4-2.8) to 2.8 (95% CI 1.9-4.2) for venous thrombosis, and 2.7 (95% CI 1.7-
4.3) to 5.6 (95% CI 3.1-9.9) for pregnancy morbidity (Table 2A). Compared to the criteria 
aPL assays, detection of anti-DI IgG was less sensitive (21.9%/26.6% for thrombosis/
pregnancy morbidity), but more specific (94.9%/93.9% for thrombosis/pregnancy 
morbidity), overall resulting in higher ORs for both clinical criteria of APS compared 
to LAC, anti-β2GPI, or anti-CL IgG except for the QUANTA Lite® ELISA platform. Similar 
ORs of anti-DI were found for thrombosis and pregnancy morbidity, and no difference 
in association was observed between venous versus arterial thrombosis. Interestingly, 
upon restriction to patients positive for anti-β2GPI IgG, anti-DI IgG positivity still 
resulted in significant—albeit lower—ORs for both clinical criteria of APS except for the 
QUANTA Lite® ELISA platform (Table 2B).
Additional clinical value of detecting anti-DI IgG on top of the currently 
used laboratory tests
Table 3 shows the number of patients testing positive or negative for anti-DI IgG in 
relation to positivity for LAC or anti-β2GPI IgG or at least one of the criteria aPL panel 
measured by HemosIL AcuStar® considering the previously defined subpopulations. 
The results of the other three solid phase assays can be found in Table S1 in supporting 
information.
From Table 3, looking at the thrombosis subpopulation, 13 out of the 19 LAC negative 
anti-DI positive patients had thrombosis. Additionally, the four samples testing negative 
for anti-β2GPI IgG by HemosIL AcuStar® but positive for anti-DI IgG all had thrombosis. 
Similarly, the two individuals testing negative for the criteria aPL panel by HemosIL 
AcuStar® and positive for anti-DI IgG both suffered from thrombosis. Concerning the 
pregnancy morbidity subpopulation, 12 out of the 18 LAC negative anti-DI IgG positive 
patients experienced pregnancy morbidity. One patient testing negative for anti-
β2GPI IgG by HemosIL AcuStar® and positive for anti-DI IgG had pregnancy morbidity. 
Moreover, only one individual negative for the criteria aPL panel by HemosIL AcuStar® 
tested positive for anti-DI IgG and suffered from pregnancy morbidity. Looking at Table 
S1, both for the thrombosis subpopulation or the pregnancy morbidity subpopulation, 
similar results were found when anti-β2GPI or anti-CL IgG/IgM were detected by 
BioPlex®2200 although more samples tested negative for anti-β2GPI IgG by Phadia® 
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TABLE 2. Additional diagnostic value of aCL and aβ2GPI IgA antibodies. Figures indicate the number of patients testing positive or negative for LAC, aCL and aβ2GPI IgG/M antibodies versus aCL and aβ2GPI IgA, for each solid-phase assay.
A. In the total population
 Manufacturer 


















LAC 851 43.7 81.5 3.4 2.5-4.7 834 47.0 71.8 2.3 1.5-3.3 834 43.2 77.1 2.6 1.9-3.5 481 48.7 81.7 4.2 2.8-6.4
Anti-CL 
IgG
HemosIL AcuStar® 851 24.7 92.5 4.1 2.6-6.3 834 31.8 86.2 2.9 1.9-4.4 834 24.4 88.7 2.5 1.7-3.7 481 29.2 91.4 4.4 2.6-7.4
BioPlex® 2200 851 26.4 89.7 3.1 2.1-4.6 834 34.1 83.9 2.7 1.8-4.1 834 25.9 85.8 2.1 1.5-3.0 481 31.8 88.1 3.4 2.1-5.5
Phadia® 851 23.6 93.1 4.1 2.7-6.5 834 31.1 87.2 3.1 2.0-4.7 834 22.6 89.1 2.4 1.6-3.5 481 29.2 92.4 5.0 2.9-8.5




HemosIL AcuStar® 851 30.1 86.4 2.7 1.9-3.9 834 36.4 80.2 2.3 1.6-3.5 834 30.0 82.8 2.1 1.5-2.9 481 33.1 84.7 2.7 1.7-4.3
BioPlex® 2200 851 26.2 88.7 2.8 1.9-4.1 834 34.1 83.5 2.6 1.7-3.9 834 25.6 85.0 2.0 1.4-2.8 481 31.8 87.5 3.3 2.0-5.2
Phadia® 851 22.5 92.3 3.5 2.6-5.4 834 29.5 87.0 2.8 1.8-4.3 834 21.8 88.7 2.2 1.5-3.2 481 25.3 91.1 3.5 2.1-5.9
QUANTA Lite ELISA® 851 16.7 96.4 5.4 3.0-9.6 834 25.8 92.2 4.1 2.5-6.6 834 15.3 92.5 2.2 1.4-3.5 481 14.3 96.0 4.0 2.0-8.2
Anti-DI 
IgG
QUANTA Flash® 851 21.9 94.9 5.2 3.1-8.5 834 27.3 88.5 2.9 1.8-4.5 834 21.5 91.1 2.8 1.9-4.2 481 26.6 93.9 5.6 3.1-9.9
Triple 
positivity
HemosIL AcuStar® 851 24.0 94.1 5.0 3.1-8.1 834 28.8 87.2 2.7 1.8-4.3 834 24.1 90.7 3.1 2.1-4.6 481 22.1 93.3 3.9 2.2-7.0
BioPlex® 2200 851 25.5 92.8 4.4 2.9-6.9 834 31.1 86.2 2.8 1.8-4.3 834 24.7 89.1 2.7 1.8-3.9 481 22.7 91.7 3.3 1.9-5.6
Phadia® 851 21.9 93.8 4.3 2.7-6.8 834 26.5 88.0 2.7 1.7-4.2 834 21.5 90.7 2.7 1.8-4.0 481 19.5 93.6 3.5 1.9-6.4





HemosIL AcuStar® 851 18.8 96.7 6.7 3.7-12.2 834 24.2 90.9 3.2 2.0-5.1 834 18.2 93.1 3.0 1.9-4.7 481 18.8 96.0 5.6 2.8-11.1
BioPlex® 2200 851 19.0 96.7 6.8 3.7-12.4 834 24.2 90.7 3.1 2.0-5.0 834 18.5 93.1 3.1 2.0-4.8 481 18.8 96.0 5.6 2.8-11.1
Phadia® 851 16.9 96.9 6.4 3.4-11.9 834 22.0 91.9 3.2 1.9-5.2 834 16.2 93.7 2.9 1.8-4.6 481 16.2 96.3 5.1 2.5-10.4
QUANTA Lite ELISA® 851 15.6 97.4 7.0 3.6-13.8 834 21.2 92.7 3.4 2.1-5.7 834 14.7 94.1 2.8 1.7-4.5 481 12.3 96.9 4.5 2.0-9.8
















HemosIL AcuStar® 192 69.8 62.3 3.8 2.0-7.4 101 78.4 60.0 5.5 2.3-13.1
BioPlex® 2200 165 79.3 54.5 4.6 2.2-9.6 90 81.6 51.2 4.7 1.8-12.0
Phadia® 134 82.7 40.0 3.2 1.3-7.8 68 87.2 37.9 4.2 1.3-13.8
QUANTA Lite ELISA® 91 89.6 14.3 1.4 0.3-7.6 35 95.5 7.7 1.8 0.1-30.6
Note: Significant ORs are shown in bold and calculated according to the outcome variable ''clinically affected versus clinically not-
affected patients’'. Abbreviations: aPLs, antiphospholipid antibodies; APS, antiphospholipid syndrome; β2GPI, β2glycoprotein I; 
CL, cardiolipin; DI, domain I; IgG, immunoglobulin G; LAC, lupus anticoagulant; N, number of patients; OR, odds ratio; 95% CI, 95% 
confidence interval; Triple positivity, LAC positive, anti-CL IgG/IgM positive and anti-β2GPI IgG/IgM positive. aThrombotic APS + non-
APS thrombosis versus non-thrombotic population (AID + normal controls). bObstetric APS + non-APS obstetric versus non-obstetric 
population (AID-female + normal controls-female). cIn the thrombosis subpopulation, 17 individuals without specified thrombosis 
type were defined as missing data. dArterial thrombosis versus non-arterial thrombosis. eVenous thrombosis versus non-venous 
thrombosis.
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TABLE 2. Additional diagnostic value of aCL and aβ2GPI IgA antibodies. Figures indicate the number of patients testing positive or negative for LAC, aCL and aβ2GPI IgG/M antibodies versus aCL and aβ2GPI IgA, for each solid-phase assay.
A. In the total population
 Manufacturer 


















LAC 851 43.7 81.5 3.4 2.5-4.7 834 47.0 71.8 2.3 1.5-3.3 834 43.2 77.1 2.6 1.9-3.5 481 48.7 81.7 4.2 2.8-6.4
Anti-CL 
IgG
HemosIL AcuStar® 851 24.7 92.5 4.1 2.6-6.3 834 31.8 86.2 2.9 1.9-4.4 834 24.4 88.7 2.5 1.7-3.7 481 29.2 91.4 4.4 2.6-7.4
BioPlex® 2200 851 26.4 89.7 3.1 2.1-4.6 834 34.1 83.9 2.7 1.8-4.1 834 25.9 85.8 2.1 1.5-3.0 481 31.8 88.1 3.4 2.1-5.5
Phadia® 851 23.6 93.1 4.1 2.7-6.5 834 31.1 87.2 3.1 2.0-4.7 834 22.6 89.1 2.4 1.6-3.5 481 29.2 92.4 5.0 2.9-8.5




HemosIL AcuStar® 851 30.1 86.4 2.7 1.9-3.9 834 36.4 80.2 2.3 1.6-3.5 834 30.0 82.8 2.1 1.5-2.9 481 33.1 84.7 2.7 1.7-4.3
BioPlex® 2200 851 26.2 88.7 2.8 1.9-4.1 834 34.1 83.5 2.6 1.7-3.9 834 25.6 85.0 2.0 1.4-2.8 481 31.8 87.5 3.3 2.0-5.2
Phadia® 851 22.5 92.3 3.5 2.6-5.4 834 29.5 87.0 2.8 1.8-4.3 834 21.8 88.7 2.2 1.5-3.2 481 25.3 91.1 3.5 2.1-5.9
QUANTA Lite ELISA® 851 16.7 96.4 5.4 3.0-9.6 834 25.8 92.2 4.1 2.5-6.6 834 15.3 92.5 2.2 1.4-3.5 481 14.3 96.0 4.0 2.0-8.2
Anti-DI 
IgG
QUANTA Flash® 851 21.9 94.9 5.2 3.1-8.5 834 27.3 88.5 2.9 1.8-4.5 834 21.5 91.1 2.8 1.9-4.2 481 26.6 93.9 5.6 3.1-9.9
Triple 
positivity
HemosIL AcuStar® 851 24.0 94.1 5.0 3.1-8.1 834 28.8 87.2 2.7 1.8-4.3 834 24.1 90.7 3.1 2.1-4.6 481 22.1 93.3 3.9 2.2-7.0
BioPlex® 2200 851 25.5 92.8 4.4 2.9-6.9 834 31.1 86.2 2.8 1.8-4.3 834 24.7 89.1 2.7 1.8-3.9 481 22.7 91.7 3.3 1.9-5.6
Phadia® 851 21.9 93.8 4.3 2.7-6.8 834 26.5 88.0 2.7 1.7-4.2 834 21.5 90.7 2.7 1.8-4.0 481 19.5 93.6 3.5 1.9-6.4





HemosIL AcuStar® 851 18.8 96.7 6.7 3.7-12.2 834 24.2 90.9 3.2 2.0-5.1 834 18.2 93.1 3.0 1.9-4.7 481 18.8 96.0 5.6 2.8-11.1
BioPlex® 2200 851 19.0 96.7 6.8 3.7-12.4 834 24.2 90.7 3.1 2.0-5.0 834 18.5 93.1 3.1 2.0-4.8 481 18.8 96.0 5.6 2.8-11.1
Phadia® 851 16.9 96.9 6.4 3.4-11.9 834 22.0 91.9 3.2 1.9-5.2 834 16.2 93.7 2.9 1.8-4.6 481 16.2 96.3 5.1 2.5-10.4
QUANTA Lite ELISA® 851 15.6 97.4 7.0 3.6-13.8 834 21.2 92.7 3.4 2.1-5.7 834 14.7 94.1 2.8 1.7-4.5 481 12.3 96.9 4.5 2.0-9.8
















HemosIL AcuStar® 192 69.8 62.3 3.8 2.0-7.4 101 78.4 60.0 5.5 2.3-13.1
BioPlex® 2200 165 79.3 54.5 4.6 2.2-9.6 90 81.6 51.2 4.7 1.8-12.0
Phadia® 134 82.7 40.0 3.2 1.3-7.8 68 87.2 37.9 4.2 1.3-13.8
QUANTA Lite ELISA® 91 89.6 14.3 1.4 0.3-7.6 35 95.5 7.7 1.8 0.1-30.6
Note: Significant ORs are shown in bold and calculated according to the outcome variable ''clinically affected versus clinically not-
affected patients’'. Abbreviations: aPLs, antiphospholipid antibodies; APS, antiphospholipid syndrome; β2GPI, β2glycoprotein I; 
CL, cardiolipin; DI, domain I; IgG, immunoglobulin G; LAC, lupus anticoagulant; N, number of patients; OR, odds ratio; 95% CI, 95% 
confidence interval; Triple positivity, LAC positive, anti-CL IgG/IgM positive and anti-β2GPI IgG/IgM positive. aThrombotic APS + non-
APS thrombosis versus non-thrombotic population (AID + normal controls). bObstetric APS + non-APS obstetric versus non-obstetric 
population (AID-female + normal controls-female). cIn the thrombosis subpopulation, 17 individuals without specified thrombosis 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































and QUANTA Lite® ELISA but positive for anti-DI IgG, and most of them had thrombosis 
or pregnancy morbidity. Including LAC, fewer individuals negative for the criteria aPL 
panel tested positive for anti-DI IgG and suffered from clinical events.
To assess the additional clinical value of anti-DI IgG on top of the currently used aPL 
measured by different platforms, anti-DI IgG was added to the criteria aPL panel or 
used as a substitute for anti-β2GPI IgG and anti-CL IgG in the criteria aPL panel. For all 
platforms, the addition of anti-DI IgG to the current criteria aPL panel hardly resulted 
in an increase of the OR for thrombosis or pregnancy morbidity. Replacement of anti-
β2GPI IgG and anti-CL IgG by anti-DI IgG resulted in comparable ORs for both clinical 
symptoms. For all platforms, a small increase was observed in specificity when replacing 
anti-β2GPI IgG and anti-CL IgG by anti-DI IgG, mostly accompanied by a decrease in 
sensitivity (Table 4).
To investigate if anti-DI antibodies are the only pathogenic antibodies, we re-evaluated 
the correlation of LAC, anti-CL IgG, and anti- β2GPI IgG with clinical manifestations of 
APS in anti-DI IgG negative patients. Interestingly, upon removal of anti-DI positive 
samples, positivity for LAC still resulted in significant ORs for thrombosis (2.5, 95% CI 
1.7-3.5) and for pregnancy morbidity (3.9, 95% CI 2.4-6.4) while correlations for anti-
β2GPI IgG and anti-CL IgG antibodies were no longer statistically significant except 
for when the anti-CL IgG was measured by Phadia® and QUANTA Lite® ELISA (OR for 
thrombosis of 2.3 (95% CI 1.1-4.8) and 2.4 (95% CI 1.0-5.5), respectively; Table 5).
Distribution of anti-DI IgG titers according to the patient’s antibody 
profile
For both the thrombosis and pregnancy morbidity subpopulation, all individuals were 
grouped according to their aPL profile into triple positive (LAC +, anti-CL IgG/IgM +, 
anti-β2GPI IgG/IgM +), double positive (LAC −, anti-CL IgG/IgM +, anti-β2GPI IgG/IgM 
+ or LAC +, anti-CL IgG/IgM +, anti-β2GPI IgG/IgM − or LAC +, anti-CL IgG/IgM −, anti-
β2GPI IgG/IgM +), and single positive (isolated positive for LAC, anti-CL IgG/IgM, or 
anti-β2GPI IgG/IgM). Results were compared with those of patients without any aPL 
reactivity (negative control). The different antibody profiles with their characteristics 
are shown in Table 6 for anti-β2GPI and anti-CL measured by HemosIL AcuStar® and in 
Table S2-S4 in supporting information for anti-β2GPI and anti-CL measured by the three 
other solid-phase assays.
Furthermore, we compared anti-DI IgG titers in the triple positive, solid-phase double-
positive (anti-CL IgG/IgM positive and anti-β2GPI IgG/ IgM positive but LAC negative), 
combined single-positive group (isolated LAC +, and isolated anti-CL IgG/IgM +, and 
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isolated anti-β2GPI IgG/IgM +), and the negative control. Comparison of anti-DI IgG 
titers between four aPL profile groups for anti-β2GPI and anti-CL measured by four 
assays is shown in Figure 1. Looking at HemosIL AcuStar®, in both the thrombosis 
subpopulation and pregnancy morbidity subpopulation anti-DI titers were significantly 
higher in triple positive samples compared to the other aPL profile groups, followed 
by the solid-phase double-positive samples. No difference was observed between anti-
DI titers of combined single positive and negative samples. Similar results were found 
for the three other assays, except that there was a significant difference between anti-
DI titers of combined single positive and negative samples for anti-β2GPI and anti-CL 
measured by QUANTA Lite® ELISA (Figure 1).
TABLE 5. ORs of LAC, anti-CL IgG and anti-β2GPI IgG with clinical manifestations of APS upon the removal of 










(N$) OR 95% CI
LAC 730 172 2.5 1.7-3.5 420 92 3.9 2.4-6.4
Anti-CL 
IgG
HemosIL AcuStar® 730 29 2.0 0.9-4.4 420 14 1.5 0.5-4.7
BioPlex® 2200 730 47 1.3 0.7-2.3 420 29 1.2 0.5-2.8
Phadia® 730 35 2.3 1.1-4.8 420 16 2.2 0.8-6.0




HemosIL AcuStar® 730 75 1.3 0.8-2.2 420 41 1.0 0.5-2.1
BioPlex® 2200 730 49 1.1 0.6-1.9 420 30 1.2 0.5-2.7
Phadia® 730 30 1.6 0.7-3.3 420 16 1.2 0.4-3.7
QUANTA Lite ELISA® 730 10 4.2 0.9-19.7 420 2 2.7 0.2-44.1
Note: Significant ORs are shown in bold and calculated according to the outcome variable “clinically affected versus clinically 
not-affected patients.” Abbreviations: APS, antiphospholipid syndrome; β2GPI, β2glycoprotein I; CL, cardiolipin; DI, domain I; IgG, 
immunoglobulin G; LAC, lupus anticoagulant; N#, number of patients; N$, number of biomarker positive cases; OR, odds ratio; 95% 
CI, 95% confidence interval. aThrombotic APS + non-APS thrombosis versus non-thrombotic population (AID + normal controls). 
bObstetric APS + non-APS obstetric versus non-obstetric population (AID - female + normal controls - female).
Association of triple positivity with anti-DI positivity
The association between DI positivity and triple positivity was studied in detail for 
anti-β2GPI and anti-CL measured by the Acustar® (Table 6). As to the thrombosis 
subpopulation (Table 6), positive values of anti-DI IgG were found in 100 out of 134 
individuals with triple positivity (74.6%), compared with 44.1% (15/34) in the solid-
phase double-positive group (Pearson chi-square, P = .002). Combined single-positive 
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FIGURE 1. Distribution of the titer of anti-DI IgG according to distinct antibody profiles for anti-CL and anti-
β2GPI measured by HemosIL AcuStar®, BioPlex®2200, Phadia®, and QUANTA Lite® ELISA in the thrombosis 
subpopulation (A) and pregnancy morbidity subpopulation (B). Investigated aPL profiles include triple 
positive (LAC +, anti-CL IgG/IgM +, anti-β2GPI IgG/IgM +), solid phase double positive (LAC −, anti-CL IgG/IgM 
+, anti-β2GPI IgG/IgM +), and combined single positive (isolated LAC +, and isolated anti-CL IgG/IgM +, and 
isolated anti-β2GPI IgG/IgM +). Patients without any aPL reactivity were defined as negative controls. Titer of 
anti-DI IgG are expressed as the median with interquartile ranges within each profile; dashed lines indicate 
the cut-off value of anti-DI IgG (20 CU). *P < .05, **P < .01, ***P < .0001, ns: not significant. Abbreviations: aPL, 
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reactivity (Fisher's exact test, P < .0001). A good agreement was found between triple 
positivity and anti-DI IgG positivity (Kappa value = 0.746, P < .0001). In this triple positive 
group, 87.0% (87/100) of anti-DI IgG positive individuals had a history of thrombosis, 
compared with 70.6% (24/34) of anti-DI IgG negative patients (Pearson chi-square, P = 
.028).
Concerning the pregnancy morbidity subpopulation (Table 6), positive values of anti-DI 
IgG were found in 42 out of 56 individuals with triple positivity (75.0%), compared with 
48.6% (17/35) in the solid-phase double-positive group (Pearson chi-square, P = .013). As 
seen in the thrombosis subpopulation, the combined single-positive group (0/81 = 0%) 
and aPL negative patients (1/287 = 0.3%) hardly showed anti-DI IgG reactivity (Fisher's 
exact test, P < 0.0001). Albeit lower than for the thrombosis subpopulation, also in the 
pregnancy morbidity subpopulation a good agreement was demonstrated between 
triple positivity and anti-DI IgG (Kappa value = 0.679, P < .0001). In this triple-positive 
group, 69.0% (29/42) of anti-DI IgG positive individuals had a history of pregnancy 
morbidity, compared with 35.7% (5/14) of anti-DI IgG negative patients (Fisher's exact 
test, P = .027). In general, similar conclusions can be drawn when anti-β2GPI and anti-CL 
were measured by the other assays (Tables S2-S5 in supporting information).
Interestingly, both for thrombosis and pregnancy morbidity, the ORs of anti-DI IgG 
were higher than the ORs of triple positivity except when anti-CL and anti-β2GPI 
were measured by the QUANTA Lite® ELISA platform for thrombosis. To verify if anti-
DI positivity has an added value in risk stratification compared to triple positivity, ORs 
of combined triple positivity and DI positivity were calculated for thrombosis and 
pregnancy morbidity. As to thrombosis, combined positivity resulted in higher OR 
compared to the separate OR for both triple positivity and DI reactivity. For pregnancy 
morbidity, ORs of anti-DI plus triple positivity were higher compared to ORs of triple 
positivity, but hardly improved compared to OR of anti-DI positivity (Table 2A).
Furthermore, as to the thrombosis subpopulation, within the triple-positive group for 
anti-β2GPI and anti-CL measured by Acustar®, anti-DI IgG titers varied greatly but no 
significant difference was observed between patients with thrombosis (n = 111) and 
unaffected individuals (n = 23), with a median (quartile[Q]25-Q75) anti-DI IgG titer 
of, respectively, 169.0 CU (25.7-761.3) and 63.7CU (3.7-625.7) (Mann-Whiney U test, 
P = .084). Similarly, concerning the pregnancy morbidity subpopulation, anti-DI IgG 
titers differed greatly but no significant difference between patients with pregnancy 
morbidity (n = 34) and unaffected individuals (n = 22) could be demonstrated with a 
median (Q25-Q75) anti-DI IgG titer of 200.2 CU (49.6-462.1) and 65.0 CU (3.7-654.3), 
respectively (Mann-Whiney U test, P = .179). Similar results were obtained with the three 
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other assays, although for the BioPlex®2200 (thrombosis and pregnancy morbidity) and 
Phadia® (thrombosis) results reached statistical significance (Table S6 in supporting 
information).
Correlation between detection of anti-DI IgG and anti-β2GPI IgG and anti-
CL IgG
Concordance was evaluated by comparing the results of the detection of IgG anti-DI 
antibodies with anti-β2GPI IgG and anti-CL IgG measured by four solid-phase assays 
(Table 7). A good agreement was established between IgG anti-DI antibodies and IgG 
anti-CL as well as with IgG anti-β2GPI antibodies (Kappa value = 0.656-0.861) in the 
thrombosis subpopulation (Table 7A) and the pregnancy morbidity subpopulation 
(Table 7B). The IgG anti-DI antibody titers were likewise significantly correlated with IgG 
anti-CL titers and IgG anti-β2GPI titers (Spearman's rho = 0.563-0.842) in the thrombosis 
subpopulation (Table 7A) and the pregnancy morbidity subpopulation (Table 7B; all P 
< .0001).
DISCUSSION
Solid phase aPL assays included in the laboratory criteria suffer from a lack of 
standardization, limiting their utility in clinical practice. Variability results not only from 
methodological shortcomings but also from the heterogeneity of aPLs.5,7 More and 
more literature evidence suggests that detection of a subset of aPLs reactive against 
DI of β2GPI is a promising classification or risk stratification tool in APS.26,27 However, a 
recent review concluded inconsistent results about the added value of the detection 
of anti-DI IgG compared to conventional aPL tests, most probably due to differences in 
study design, study population, and the methodology to detect the anti-DI antibodies.28
In this multicenter study, all samples were measured for aPL reactivity by one technician 
in the same lab to avoid variability coming from differences in working conditions. In 
most studies evaluating the added value of anti-DI IgG, the only commercially available 
assay (CIA of QUANTA Flash®) is compared with anti-β2GPI and anti-CL of the same 
manufacturer.29-35 Importantly, we hypothesized that the added value of the anti-DI 
IgG assay measured by QUANTA Flash® depends on the platform used to detect anti-
β2GPI and anti-CL IgG. This hypothesis comes from our previously published results 
demonstrating a variable exposure of the G40-R43 epitope on domain I of β2GPI 
coated in the different commercially available anti-CL and anti-β2GPI assays.8,36,37 In this 
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multicenter study, we therefore determined the added value of anti-DI testing to the 
current APS classification criteria, when anti-CL and anti-β2GPI were measured by our 
different commercially available assays.
As literature is inconclusive whether the same aPL subset induces thrombosis 
and pregnancy morbidity, separate analyses were performed in a thrombosis and 
pregnancy morbidity subpopulation, including proper control populations. Both for the 
thrombosis and the pregnancy morbidity subpopulation, we found that the detection 
of anti-DI IgG was less sensitive but more specific compared to the laboratory criteria 
aPL tests, resulting in a higher OR for thrombosis and pregnancy morbidity compared to 
LAC, anti-β2GPI, or anti-CL IgG, except for the QUANTA Lite® ELISA. Interestingly, upon 
restriction to patients positive for anti-β2GPI IgG, anti-DI IgG positivity still resulted 
in significant ORs for clinical complications, except for the QUANTA Lite® ELISA (Table 
2B); that could be explained by the lower number of anti-β2GPI IgG detected by this 
assay (Table S1). These findings are consistent with previous studies.19,20,29,30,32 Based on 
these results, apart from those obtained by the QUANTA Lite® ELISA, we expected anti-
DI IgG to have an additional value on top of the current laboratory criteria, or to be 
a candidate to replace the anti-β2GPI IgG detection. Contrary to our expectation, the 
addition of anti-DI or replacement of anti-β2GPI IgG by anti-DI hardly improved the ORs 
for thrombosis or pregnancy morbidity. The absence of an added value of anti-DI to the 
current aPL criteria panel was also found in previous studies.34,35
This at-first-sight contradiction can be explained by the results presented in Table 3 and 
Table S1. Independent of the assay used, only few individuals (n = 11) negative for the 
criteria aPL panel (with one or more platforms) become positive when anti-DI IgG is 
added to the criteria aPLs panel or used as a substitute for anti-β2GPI IgG and/or anti-CL 
IgG, even though most of them experienced clinical events (n = 7 with thrombosis, n = 
2 with pregnancy morbidity). Of note, despite anti-DI IgG positivity, the titers of anti-DI 
IgG in these individuals proved to be low (from 21.1 to 73.2 CU).
Interestingly, upon removal of anti-DI IgG positive patients, anti-CL IgG and anti-
β2GPI IgG were no longer significantly correlated with thrombosis and pregnancy 
morbidity, except for anti-CL IgG measured by Phadia® and by QUANTA Lite® ELISA (OR 
for thrombosis of 2.3 [95% CI 1.1-4.8] and 2.4 [95% CI 1.0-5.5], respectively; Table 5). 
Although the OR for thrombosis of anti-CL IgG measured by Phadia® and by QUANTA 
Lite® ELISA was still significant, the lower limit was adjacent to 1. These findings are in 
agreement with previous studies demonstrating that especially anti-DI antibodies are 
pathogenic while antibodies targeting other domains such as domain 4/5 are innocent 
or even protective antibodies.20,23,38,39
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We previously demonstrated that the large variability observed in commercially 
available anti-β2GPI assays results at least in part from a variable exposure of the 
pathogenic G40-R43 DI epitope.8 Importantly, our recent data show that, as for 
anti-β2GPI IgG assays, the pathogenic DI epitope is not exposed correctly in the 
commercially available anti-DI CIA assay.28 Furthermore, both as categorical variables 
(positive/negative) and as quantitative variables (titer), anti-DI IgG strongly correlated 
with anti-CL IgG and anti-β2GPI IgG on the same AcuStar® CIA. The high correlation 
between anti-DI IgG and anti-β2GPI IgG suggests a high overlap between both assays 
performed on the automated CIA platform. Previous studies also observed a high 
agreement (69%-92%) between anti-DI IgG and anti-β2GPI IgG when measured using 
the CIA methodology.29,34,35,40 These results may explain the absence of an added value 
of measuring anti-DI using this assay. In this study, and also for the other platforms, a 
high agreement was found between anti-DI and the anti-CL IgG and anti-β2GPI IgG and 
no added value of measuring anti-DI could be demonstrated (Table 7).
Of note, apart from the anti-DI CIA assay used in this study, other methods are available 
to detect anti-DI antibodies.28 Previously a home-made two-step ELISA strongly 
indicated that testing for IgG anti-DI enables identification of the patients at highest 
risk for developing thrombosis or pregnancy morbidity.19,20 In contrast to the results 
obtained by CIA assays, only 50% of the anti-β2GPI IgG antibodies tested by this 
home-made two-step ELISA were demonstrated to be reactive against DI. Importantly, 
using this two-step ELISA assay, correct exposure of the G40-R43 epitope was already 
confirmed.20 The added value of measuring anti-DI reactivity using this assay remains to 
be determined.
Interestingly, LAC remained significantly correlated with thrombosis and pregnancy 
morbidity upon removal of anti-DI IgG positive patients. Further illustrated by the only 
fair to moderate agreement between IgG anti-DI and functional LAC in the thrombosis 
subpopulation (Kappa value = 0.398) and the pregnancy morbidity subpopulation 
(Kappa value = 0.320), these data illustrate that the CIA anti-DI IgG assay only detects 
part of the pathogenic aPLs. The presence of pathogenic anti-phosphatidylserine/
prothrombin (anti-PS/PT) antibodies able to induce LAC positivity may explain the 
remaining correlation between LAC and thrombosis. Indeed, previous studies have 
demonstrated correlations of anti-PS/PT with clinical symptoms in APS patients and 
positivity proved to be associated with LAC.41,42
Evidence is growing that the determination of combined antibody positivity helps to 
categorize patients according to their risk profile. Especially triple-positive patients 
(positive for LAC and anti-CL and anti-β2GPI IgG/IgM) show a strong association with 
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thrombotic and obstetric manifestations.43,44 Clinical studies confirm that triple positivity 
in APS patients and asymptomatic aPL carriers indicates a high risk of recurrence of 
thrombosis or development of a first thrombotic event, respectively.44,45 Although 
identification of triple positives is dependent on the solid-phase assay used,46 the 
percentage of anti-DI IgG positives in individuals with distinct antibody profiles were 
comparable for the four tested solid-phase assays. In this study, a very good agreement 
was found between triple positivity and anti-DI IgG positivity, irrespective of the solid-
phase assay used (Table S5), which is consistent with previous studies.30-32,35,40 Moreover, 
independent of the platform used to measure anti-CL and anti-β2GPI IgG/IgM, we 
observed that anti-DI IgG antibodies are mainly present in triple positive individuals, 
also showing significantly higher titers compared to patients with other aPL profiles. 
More importantly, within the triple positive group, a higher percentage of clinically 
affected cases was present in the anti-DI IgG positive compared to the anti-DI IgG 
negative group. Furthermore, the higher ORs of combined DI and triple positivity for 
both thrombosis and pregnancy morbidity compared to only triple positivity, support 
the idea that detection of anti-DI IgG is interesting to identify patients at risk.
We acknowledge that our study has some limitations. First, as in both the thrombotic 
and obstetric patient groups, a small number of patients (8.9% and 7.4%, respectively) 
also suffers from the other clinical manifestation, the correlation with the specific 
clinical manifestation may be affected by the comorbidity of the other manifestation. 
Also, the different groups in our study population did not match according to age and 
gender, but were representative to population groups tested in daily practice. Another 
limitation of our study is the retrospective design. Interestingly, in the AID and normal 
control group, a number of the triple positives were also positive for anti-DI reactivity 
(depending on the platform 11/22 [50%]-9/14 [64%] for AID; 1/3 [33%]-2/4 [50%] for 
the normal controls). Prospective studies are necessary to verify the risk of patients 
with these characteristics to develop clinical manifestations of APS, with possible 
implications for their treatment.
This study showed again that the choice of the commercial assays used to detect 
the presence of antiphospholipid antibodies influences the classification of APS. It is 
impossible to determine which commercial assay is the best because we lack a gold 
standard. However, a good agreement with a domain I specific assay seems to be 





Despite the higher OR of anti-DI antibody detection for clinical manifestations of APS, 
our study was unable to demonstrate an added value of measuring anti-DI IgG on top of 
the laboratory criteria, independent of the platform used to measure anti-CL and anti-
β2GPI. We put the hypothesis forward that the reduced exposure of the pathogenic 
DI epitope in this automated assay possibly explains the absence of an added value. 
Therefore, it may be interesting to re-evaluate the added value of anti-DI using the in-
house anti-DI assay previously developed, for which correct exposure of the pathogenic 
epitope was already demonstrated. The high correlation between anti-DI IgG and triple 
positivity indicates that anti-DI IgG positivity confirms the patients at higher risk for 
clinical events in APS. Importantly, combined DI and triple positivity confirms a higher 
risk for both thrombosis and pregnancy morbidity compared to only triple positivity. 
As LAC positivity remains significantly correlated with thrombosis and pregnancy 
morbidity upon removal of anti-DI positive patients, the anti-DI IgG assay only detects 
part of the pathogenic aPLs.
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ADDENDUM
K. M. J. Devreese, B. de Laat and H. Kelchtermans designed the study. K. M. J. Devreese 
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J-C Gris, S. Zuily and J. Musiał collected samples and identified sample characteristics. 
Samples were analyzed under the supervision of K. M. J. Devreese. D.Yin, K. M. J. 
Devreese, B. de Laat, H. Kelchtermans and W. Chayouâ interpreted data, performed 
statistical analyses and wrote the manuscript. P. G. de Groot, G. W. Moore, J-C Gris, S. 
Zuily and J. Musiał critically reviewed the manuscript.
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SUPPLEMENTARY TABLE 5. Agreement between anti-DI IgG positivity and triple positivity for four platforms 






In the thrombosis 
subpopulation
0.746*** 0.712*** 0.686*** 0.680***
In the pregnancy 
morbidiy 
subpopulation
0.679*** 0.636*** 0.616*** 0.556***
1 Kappa values are shown
*** P < 0.0001
SUPPLEMENTARY TABLE 6. Comparison of anti-DI IgG titers between triple positive patients with and 
without clinial events
Manufacturers 
for anti-CL and 
anti-β2GPI
In the thrombosis population
In the pregnnacy 
morbidity population
With T Without T P value With P Without P P value




































Abbreviations: β2GPI, β2glycoprotein I; CL, cardiolipin; CU, chemiluminescence units; DI, domain I; P, pregnancy 
morbidity; T, thrombosis
Titer of anti-DI IgG are expressed as the median (quartile(Q)25- Q75), Mann–Whiney U test was used to compare 
difference of two groups, the significant p values are showed in bold
8
Antiprothrombin antibodies 
induce platelet activation: a 
possible explanation for anti-FXa 
therapy failure in patients with 
antiphospholipid syndrome?
Walid Chayoua, Phillip L.R. Nicolson, Joost C.M. Meijers, Caroline Kardeby, Lourdes Garcia-





Background: Arterial and venous thrombosis are both common in antiphospholipid 
syndrome (APS). Recent studies have shown that anti-FXa therapy in APS patients 
leads to a greater number of patients with arterial thrombosis than with warfarin. We 
hypothesise that this may be due to the lowering of prothrombin levels by warfarin.
Objectives: To investigate whether antiprothrombin antibodies induce platelet 
aggregation and to identify the platelet receptors involved. A second aim was to 
investigate the effect of reduced prothrombin levels on antiprothrombin antibody-
induced platelet aggregation.
Methods: Enzyme-linked immunosorbent assays (ELISAs) were performed to measure 
binding of antiprothrombin antibodies to prothrombin fragment 1+2 and prothrombin. 
Platelet aggregation assays in washed platelets were performed. FcγRIIA was 
immunoprecipitated and tyrosine-phosphorylated FcγRIIA was measured by western 
blot.
Results: The antiprothrombin antibodies 28F4 and 3B1 had lupus anticoagulant (LAC) 
activity and caused platelet aggregation in the presence of Ca2+ and prothrombin. 
Antiprothrombin antibodies without LAC activity did not activate platelets. Inhibition 
of Syk, Src and FcγRIIA blocked platelet aggregation. Fab and F(ab')2 fragments of 
28F4 were unable to induce platelet aggregation. Immunoprecipitations showed that 
whole 28F4 IgG induced tyrosine phosphorylation of FcγRIIA. Platelet aggregation was 
significantly reduced when prothrombin levels were reduced from 1 µM to 0.2 µM.
Conclusions: Antiprothrombin antibodies with LAC activity are able to activate 
platelets via FcγRIIA. Decreased prothrombin levels resulted in less antiprothrombin 
antibody-mediated platelet aggregation. This may explain the lower incidence of 
arterial thrombosis in patients treated with warfarin than with anti-FXa therapy.
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INTRODUC TION
Antiphospholipid syndrome (APS) is characterized by thrombosis and/or pregnancy 
complications due to the persistent presence of antiphospholipid (aPL) antibodies [1]. 
Laboratory criteria for classification of APS include detection of lupus anticoagulant 
(LAC), anti-β2-glycoprotein I (aβ2GPI) and anticardiolipin (aCL) IgG/M antibodies [1]. 
Clinical criteria for classification of thrombotic APS include venous, arterial and small 
vessel thrombosis. The updated European League Against Rheumatism (EULAR) 
recommendations on managing thrombotic APS patients recommend long-term 
vitamin K antagonists as the standard of care [2].
Direct oral anticoagulants (DOACs) like rivaroxaban, a direct FXa inhibitor, are currently 
prescribed to patients with venous thromboembolism and atrial fibrillation. The 
advantage of DOACs is that they are given at a fixed dose and do not need laboratory 
monitoring. Interestingly, two trials reported predominantly arterial thrombosis in 
patients treated with rivaroxaban with a high rate of stroke [3,4]. No cases of stroke 
were reported in patients treated with warfarin [3,4]. Recent professional guidance 
statements have been issued regarding the use of DOACs in APS patients and 
recommended against DOACs in triple positive APS patients (defined by the presence 
of LAC, aβ2GPI and aCL antibodies) and in arterial thrombosis [5].
Blood platelets play a key role in arterial thrombosis [6]. Antibodies against β2GPI are 
known to activate platelets via glycoprotein (GP) Ibα and apolipoprotein E receptor 
2 [7,8]. Triple positive APS patients have the highest risk of thrombotic complications 
and these patients usually have both aβ2GPI antibodies and anti-phosphatidylserine/
prothrombin (aPS/PT) antibodies [9]. A systematic review identified aPS/PT antibodies 
as a risk factor for arterial thrombosis [10]. Still, experimental data on aPS/PT antibodies 
and platelet aggregation are lacking.
The overall aim was to investigate whether antiprothrombin antibodies stimulate 
platelet activation and to identify the underlying mechanism. This included 
investigation of the effect of reduced prothrombin levels on platelet aggregation as 
warfarin reduces the synthesis of prothrombin, while DOACs do not [11]. Decreased 
levels of prothrombin may explain why warfarin-treated APS patients are protected 





Purified human prothrombin was from Synapse Research Institute (Maastricht, The 
Netherlands) and rivaroxaban (Xarelto) was from Bayer Schering Pharma AG (Berlin, 
Germany). Anti-FcγRIIA mAb IV.3 was purified in the laboratory from a hybridoma [12]. 
The antiprothrombin monoclonal antibody (mAb) 28F4 is a mouse IgG antibody as 
described previously [13,14]. Antiprothrombin fragment 1+2 mAbs 3B1, 6A3, 11H2 and 
8H11 were developed and produced according to standard procedures [15]. LAC was 
measured by activated Partial Thromboplastin Time (aPTT; Diagnostica Stago, Asnières 
sur Seine, France), dilute Russell Viper Venom Time (dRVVT; Diagnostica Stago), and 
Ecarin Clotting Time (ECT; Diagnostic Reagents, Thame, UK). The Pierce Classic IP Kit 
from Thermo Fisher Scientific (Waltam, MA, USA) was used for immunoprecipitation. 
High-binding ELISA plates from Costar (New York, NY, USA) were used for the ELISAs. 
Sheep anti-human prothrombin IgG HRP labeled antibody was from Affinity Biologicals, 
Inc. (Ancaster, ON, Canada), prothrombin fragment 1+2 was from Haematologic 
Technologies, Inc. (Essex Junction, VT, USA). All other reagents are previously described 
or are from Sigma-Aldrich (Poole, UK) [16].
Preparation of washed platelets
Blood was drawn by venipuncture into 4% sodium citrate from consenting, self-
reported healthy volunteers. Platelet rich plasma (PRP) was obtained by centrifugation 
at 200 g for 20 minutes at room temperature. Washed platelets were obtained by 
further centrifugation of PRP at 1,000 g for 10 minutes in the presence of 0.2 μg/mL 
prostacyclin and resuspended in modified-Tyrode’s-HEPES buffer (134 mM NaCl, 0.34 
mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM HEPES, 5mM glucose, 1 mM MgCl2; 
pH 7.3) as previously described [16]. Platelets were used at 2×108/mL and 4×108/mL for 
aggregation studies and immunoprecipitation, respectively.
Fab and F(ab')2 antibody fragments
Fab fragments from 28F4 were generated by 4 hour incubation of 5 mg/mL antibody 
with immobilized Ficin in the presence of 25 mM cysteine (Pierce, ThermoFisher) at 
37°C. F(ab')2 fragments from 28F4 were generated by 24 hour incubation of 5 mg/mL 
antibody with immobilized Ficin in the presence of 4 mM cysteine (Pierce) at 37°C. 
Preparations were then applied to an immobilized protein A column (Pierce) followed 
by dialysis to remove any remaining cysteine. The purity of the Fab and F(ab')2 fragments 
was verified by SDS-PAGE.
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Lupus anticoagulant testing
Normal pooled plasma was incubated with 50 µg/ml mAb for 10 min at 37°C prior to 
LAC testing. LAC was performed according to the SSC guidelines and manufacturer’s 
instructions for ECT were followed [17,18].
ELISA
The mAb 28F4 (5 µg/ml) was coated onto an ELISA plate overnight at 4°C. Blocking 
buffer consisted of 5% Bovine Serum Albumin (BSA) and 5 mM CaCl2 in Tris Buffered 
Saline (TBS), (pH 7.6). Washing buffer was 5 mM CaCl2 and 0.1% Tween in TBS, pH 7.6. 
Increasing concentrations of antigen (prothrombin fragment 1+2, purified prothrombin 
or platelet poor plasma) was incubated for 1 hour at room temperature. Sheep anti-
human prothrombin IgG HRP-labeled antibody (1:1000) was used as secondary 
antibody followed by staining with tetra methyl benzidine (TMB) (ThermoFisher). The 
reaction was stopped with 2M H2SO4 and absorption was measured at 405 nm.
Platelet aggregation assay
Platelet aggregation was assessed by light transmission aggregometry (LTA) in a PAP-8E 
(Bio/Data Corporation, Horsham, PA, USA) aggregometer for up to 30 minutes. Washed 
platelets were incubated with aPT antibodies for 5 min with an antiprothrombin 
antibody (50 μg/mL) followed by CaCl2 (10 mM) and purified human prothrombin (1 
µM). In some studies, platelets were preincubated with eptifibatide (9 µM), vorapaxar 
(1 µM) + BMS-986120 (1 µM), indomethacin (10 µM), ticagrelor (10 µM), PRT-060318 (5 
µM), dasatinib (10 µM), mAb IV.3 (10 µg/ml) or rivaroxaban (200, 400, 800, or 1000 nM) 
for 10 min.
Immunoprecipitation and western blotting
Washed platelets were pretreated with 9 μM eptifibatide to block integrin αIIbβ3. Cross-
linking of IV.3 IgG (10 µg/ml) with 10 µg/ml anti-Fc (Biolegend, San Diego, CA, USA) 
served as a positive control. Platelets were stimulated at 37°C with stirring at 1200 rpm 
on a PAP-8E aggregometer. Reactions were terminated by addition of ice-cold lysis 
buffer (0.025M Tris, 0.15M NaCl, 0.001M EDTA, 1% NP-40, 5% glycerol, pH 7.4). Lysates 
were incubated overnight with mAb IV.3 to form immune complexes. Precipitated 
proteins were separated by reducing SDS-PAGE, electro-transferred and Western 
blotted with the anti-phosphotyrosine antibody, clone 4G10.
Ethics
Ethical approval for collecting blood healthy volunteers was granted by Birmingham 




All data are presented as mean ± standard deviation (SD). A p-value <0.05 was 
considered statistically significant. Statistical analysis was performed using Wilcoxon 
signed rank test, Kruskal-Wallis test with Dunn's Multiple Comparison Test and Mann-
Whitney U test as stated. All statistical analyses were performed using GraphPad Prism 
7 (GraphPad Software Inc. La Jolla, Ca).
RESULTS
Lupus anticoagulant activity
The five antiprothrombin mAbs (28F4, 3B1, 6A3, 11H2 and 8H11) were raised against 
F1+2, the activation peptide of prothrombin. Of these mAbs, only 28F4 and 3B1 caused 
LAC activity in the dilute Russell Viper Venom Time (dRVVT) and activated Partial 
Thromboplastin Time (aPTT) tests. The other three mAbs (11H2, 6A3 and 8H11) had 
no effect on the clotting time (Supplemental Table 1). The Ecarin Clotting Time (ECT) 
reagent converts prothrombin into thrombin, independently of phospholipids. The 
mAbs 28F4 and 3B1 did not prolong the ECT and did not inhibit thrombin activity 
when tested with a fluorescent substrate. However, mAb 28F4 did bind to prothrombin 
fragment 1+2, purified prothrombin and native prothrombin in plasma in an Enzyme-
linked immunosorbent assay (Supplemental Figure 1).
Platelet aggregation
Adding mAbs 28F4 and 3B1, but not 11H2, 6A3 and 8H11, resulted in aggregation 
of washed platelets in the presence of prothrombin and Ca2+ (Figure 1A), indicating 
a correlation between LAC-activity and platelet aggregation. mAb 28F4 induced 
aggregation in washed platelets in the presence but not absence of Ca2+ (Supplemental 
Figure 2) or prothrombin (not shown). 28F4 was the most potent at inducing platelet 
aggregation and LAC-activity. Preincubation of washed platelets with 1 µg/ml 28F4 
resulted in partial aggregation. Full platelet aggregation was achieved with 10 µg/ml 
28F4. Addition of 200 - 1000 nM rivaroxaban to washed platelets did not influence the 
aggregation profile.
Platelet signalling
Inhibitors were used to investigate the mechanism involved in antiprothrombin-
induced platelet aggregation to low (10 µg/ml) and high (50 µg/ml) concentrations of 
mAb 28F4. Pretreatment of platelets with the αIIbβ3 antagonist eptifibatide inhibited 
platelet aggregation to both concentrations of mAb 28F4 (Table 1). Indomethacin and 
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ticagrelor, which block cyclooxygenase and the P2Y12 receptor, respectively, attenuated 
but did not block platelet aggregation. Platelet aggregation induced by mAb 28F4 was 
not altered in the combined presence of the PAR-1 and PAR-4 antagonists, vorapaxar and 
BMS-986120, respectively. The same Low-dose of mAb 28F4 (10 µg/ml) and high dose 
of mAb 28F4 (50 µg/ml) was used to assess the effect of platelet antagonists. Platelet 
aggregation was measured as increase of light transmission. Results are shown as mean 
±SD (n=3) concentrations of the two antagonists blocked thrombin mediated platelet 
aggregation (data not shown). The Syk and Src inhibitors, PRT-060318 and dasatinib, 
respectively, blocked aggregation to both concentrations of mAb 28F4, which indicates 
involvement of signalling via receptors containing an immunoreceptor tyrosine-based 
activation motif (ITAM). Three ITAM‐containing receptors of human platelets are known 
including: C-type lectin-like receptor 2 (CLEC-2), glycoprotein VI (GPVI) and FcγRIIA (Fc 
receptor for IgG).
















FIGURE 1. The mAbs 28F4 and 3B1 induce platelet aggregation in the presence of Ca2+ and 
prothrombin. A) Representative traces of light transmission aggregometry using washed platelets at a 
concentration of 2x108/ml. Aliquots of platelet suspension were stimulated with 50 µg/ml of mAbs 28F4, 3B1, 
6A3, 11H2, or 8H11 in the presence of 10 mM Ca2+ and 1 µM prothrombin (n=3). B) Quantification of platelet 
aggregation induced by increasing doses of mAb 28F4. Platelet aggregation was measured as increase of 
light transmission. Results are shown as mean ± SD (n=3). Statistical significance was analyzed using the 
Kruskal-Wallis test. *P<0.05. NS, not significant.
188
Chapter 8
TABLE 1. ITAM signaling is involved in antiprothrombin induced platelet aggregation
28F4 (10 µg/ml)
% aggregation ± SD
28F4 (50 µg/ml)
% aggregation ± SD
Vehicle 65.4 ± 10.2 70.0 ± 8.1
Eptifibatide (9 µM) 4.5 ± 1.4 18.0 ± 9.2
Indomethacin (10 µM) 22.3 ± 11.2 38.9 ± 18.2
PRT-06318 (5 µM) 2.5 ± 2.8 3.9 ± 1.8
Ticagrelor (10 µM) 11.0 ± 6.0 19.6 ± 15.7
Dasatinib (10 µM) 2.7 ± 1.7 4.2 ± 2.6
Vorapaxar (1 µM) + BMS-986120 (1 µM) 65.8 ± 2.3 74.6 ± 4.1
Involvement of FcγRIIA
Of the three platelet ITAM-containing receptors, the FcγRIIA receptor was felt to be 
the most likely to be involved in the response to the antiprothrombin antibodies as 
it is a low affinity receptor for the Fc domain. Tyrosine phosphorylation of FcγRIIA was 
induced by mAb 28F4 as measured by immunoprecipitation and western blotting 
(Figure 2). Crosslinked IV.3 (anti-FcγRIIA antibody) was used as a positive control. As 
expected, rhodocytin and CRP, known stimulators of CLEC-2 and GPVI respectively, did 
not result in tyrosine phosphorylation of FcγRIIA. Non-crosslinked mAb IV.3 inhibited 
28F4 and 3B1-induced platelet aggregation (Figure 3 and not shown). Fab and F(ab')2 
antibody fragments of mAb 28F4 were unable to induce platelet aggregation (not 
shown) confirming the critical role of the Fc domain.
The link between prothrombin levels and platelet aggregation
We investigated whether prothrombin levels affected mAb 28F4-induced platelet 
aggregation as a possible explanation for anti-FXa therapy failure in patients with APS. 
Platelet aggregation was assessed in washed platelets in the presence of 50 µg/ml 28F4 
with two concentrations of prothrombin. Aggregation was found to be attenuated by 
59% when prothrombin levels were reduced from 1 µM to 0.2 µM, suggesting a direct 
link between prothrombin levels and platelet aggregation (Figure 4).
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A B
FIGURE 2. FcγRIIA is tyrosine-phosphorylated in the presence of mAb 28F4. A. Representative blot of 
five experiments. B. Mean data of signal for p-FcγRIIA. The signal obtained from cross-linked mAb IV.3 was 
normalized against total FcγRIIA and set as a reference (1 AU). Differences were analyzed with the Kruskal-
Wallis test. Results are shown as mean ± SD with n=5. *P<0.05. NS, not significant.
FIGURE 3. Antiprothrombin induced platelet aggregation can be blocked by mAb IV.3 (anti-FcγRIIA) 
antibody. Aliquots of platelet suspension were preincubated with mAb IV.3 (10 µg/ml) followed by 
stimulation using mAbs 28F4 (50 µg/ml) or 3B1 (50 µg/ml). Platelet aggregation was measured as increase 
of light transmission. Results are shown as mean ±SD (n=5). Statistical significance was analyzed using the 




FIGURE 4. Decreased prothrombin levels results in attenuated platelet aggregation. A) Representative 
traces of light transmission aggregometry using washed platelets at a concentration of 2x108/ml. Aliquots 
of platelet suspension were preincubated with 0.2 μM prothrombin or 1 μM prothrombin, followed by 
stimulation using 50 μg/ml mAb 28F4. B) Quantification of platelet aggregation in the presence of two 
concentrations of prothrombin. Platelet aggregation was measured as increase of light transmission. Results 
are shown as mean ± SD (n=5). Statistical significance was analyzed using the Mann-Whitney U test (* p<0.05).
DISCUSSION
In this study, we show that (i) antiprothrombin antibodies with LAC activity, but not 
those without LAC activity, are able to activate platelets via the FcγRIIA receptor and 
(ii) decreased prothrombin levels result in less antiprothrombin antibody-mediated 
platelet aggregation. These results suggest an important role of antiprothrombin 
antibodies with LAC activity in platelet activation. We speculate that the LAC activity 
is required for binding of the prothrombin/antiprothrombin complex to the platelet 
surface leading to binding of the Fc portion of the antiprothrombin antibodies to 
FcγRIIA and platelet activation.
Antiprothrombin antibodies with LAC activity are associated with APC resistance 
[19]. We were able to demonstrate platelet aggregation caused by antiprothrombin 
antibodies with LAC activity, indicating that antiprothrombin antibodies with LAC 
activity are potentially pathogenic. Antiprothrombin antibodies can be detected by 
coating prothrombin on irradiated ELISA plates or using phosphatidylserine (PS)-
prothrombin complex as antigen [10]. The presence of aPS/PT antibodies is considered 
to be a stronger predictor of thrombosis than antiprothrombin antibodies [10]. However, 
we demonstrated binding of mAb 28F4 to prothrombin in the absence of PS, by ELISA. A 
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recent study showed that at least two subpopulations of aPS/PT antibodies exist; aPS/PT 
antibodies that bind to the “open” conformation of prothrombin and aPS/PT antibodies 
able to react with “closed” prothrombin [20]. There were, however, no different 
pathological effects found between the two subpopulations of aPS/PT antibodies. In 
contrast, we were able to distinguish between antiprothrombin antibodies that were 
able to induce platelet aggregation and those that did not by measuring LAC activity. 
From the five antiprothrombin antibodies investigated, only mAbs 28F4 and 3B1 were 
able to induce platelet aggregation and LAC activity. Although mAb 28F4 is able to bind 
closed prothrombin, thrombin activity was not inhibited. Which could be explained by 
the affinity of the investigated mAbs towards the activation peptide of prothrombin, 
fragment 1+2, and not thrombin. These data indicate that LAC activity determines the 
ability of antiprothrombin antibodies to induce platelet aggregation.
Data on the role of antiprothrombin antibodies in platelet activation are limited, 
probably because platelet aggregation studies are performed in citrated plasma and 
prothrombin needs Ca2+ to bind to platelets [21]. Although platelet function assays were 
not performed, one study showed the potency of mAb 28F4 to induce platelet activation 
by measuring thromboxane B2 levels, phospholipid related platelet procoagulant 
activity, and thrombin generation [19]. The platelet-dependent effect of mAb 28F4 was 
found to be reduced in the presence of an integrin αIIbβ3 inhibitor, but not with IV.3 
[19]. The inability of showing involvement of the FcγRIIA receptor might be due to the 
low concentration of mAb IV.3 used in their study [19]. We have showed involvement of 
the FcγRIIA receptor in mAb 28F4 induced platelet activation in three ways; (i) inhibited 
platelet aggregation by IV.3, (ii) tyrosine phosphorylation of the FcγRIIA receptor, and 
(iii) the inability of Fab and F(ab')2 fragments of mAb 28F4 to aggregate platelets. In 
this respect, the mechanism of platelet activation by aPT antibodies mimics another 
auto-immune disease; heparin-induced thrombocytopenia (HIT) and thrombosis 
[22]. The presence of Ca2+ proved to be essential for platelet aggregation induced by 
antiprothrombin antibodies, suggesting Ca2+ dependent binding of antiprothrombin-
prothrombin immune complexes to negatively charged phospholipids expressed by 
platelets. Here we show a major role for FcγRIIA in antiprothrombin-induced platelet 
aggregation.
The TRAPS trial included APS patients with exclusively triple positive aPL (LAC, aCL 
and aβ2GPI antibodies) in which rivaroxaban was compared with warfarin therapy [3]. 
Although aPS/PT antibodies were not measured in the trial, aPS/PT antibodies have 
shown to correlate well with triple positivity in other studies [20,23]. We found that 
platelet aggregation was attenuated when prothrombin levels were reduced. The link 
between prothrombin levels and platelet aggregation may explain the failure of anti-
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FXa therapy in patients with APS as rivaroxaban does not affect prothrombin levels in 
plasma, while vitamin K antagonists (e.g. warfarin) reduce active prothrombin (antigen) 
levels.
There are several limitations in our study, we used mAbs that recognize the prothrombin 
F1+2 fragment, but we did not further specify the site of recognition. In addition, we did 
not confirm our findings with patient antibodies and did not evaluate antiprothrombin-
induced platelet activation in patients receiving vitamin K antagonists or rivaroxaban 
therapy. Additional data are needed on the specification of antiprothrombin antibodies 
and their effect on platelets.
Here, we have shown that only antiprothrombin antibodies with LAC activity are able 
to activate platelets via the FcγRIIA receptor. Decreased prothrombin levels resulted in 
attenuated platelet aggregation which might be an explanation for the low prevalence 
of arterial thrombosis in APS patients treated with warfarin compared to rivaroxaban 
therapy.
193
Antiprothrombin antibodies in platelet activation
ACKNOWLEDGEMENTS
The authors thank Ying Di for her technical assistance. W.C. was supported by a 
grant (HS-BAFTA, Harry Struijker-Boudier Award For Talented Academics) issued by 
Cardiovascular Research Institute Maastricht (CARIM).
AUTHORSHIP CONTRIBUTIONS
W.C., P.G.dG., P.L.R.N., and S.P.W. designed the study. W.C., P.L.R.N., C.K., and L.G-Q. 
performed the measurements. LAC was measured under supervision of J.C.M.M. and 
K.M.J.D. W.C., P.L.R.N., S.P.W., B.dL., and P.G.dG. interpreted data, performed statistical 
analyses and wrote the manuscript. J.C.M.M., C.K., L.G-Q., and K.M.J.D. critically reviewed 
the manuscript.
DISCLOSURE OF CONFLIC TS OF INTEREST
W.C. and B.dL. are employees of Synapse Research Institute, part of Diagnostica Stago 
SAS. P.G.dG is an advisor of Synapse Research Institute. SPW holds a BHF Chair (03/003). 




1  Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RHWM, Groot 
PGD, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. 
International consensus statement on an update of the classification criteria for definite 
antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis 2006; 4: 295–306.
2  Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, 
Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, Khamashta MA, King J, Marchiori 
F, Meroni PL, Mosca M, Pengo V, Raio L, Ruiz-Irastorza G, Shoenfeld Y, Stojanovich L, et al. 
EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann 
Rheum Dis 2019; 78: 1296–304.
3  Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci 
C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, 
Martinelli I, Testa S, Barcellona D, et al. Rivaroxaban vs warfarin in high-risk patients with 
antiphospholipid syndrome. Blood 2018; 132: 1365–71.
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SUPPLEMENTAL TABLE 1. mAbs 28F4 and 3B1 induce LAC activity.







Normal pooled plasma (NPP) was incubated with 50 µg/ml monoclonal antibody (28F4, 
3B1, 6A3, 11H2 or 8H11) for 10 min at 37°C prior to LAC testing. LAC was performed 
according to the SSC guidelines [17]. Cut-off ratio for dRVVT and aPTT was 1.2, positive 
LAC results are shown in bold.
Supplemental Figure 1. The mAb 28F4 binds to closed prothrombin. 28F4 (5 µg/ml) was incubated onto 
an ELISA plate with increasing antigen concentration; prothrombin fragment 1+2, (purified) prothrombin or 
platelet poor plasma in the presence of Ca2+ for 1 hour. Results are shown as mean ±SD (n=3). OD, optical 
density.
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Supplemental Figure 2. Ca2+ is essential for 28F4-induced platelet aggregation. Representative traces 
of light transmission aggregometry using washed platelets at a concentration of 2x108/ml. Aliquots of 
platelet suspension were stimulated with 50 µg/ml of mAbs 28F4 in the presence of 10 mM Ca2+ and 1 µM 
prothrombin or in the absence of Ca2+. (n=2)
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General discussion, summary and future perspectives
GENER AL DISCUSSION, SUMMARY AND FUTURE 
PERSPEC TIVES
The antiphospholipid syndrome (APS) is defined by thrombosis and/or specific 
pregnancy morbidity with the persistent presence of lupus anticoagulant (LAC), anti-
cardiolipin (aCL) IgG/M and/or anti-β2glycoprotein I (aβ2GPI) IgG/M antibodies [1]. 
Detection of antiphospholipid (aPL) antibodies is therefore of great importance for the 
diagnosis of APS. aCL and aβ2GPI antibodies are traditionally detected using an enzyme 
linked immunosorbent assay (ELISA). However, technology has paved the way for new 
methods for the detection of aCL and aβ2GPI antibodies [2–6]. Detection of non-criteria 
aPL antibodies, e.g. aCL IgA, aβ2GPI IgA, anti-phosphatidylserine/prothrombin (aPS/PT) 
IgG/M have been proposed in the updated classification criteria [7–13]. However, their 
relevance in the current aPL panel is unknown due to a lack of well-designed studies 
with large patient cohorts. Moreover, the role of the different aPL antibodies in clinical 
manifestations of APS and their interplay is not fully understood.
Antiphospholipid antibodies and their importance in the laboratory 
diagnosis of APS
Since the 1960’s, correlations have been established between aPL antibodies and 
clinical manifestations of APS (thrombosis and/or pregnancy morbidity) [14]. In chapter 
2, 3 and 4 we confirmed that aCL IgG/M and aβ2GPI IgG/M antibodies correlate with 
thrombotic events and/or pregnancy morbidity. ELISAs detecting aCL and aβ2GPI 
antibodies are poorly standardized and external quality control programs have shown 
that aPL assays produce variable results [15,16]. In chapter 2 we report low agreement 
of a new generation ELISA and automated systems detecting aCL and aβ2GPI IgG/M 
antibodies, which could affect diagnosis of APS. Remarkably, the diagnostic accuracy 
was comparable, which was also illustrated in other studies [5,6,17–19].
Combined positivity for LAC, aCL and aβ2GPI antibodies (triple positivity) is a high-
risk profile of which the identification is suggested to be less affected by inter-
method variation [20]. However, as described in chapter 3, identification of triple 
positivity is dependent on the solid phase assay used to detect aCL and aβ2GPI 
antibodies. Interestingly, computed ORs for thrombosis were comparable. Since the 
laboratory diagnosis of APS relies on the detection of aPL antibodies, LAC testing and 
immunoassays should be reliable. Unfortunately, aPL antibody immunoassays obtained 
from different manufacturers are accompanied by a large inter-assay and inter-
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laboratory variation [16,21–24]. With five different aPL assays in the current criteria, 
many possible combinations (aPL profiles) are possible. However, knowledge about the 
clinical value of all possible aPL profiles is limited.
There is an ongoing discussion on the role of IgM aPL antibodies in the laboratory 
diagnosis of thrombotic APS [4,25–30]. A review of literature found more correlations 
for aCL and aβ2GPI IgG antibodies than for the IgM isotype [25]. However, due to 
unavailability of paired IgG and IgM results, the added value of IgM aPL antibodies 
within the current aPL panel could not be established [1,25]. In chapter 4, the added 
value of aCL and aβ2GPI IgM antibodies was investigated within the current aPL panel 
[1]. In agreement with literature, we found a higher association for IgG aPL antibodies 
with thrombosis and pregnancy morbidity than the IgM isotype [25]. IgM positivity was 
not independently associated with thrombosis, but was independently associated with 
pregnancy morbidity. The complement system has proven to play an important role in 
aPL antibody induced pregnancy morbidity [31]. Complement C3 activation has shown 
to be required for IgG aPL antibody induced fetal loss in mice [32]. IgM aPL antibodies 
might also induce fetal loss via a similar mechanism. However, data on complement 
activation by IgM aPL antibodies is lacking [33].
Non-criteria aPL (e.g. aCL IgA, aβ2GPI IgA, aPS/PT IgG and aPS/PT IgM antibodies) have 
been suggested to improve the laboratory diagnosis of APS. Chapter 5, describes the 
added value of detecting aCL and aβ2GPI IgA antibodies in APS. In agreement with 
multiple studies, aCL and aβ2GPI IgA antibodies correlated with thrombosis and/or 
pregnancy morbidity [8–11,34–39]. However, we were unable to demonstrate an added 
value for aCL and aβ2GPI IgA antibodies testing on top of the current aPL panel. Other 
groups have suggested that aCL and aβ2GPI IgA solid phase assays should be included 
in the classification criteria of APS as they could demonstrate a significant association 
of so-called “isolated” aCL and aβ2GPI IgA antibodies with clinical manifestations of 
APS [8–13]. However, many of these studies did not include LAC testing, hampering 
assessment of truly isolated IgA positivity [9,11–13].
Antibodies against domain I of β2GPI (anti-DI) have been proven to be pathogenic 
in multiple studies [40–49]. In chapter 6, the performance characteristics of different 
anti-DI IgG assays is summarized and the significance of anti-DI antibodies in APS is 
discussed. We found a large variation in odds ratios (ORs) between studies, probably due 
to differences in patient and control population, but also as a result of differences in the 
detection method. In chapter 7 we were able to demonstrate a significant correlation of 
anti-DI positivity with previous thrombosis or pregnancy morbidity. However, addition 
of anti-DI IgG into the current aPL panel did not improve the association with clinical 
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manifestations of APS. As suggested in our review, the clinical association could be the 
result of the solid phase assay used to detect anti-DI IgG antibodies [50]. A recent review, 
confirmed this hypothesis and demonstrated that the chemiluminescence assay (CIA) 
used in chapter 7 to detect anti-DI does not expose the essential epitope containing 
Gly40-Arg43 on the antigen correctly [51].
In chapter 8 we demonstrated platelet aggregation induced by anti-prothrombin 
antibodies via the platelet FcγRIIA receptor. Interestingly, only the anti-prothrombin 
antibodies that also caused LAC activity could induce platelet aggregation. This would 
indicate that anti-prothrombin antibodies with LAC activity are a distinct group of 
anti-prothrombin antibodies. Decreased prothrombin levels resulted in less anti-
prothrombin antibody-mediated platelet aggregation. The link between prothrombin 
levels and platelet aggregation may explain the results of the clinical trials describing 
the failure of anti-FXa therapy (e.g. rivaroxaban) in patients with APS [52,53]. Because 
anti-FXa therapy does not affect prothrombin levels in plasma, anti-prothrombin 
antibodies can still induce platelet aggregation. On the contrary, vitamin K antagonists 
(e.g. warfarin) reduce active prothrombin (antigen) levels, thereby also reducing platelet 
aggregation mediated by anti-prothrombin antibodies
Other reasons to test for anti-phospholipid antibodies
Testing for aPL antibodies is mandatory to fulfill the laboratory criterion in the diagnosis 
of APS. Also, detection of aPL antibodies could be useful to explain the occurrence 
of thrombotic or obstetric events. In vitro experiments have shown that the presence 
of aPL antibodies can induce a pro-thrombogenic and inflammatory state [54–59]. In 
vivo, aPL antibodies have shown to induce thrombosis and pregnancy morbidity in 
animal models [49,60–63]. Another more important reason to detect aPL antibodies 
is assessing the risk of a future thrombotic event as clinical studies have shown that 
APS patients have a higher risk of a thrombotic recurrence compared to thrombotic 
patients without aPL antibodies [64,65]. Patients with thrombotic APS are therefore 
often prescribed long-term anticoagulation [66,67]. To avoid overdiagnosis, testing for 
aPL antibodies is only useful in patients with a significant probability of having APS. 
The presence of aPL antibodies can help to explain the occurrence of thrombotic or 
obstetric event and predict the risk of a recurrent clinical event.
Besides thrombosis and pregnancy morbidity, aPL antibodies have also been associated 
with non-criteria manifestations such as thrombocytopenia, nephropathy, cardiac valve 
disease, cognitive dysfunction and skin ulcers [68]. Detection of aPL antibodies is also 
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one of the items for the classification of systemic lupus erythematosus (SLE). Also when 
a patient has an unexplained prolonged activated partial thromboplastin time (aPTT), 
aPL detection (LAC) could explain this [69].
To more harmonized anti-phospholipid antibody testing
The detection of LAC is associated with considerable inter-laboratory variability and 
high rates of false negative and false positive results [16,70,71]. However, the aim here is 
to elaborate on solid phase assays detecting aPL antibodies.
Why we should consider centralized laboratory testing
Detection of aPL antibodies by ELISAs are known to be associated with large inter-assay 
and inter-laboratory variation [21,22]. External quality programs have shown variation 
in antibody titers and classification of the same sample using aCL and aβ2GPI ELISAs 
[22]. Pre-, post- and analytical conditions contribute to the variability in test results for 
aPL antibodies [21]. The contributing factors are both biological and methodical; the 
heterogeneity of the autoimmune antibodies, inadequate standardization of assays, 
differences in local working conditions, discussions or limited knowledge on the 
relevance of the antibodies, difficulties in correct interpretation of the results, lack of 
large prospective evaluation studies and the determination of the pathological cut-off 
level. Moreover, the lack of a link between antibody potency and recurrent thrombosis 
also contributes to the observed variation [4,21]. In the last 25 years, guidelines and 
proposals have been published in an attempt to standardize aPL antibody assays [4]. 
Moreover, complete standardization of aPL antibody assays is far from reached. With 
a lack of well standardized solid phase assays, centralized laboratory testing for aPL 
antibodies by solid phase assays could be an effective and adequate (interim) solution.
The ideal solid phase assay
Technology has advanced since the first description of a radioimmunoassay for the 
detection of aCL antibodies in 1983 [72]. Shortly after, an ELISA for the detection of 
aCL antibodies was described [73]. Nowadays automated assays have become available 
that use different solid phases (e.g. magnetic particles, microbeads, membranes, 
and coated polystyrene cups) with various detection methods (e.g. fluorescence, 
chemiluminescence and multiplex systems) [2–6]. Automated systems can reduce 
the inter-laboratory and intra-laboratory variation, but inter-assay variation still exists 
[23,74]. Despite the large inter-assay variation, diagnostic performance of solid phase 
assays detecting aCL and aβ2GPI antibodies is comparable [23]. Antibodies directed 
against Gly40-Arg43, located in DI of β2GPI have shown to be pathogenic [40,75]. In 
agreement, we found that the solid phase assay, that was most sensitive in detecting 
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a monoclonal antibody against Gly40-Arg43, reached the highest odds ratio (OR) for 
thrombosis [23]. In addition, sensitivity to the cryptic epitope Gly40-Arg43 ensures 
correct exposure of β2GPI [76]. Therefore, a suitable assay should be preferably fully 
automated and sensitive to (pathogenic) antibodies against Gly40-Arg43.
The ideal reference laboratory
The aPL antibody performing laboratory should be a center of expertise within APS 
and able to evaluate the obtained results from solid phase assays in correlation with 
LAC results. Academic hospitals are located across the country, have an expertise in rare 
syndromes and have mostly fully equipped laboratories. Centralized testing opens the 
door to new possibilities like initiating a database and biobank for further research into 
APS. Conducting research is one of the core tasks of academic hospitals, making them 
excellent candidates for reference laboratories.
Wide range of solid phase assays
A variety of aPL antibody assays are available for the laboratories [66]. Some clinical 
laboratories do not measure all recommended aPL antibodies, while other laboratories 
also measure non-recommended aPL antibodies (e.g. aPS/PT IgG, aPS/PT IgM, aCL IgA 
and aβ2GPI IgA) for the diagnosis of APS [77]. With a reference lab, this issue can be 
resolved by offering testing for all required assays (aCL IgG, aβ2GPI IgG, aCL IgM and 
aβ2GPI IgM). In addition, aPL antibody assays that have shown to be valuable in risk 
stratification like aPS/PT IgG and anti-DI aβ2GPI IgG can also be offered [51].
Clinical cut-off values
An issue influencing interpretation of the results, is that most laboratories are unable to 
calculate in-house cut-off values from a sufficient number of healthy volunteers [78,79]. 
Alternatively, manufacturer’s cut-off values may be transferred after validation using 20 
healthy volunteers [2]. However, it is unsure whether the manufacturer calculated their 
cut-off value in an appropriate manner [3,78]. Specialized laboratories might be able 
to calculate cut-off values in a multicenter and clinical approach, which may improve 
diagnosis of APS [78].
Paving a way for standardization
Centralized laboratory testing might be a (interim) solution to reduce analytical and post 
analytical errors. However, we still have to acknowledge that variation between solid 
phase assays will still exist. Therefore, the designated laboratories should participate in 
quality control programs to improve harmonization.
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Efforts have been made for standardization by international reference materials 
including Harris standards (pool of patient material) and Koike standards (monoclonal 
antibodies) [21]. However, both standards have their disadvantage. The Harris standards 
are limited in production and Koike standards are directed against a single epitope, 
thus decreasing the sensitivity of the assay in which it is used [21]. Initiatives have been 
taken to ensure availability of international standards for the aCL and aβ2GPI assay [80].
Centralized testing can pave the way for more harmonized aPL antibody testing by 
concentration of data from patient samples that might provide new insights in APS. Of 
note, logistical problems might arise in centralized testing.
Testing for antiphospholipid antibodies in an academic, general and rural 
hospital
Every patient should have access to the best healthcare available. However, in some 
cases, hospitals are limited by knowledge about rare diseases and/or the possibility 
to perform specific diagnostic assays. Here, we aim to discuss which laboratory tests 
should be performed in case a patient is suspected of APS and admitted to an academic 
hospital, general hospital or rural hospital in a developing country.
Academic hospital
Academic hospitals are equipped with specialized facilities and provide specialized care. 
If a patient is suspected of having APS, an academic hospital must be able to perform 
extensive testing. LAC, aCL IgG/M and aβ2GPI IgG/M testing are recommended for the 
classification of APS in patients with thrombosis or pregnancy morbidity. Although 
additional aPL antibodies can be tested, we need to bear in mind that immunoassays 
are associated with false negative and positive results [4].
aCL and aβ2GPI IgM antibodies in thrombotic APS
Studies that investigated the added value of IgM aPL in large patient cohorts are limited 
[25,81]. In our multicenter study, the detection of aCL and aβ2GPI IgM antibodies was 
found to be of little value in thrombotic APS [81]. Prospective data on the role of aCL 
and aβ2GPI IgM antibodies within the current aPL panel is needed to exclude IgM aPL 
from the classification criteria for APS.
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Antiphospholipid antibody profiles
Multiple studies have shown that it is more important to evaluate all aPL antibody 
results (aPL antibody profile) instead of single serological markers for APS [64,65,82–84]. 
Evaluation of complete aPL antibody profiles can be used to evaluate the “reliability” of 
diagnosis and to evaluate the risk of a recurrent event [82].
Reliability of diagnosis
The clinical relevance of single and double positivity for aCL and aβ2GPI IgG/M is 
uncertain [82]. One of the reasons might be interferences with solid phase assays that 
induce false positive results. Evaluation of the complete aPL antibody profile can be 
used to evaluate the “reliability” of diagnosis. Figure 1 illustrates different aPL profiles 
from patients with negative LAC results and three possible interferences. Rheumatoid 
factor can give false positive aCL and/or aβ2GPI IgM results [1,85]. If diagnosis of APS is 
solely dependent on IgM aPL, rheumatoid factor testing might be considered for the 
correct interpretation of the aPL antibody results [1,85]. Positivity for aCL but not for 
aβ2GPI antibodies might be the result of an infectious disease (e.g. Syphilis and HIV) 
[85]. However, aβ2GPI antibodies have shown to be present in patients with infectious 
diseases (e.g. leprosy) [73,86]. Interestingly, epitopes on domain IV or V have shown 
to be preferentially recognized by IgG antibodies in sera from antiphospholipid-
positive individuals with leprosy [50,86]. While anti-DI antibodies, and not anti-D4/D5 
antibodies are considered pathogenic [49]. Further evaluation of epitope specificity in 
aPL antibody positive patients with negative LAC results could distinguish between 
pathological and non-pathological aPL antibodies. Common infectious diseases should 
be ruled out if a patient is suspected of having APS with isolated aCL positivity. Finally, 
disagreement of the isotype should be labeled as inappropriate and re-testing should 
be considered [82].
Risk stratification
Once a patient is diagnosed with APS, it might be interesting to evaluate the aPL 
antibody profile for thrombotic risk stratification. Triple positivity is considered as a high-
risk profile for thrombosis [87,88]. However, triple positivity does not take the isotype 
for which it is positive into an account [82]. Positivity for LAC, aCL IgG and aβ2GPI IgG is 
considered a triple positive aPL profile. Likewise, positive results for LAC, aCL IgM and 
aβ2GPI IgM and positive results for LAC, aCL IgG, aβ2GPI IgG, aCL IgM and aβ2GPI IgM 
are considered triple positive.
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FIGURE 1. Reliability of aCL and aβ2GPI IgG/M results in LAC negative patients suspected of APS. 
Rheumatoid factor is associated with false positive IgM results and should be considered testing if IgG 
aPL antibodies are negative. Positivity for aCL antibodies with negative aβ2GPI could be an indication for 
infectious diseases. Re-testing should be considered if there is a disagreement of isotype.
In our study, we have shown that the thrombotic association of triple positivity is 
predominately caused by IgG aPL antibodies [24]. Patients with positive LAC, aCL IgM 
and aβ2GPI IgM (i.e. triple positive) results are strongly associated with a previous 
thrombosis [24]. However, if IgG aPL are absent, the clinical significance is low [24]. 
Positivity for LAC, aCL IgG and aβ2GPI IgG is strongly correlated with thrombosis even 
if IgM aPL antibodies are negative. The presence of all criteria aPL antibodies (LAC, aCL 
IgG/M and aβ2GPI IgG/M) results in the strongest association with thrombosis [24]. 
Therefore, all criteria aPL antibodies results should be considered to evaluate the clinical 
significance of an aPL profile (Figure 2).
Additional testing for risk stratification
Additional aPL antibody testing might be performed in triple positive patients within 
an academic setting. Anti-DI aPL antibodies might be detected for risk stratification as 
combined anti-DI and triple positivity resulted in a higher OR than only triple positivity 
[51]. Also, the presence of aPS/PT IgG has shown to increase ORs in triple positive 
patients positive for LAC, aCL IgG and aβ2GPI IgG [24].
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Other laboratory markers for thrombosis could be considered for thrombotic risk 
stratification in definite APS patients. Activated protein C resistance together with 
LAC positivity has shown to be strongly correlated with thrombosis [89]. Activated 
protein C resistance can also be determined with a thrombin generation-based test 
and has shown to be associated with thrombosis in LAC positive patients [90]. Using 
thrombin generation, LAC titers can be quantified and could be useful for thrombotic 
risk stratification together with soluble P-selectin and factor VII results [91]. However, 
data on the value of each single laboratory marker within thrombotic risk stratification 
of APS patients is lacking. A well-designed prospective multicenter study is needed for 
the evaluation of additional aPL antibody assays and established laboratory markers in 
thrombotic risk stratification of APS patients.
General hospital
In case that centralization of testing is not available, general hospital laboratories should 
provide LAC, aCL IgG/M and aβ2GPI IgG/M assays for the detection of APS. Due to the 
high variability among immunoassays detecting aCL and aβ2GPI antibodies, it seems 
important that in daily practice, aCL IgG/M and aβ2GPI IgG/M antibodies are measured 
with the same platform. A medical laboratory should take this into an account if not all 
assays are available in-house and additional aPL testing is needed elsewhere.
Automated algorithm for the interpretation of lupus anticoagulant
Nowadays, LAC assays have integrated a screening and confirmation step into one 
single assay, which may increase the accuracy and inter-laboratory agreement [92]. 
However, the mixing procedure should still be performed [92]. Difficulties in performing 
the mixing step, interpretation of results and calculation of cut-off values may lead to 
false positive or false negative results [3,4,21,92]. The introduction of an automated 
algorithm for the interpretation of LAC might be a practical solution [93]. Research has 
shown that such an algorithm has a high sensitivity and specificity for LAC detection and 
reduced hands-on time with 60% [93]. An automated algorithm for the interpretation 
of LAC might also take established interfering factors into consideration including 
anticoagulation, coagulation factor deficiencies, reduced fibrinogen and elevated 
C-reactive protein (CRP) levels [94]. For instance, isolated positivity for the aPTT-based 
LAC assay might require testing of plasma CRP levels as research has shown that CRP 
levels >50 mg/L can mimic the presence of LAC in all three steps of the aPTT but not 
in the dilute Russell Viper Venom Time (dRVVT)-LAC assay [95]. Isolated positivity for 
the aPTT-LAC assay with high CRP levels should therefore be interpreted with care and 
retesting at a later moment can be considered. A universal automated algorithm could 
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FIGURE 2. Significance of aPL antibody profiles in thrombosis.
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Risk stratification
General hospital laboratories should evaluate the profile of patients with thrombotic 
APS. One could consider extensive testing similar to an academic setting. However, a 
distinction between APS patients that are triple positive and patients without triple 
positivity might be sufficient. Triple positivity is generally accepted to be a high-risk 
profile for thrombosis. Triple positive patients with additional aPL antibodies could 
have a higher risk for recurrent thrombosis. However, treatment of triple-positive 
patients with additional aPL antibodies is most likely not different from patients with 
triple positivity alone [66,67,83]. Therefore, it would be more convenient to limit risk 
stratification of patients with thrombotic APS to triple positivity or non-triple positivity 
and avoid additional aPL antibody testing for risk stratification in general hospitals.
Rural hospitals in developing countries
Rural hospitals in developing countries have limited resources and only selected 
laboratory assays available. It is therefore not evident to perform all assays suggested 
by the Sydney criteria [1]. From all types of aPL antibodies in the current criteria, LAC 
is considered the strongest predictor of thrombosis and pregnancy morbidity [96–98]. 
However, LAC is labor intensive and complicated to interpret which makes it difficult to 
perform the assay in a rural hospital with limited resources.
Point of care-lupus anticoagulant
Point of care (POC) diagnostics might be a solution in a low resource setting as rural 
hospitals in developing countries. Unfortunately, no POC assay exists for the detection 
of LAC. International guidelines recommend the use of a dRVVT and aPTT based assay 
in LAC detection [1,99,100]. With the existence of POC assays measuring prothrombin 
time (PT) and aPTT, a POC-LAC assay seems to be technically feasible [101]. However, 
more research is needed to evaluate the feasibility of a POC-LAC that is in agreement 
with the current guidelines [1,100]. In developing countries, infectious diseases are very 
common and considered to cause the development of aPL antibodies. International 
guidelines should be followed for the detection of LAC, also in a POC testing [1,99,100]. 
An automated algorithm for clear LAC results is preferred in this setting.
Solid phase assays in rural hospitals
Detection of aCL and aβ2GPI antibodies by ELISA is labor intensive and requires trained 
personnel. Automated systems are less labor intensive and easy to perform. However, 
such systems and reagents are too expensive for rural laboratories in developing 
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countries. Exclusion of aCL IgG/M and aβ2GPI IgG/M testing might result in decreased 
sensitivity for APS diagnosis. Another limitation is the inability of risk stratification 
without aCL and aβ2GPI results.
Lupus anticoagulant versus aCL and aβ2GPI antibodies
In developing countries, the prevalence of infectious diseases is high [102]. Viral 
infectious diseases like HIV and syphilis can give arise to false positive aPL antibody 
results [103]. Still, LAC has shown to be strongly associated with stroke in a population 
from urban and rural Tanzania [104]. The presence of aPL antibodies detected by solid 
phase assays (aCL, aβ2GPI and aPS/PT) was found to be of only little value as a biomarker 
for stroke [104]. Therefore, the development of a POC-LAC assay could be a useful 
biomarker for (arterial) thrombosis in rural areas. Due to the limited data available on 
prevention of a recurrent stroke, several therapy strategies are possible [66,105–107]. 
The European League Against Rheumatism (EULAR) recommend the use of VKA over 
low-dose aspirin (LDA) in APS patients with a first arterial thrombosis [67]. However, in 
APS patients with a first stroke, therapy with either VKA or clopidogrel is also justified 
[66]. Antiplatelet therapy could be a good alternative for the prevention of recurrent 
stroke in APS patients as VKA therapy requires regular monitoring and is therefore not 
preferred in rural areas of developing countries. Still, more data is needed to evaluate 
the importance of a POC-LAC assay and its implication on treatment strategies in rural 
hospitals.
CONCLUSION
This thesis describes the importance of detecting aPL antibodies by immunoassays 
in the laboratory diagnosis of APS. The newer generation aPL antibody assays are still 
associated with high inter-assay variation, even in triple positive patients. Isolated 
aCL and aβ2GPI IgM antibody results should be interpreted with care in thrombotic 
APS. Detection of aCL and aβ2GPI IgA antibodies did not add value to the laboratory 
diagnosis of APS within the current aPL panel. The presence of anti-DI antibodies may 
help in identifying high-risk patients. Well-designed prospective multicenter studies 
are needed to evaluate aPL antibody profiles and the risk of recurrent thrombosis in 
APS patients. Anti-prothrombin antibodies with LAC activity are able to induce platelet 
aggregation via the FcγRIIA receptor. However, more data is needed to determine the 
role of anti-prothrombin antibodies in the failure of anti-FXa therapy in patients with 
APS.
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Het antifosfolipiden syndroom (APS) is een auto-immuunziekte en wordt gekenmerkt 
door trombose en/of zwangerschapscomplicaties met de aanwezigheid van 
antifosfolipiden (aPL) antilichamen. Trombose en zwangerschapscomplicaties komen 
veelal voor zonder een indicatie voor APS. De diagnose APS is daarom voornamelijk 
afhankelijk van diagnostische testen. Laboratorium criteria voor de diagnose APS 
bestaan uit de detectie van; 1) lupus anticoagulans (LAC), 2) anti-cardiolipine (aCL) 
IgG/M antilichamen en 3) anti-β2glycoproteïne I (aβ2GPI) IgG/M antilichamen. Dit 
proefschrift beoogt de optimalisatie van de diagnose en risicostratificatie van patiënten 
met APS. Hierbij is de klinische relevantie van verschillende immunologische- en 
stollingstesten binnen APS onderzocht.
In hoofdstuk 2 is aangetoond dat de detectie van aCL en aβ2GPI antilichamen 
afhankelijk is van de immunologische test die gebruikt wordt. Desalniettemin is 
de associatie van deze antilichamen met trombose en zwangerschapsmorbiditeit 
vergelijkbaar tussen immunologische testen. De verkregen resultaten benadrukken 
dat bij het stellen van de diagnose APS, er rekening gehouden moet worden met de 
variatie die de immunologische testen teweegbrengen. De aanwezigheid van LAC, aCL 
en aβ2GPI antilichamen (triple positiviteit) in APS-patiënten is een hoog risicoprofiel 
voor recidief (terugkomende) trombose. In hoofdstuk 3 is aangetoond dat ook de 
identificatie van deze hoog-risico patiënten afhankelijk is van de immunologische 
test die gebruikt wordt. Daarnaast blijkt positiviteit voor aCL en aβ2GPI IgG uitermate 
belangrijk te zijn voor de sterke associatie van triple positiviteit met trombose, terwijl 
positiviteit voor aCL en aβ2GPI IgM maar een geringe bijdage leveren aan de associatie 
van triple positiviteit met trombose.
De diagnostische waarde van aCL en aβ2GPI IgM antilichamen in APS staat al kort 
na de introductie van de herziene criteria voor het vastellen van APS ter discussie. 
Hoofdstuk  4 omschrijft de klinische relevantie van aCL en aβ2GPI IgM binnen APS. 
De detectie van aCL en aβ2GPI IgM antilichamen is overbodig bevonden voor het 
opsporen van trombotische APS indien er al getest wordt voor LAC, aCL IgG en aβ2GPI 
IgG antilichamen. De detectie van aCL en aβ2GPI IgM antilichamen was wel van belang 
bij het opsporen van obstetrische APS. Deze resultaten suggereren een andere strategie 
voor het testen van aPL antilichamen bij verdenking van trombotische en obstetrische 
APS.
Naast LAC, aCL IgG/M en aβ2GPI IgG/M antilichamen is ook voorgesteld om andere aPL 
antilichamen te includeren in de classificatie criteria van APS, waaronder aCL en aβ2GPI 
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IgA antilichamen. In hoofdstuk 5 is de correlatie van aCL en aβ2GPI IgA antilichamen 
met trombose en zwangerschapscomplicaties bevestigd. Desalniettemin zijn patiënten 
met aCL en/of aβ2GPI IgA antilichamen, maar negatief voor LAC, aCL IgG/M en/of 
aβ2GPI IgG/M, zeldzaam. Hieruit kan geconcludeerd worden dat positiviteit voor 
aCL en aβ2GPI IgA antilichamen geen toegevoegde waarde heeft naast de huidige 
laboratorium criteria voor APS.
Hoofdstuk 6 biedt relevante achtergrondinformatie over het belang van het testen 
van antilichamen die gericht zijn tegen het eerste domein van β2GPI (anti-DI). Daarbij 
werden de pathogeniciteit en de klinische significantie van anti-DI antilichamen 
onderzocht. In hoofdstuk 7 is aangetoond dat anti-DI antilichamen gecorreleerd 
zijn met trombose en zwangerschapscomplicaties, maar dat het meten van deze 
antilichamen geen toegevoegde waarde heeft naast de huidige laboratorium criteria 
voor de diagnose van APS.
Aggregatie van bloedplaatjes speelt een cruciale rol in het ontwikkelen van arteriële 
trombose. Toch is er maar weinig bekend over het effect van aPL antilichamen 
op plaatjesaggregatie. In hoofdstuk 8 is aangetoond dat de aanwezigheid 
van antiprotrombine antilichamen met LAC activiteit kan leiden tot aggregatie 
van bloedplaatjes via de FcγRIIA receptor. Vitamine K antagonisten (VKAs) zijn 
antistollingsmiddelen die de productie van vitamine K-afhankelijke stollingsfactoren, 
waaronder protrombine, remmen. Het directe orale anticoagulans (DOAC) rivaroxaban 
is een directe remmer van geactiveerde stollingsfactor Xa. Klinisch onderzoek heeft 
aangetoond dat in vergelijking met het gebruik van VKAs, het gebruik van DOACs 
het risico kan verhogen op arteriële trombose in triple positieve APS patiënten. In 
hoofdstuk 8 is ook aangetoond dat het verlagen van de protrombine concentratie zorgt 
voor verminderde bloedplaatjes aggregatie. Daarentegen wordt plaatjes aggregatie 
door antiprotrombine antilichamen niet beïnvloed door rivaroxaban. Aggregatie van 
bloedplaatjes door antiprotrombine antilichamen en het effect van antistolling hierop, 
kan een mogelijke verklaring zijn voor het falen van DOAC-therapie in triple positieve 
APS patiënten.
In hoofdstuk 9 worden de belangrijkste bevindingen van dit proefschrift besproken 
in het licht van de huidige literatuur. Hierin wordt beargumenteerd wat de 
klinische relevantie is van aPL antilichamen die gemeten worden door middel van 
immunologische testen en hoe deze testen beter gestandaardiseerd kunnen worden. 
Daarnaast is beargumenteerd welke laboratoriumtesten nodig zijn bij het vaststellen 
van APS in een academisch ziekenhuis, een algemeen ziekenhuis, alsook een (afgelegen) 




The antiphospholipid syndrome (APS) is a rare autoimmune disorder, characterized 
by thrombosis and/or pregnancy morbidity with the persistent presence of 
antiphospholipid (aPL) antibodies (1). Clinical manifestations of APS (thrombosis 
and pregnancy morbidity) occur frequently without any indication of APS (1). This 
makes the detection of aPL antibodies by laboratory assays crucial in the diagnosis of 
APS. Laboratory assays used for the diagnosis of APS include the detection of lupus 
anticoagulant (LAC), anti-cardiolipin (aCL) IgG/M antibodies and anti-β2glycoprotein I 
(aβ2GPI) IgG/M antibodies (1). We aimed to optimize the diagnosis and risk stratification 
of patients with APS. The clinical relevance of several immunoassays and non-criteria 
aPL antibodies (e.g. aCL IgA, aβ2GPI IgA and anti-domain I β2GPI IgG) within APS was 
investigated.
Key findings
We found that the detection of aCL and aβ2GPI IgG/M antibodies differs between 
immunoassays without affecting the association with clinical manifestations of APS. In 
addition, the identification of high thrombotic risk triple-positive APS patients (i.e. LAC, 
aCL and aβ2GPI positive) is dependent on the aCL and aβ2GPI antibody detection assay 
used.
The role of aCL and aβ2GPI IgM antibodies in thrombotic APS is debated by experts in 
the field, since conclusive data on the role of aCL and aβ2GPI IgM within APS is lacking 
in current literature (2). Our data support the usage of two separate decision trees, 
depending on the clinical presentation. We have suggested to test aCL and aβ2GPI IgM 
in women suspected of obstetric APS, but not in patients suspected of thrombotic APS 
(Figure 1).
Although not included in the laboratory criteria for the diagnosis of APS, antiprothrombin 
antibodies are common in patients with APS (3). Antiprothrombin antibodies have 
shown to be correlated with arterial thrombosis, in which platelets play a key role. 
However, data on antiprothrombin antibodies and platelet activation are lacking. We 
found that antiprothrombin antibodies with LAC activity are able to induce platelet 
aggregation via the FcγRIIA receptor.
Recent studies have shown that therapy with direct oral anticoagulants (rivaroxaban) 
in patients with APS leads to a high incidence of arterial thrombosis compared with 







































































































































































levels resulted in less antiprothrombin antibody-mediated platelet aggregation. We 
therefore hypothesize that the reduction in antiprothrombin levels by VKA attributes to 
the lower incidence of arterial thrombosis in patients treated with rivaroxaban.
Diagnosis of APS should be independent of the immunoassay used to 
detect aPL antibodies
We have shown that detection of aPL antibodies varies among immunoassays, 
which can affect the diagnosis of APS. Medical specialists should be aware of the low 
agreement between immunoassays and limit testing for aPL antibodies in patients with 
a significant probability of having APS, to avoid overdiagnosis (1,6). Also, retesting of 
aPL antibodies in patients with definite APS in a different laboratory and with another 
immunoassay can result in dilemmas when unexpected aPL results are obtained. 
Negative aPL results will not support the diagnosis APS and lifelong anticoagulation 
therapy becomes debatable.
Manufacturers of immunoassays should make more effort in standardizing the detecting 
of aPL antibodies. Development of an international standard together with the efforts 
of scientists and medical specialists to provide new insights in the pathogenesis of APS 
may contribute to a better laboratory diagnosis of APS.
Personalized aPL antibody testing
We have proposed two separate decision trees for thrombosis versus pregnancy 
morbidity. Exclusion of IgM aPL antibody testing for the diagnosis of thrombotic APS 
could lead to less false positives. Moreover, risk stratification using IgM aPL antibodies 
was only found to be useful in thrombotic APS and not obstetric APS. Altogether, these 
results will lead to improved diagnosis of APS and consequent treatment of patients 
with APS.
Detection of antiprothrombin antibodies that induce platelet 
aggregation enables DOAC use in patients with APS
We identified a specific subgroup of antiprothrombin antibodies, able to induce platelet 
aggregation. We hypothesize that these antiprothrombin antibodies are responsible for 
the high incidence of arterial thrombosis in patients with APS receiving DOAC therapy. 
More data are needed to confirm this hypothesis. However, future studies should focus 
on a diagnostic assay to distinguish between antiprothrombin antibodies that are able 
to induce platelet aggregation and those that do not induce aggregation of platelets. 
In the absence of antiprothrombin antibodies that induce platelet aggregation, DOAC 
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use might be feasible. Although not established in thrombotic APS due to the lack of 
definite evidence, the use of DOACs over VKAs has many advantageous, including no 
need for frequent laboratory monitoring, what can be a problem in APS (7,8).
CONCLUSION
The research presented in this thesis provides insight into the diagnostic performance 
of immunoassays detecting aPL antibodies. The immunoassays used in these studies are 
commercially available and often used in medical laboratories. Therefore, our findings 
can be directly related to current practice. Next, we have suggested different decision 
trees for the laboratory diagnosis of thrombotic and obstetric APS which should be 
further evaluated in well-designed large prospective multicenter studies. In addition, 
we provided the first steps of evidence towards DOAC use in APS patients which is a 
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LIST OF ABBRE VIATIONS
ABS adult bovine serum
aCL anti-cardiolipin
AID autoimmune disease
APC activated protein C
aPL antiphospholipid antibodies
APS antiphospholipid syndrome 
aPS/PT anti-phosphatidylserine/prothrombin
aPT anti-prothrombin 






BSA bovine serum albumin




CLEC-2 C-type lectin-like receptor 2
CRP C-reactive protein
DI domain I
DOAC direct oral anticoagulants
dRVVT dilute Russell's viper venom time
DV domain V
ECAT external quality control of diagnostic assays and tests
ECT Ecarin clotting time
ELISA enzyme-linked immunosorbent assay
EULAR European league against rheumatism
F (coagulation) factor





HIT heparin induced thrombocytopenia
Ig Immunoglobulin
ISTH international society on thrombosis and haemostasis




LOD lower limit of detection
LTA light transmission aggregometry
mAb monoclonal antibody
NFκB nuclear factor kappa B
NPV negative predictive value 
OD optical density
OR odds ratio
PAPS primary antiphospholipid syndrome
PBS phosphate buffered saline
PL phospholipid
POC point-of-care
PPV positive predictive value
PRP platelet-rich plasma
PT prothrombin time
ROC receiver operating characteristic
SAPS secondary antiphospholipid syndrome
SD standard deviation
SLE systemic lupus erythematosus
SSC scientific and standardization committee
TBS tris-buffered saline
TIA transient ischemic attack
TLR4 toll-like receptor 4
TMB 3,3',5,5'-tetramethylbenzidine
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